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Abstract 
The primary intent of this thesis is to delineate the relative roles of local membrane and systemic 
consequences of peritoneal dialysis therapy, with particular reference to the role of inflammation 
and a severe, uncommon complication, encapsulating peritoneal sclerosis (EPS). Data sources 
comprised observational cohort studies as well as registry data: the Stoke PD study, a single centre 
study with clinical data, the Global Fluid Study (GFS), a multinational study with clinical data and 
repeated dialysate and plasma samples, and Scottish Renal Registry (SRR) and AnzData registry data.  
Through a cross sectional analysis of dialysate and plasma samples from GFS for inflammatory 
cytokines, we demonstrated that peritoneal and systemic inflammation are mostly separate 
processes although there is an association for IL-6 along with a steep concentration gradient from 
dialysate to plasma. Peritoneal inflammation, though IL-6, is the strongest determinant of peritoneal 
solute transport, and systemic inflammation, though IL-6, is a strong predictor of patient survival 
although peritoneal may contribute to systemic inflammation.  
Through a nested case control study of GFS we showed that inflammatory cytokines are upregulated 
within the peritoneum prior to developing EPS. With a nested case control design from the Stoke PD 
study, we showed that a decrease in ultrafiltration, likely due to increased fibrosis causing a 
reduction in osmotic conductance to glucose, also predisposes to EPS. A competing risks analysis of 
SRR and AnzData showed that patients at a high risk of death, have a low risk of EPS. These findings 
provide supporting evidence for the theory that the risk of EPS develops through the accumulation 
of inflammation-driven fibrosis due to dialysate exposure over a long period of time.  
Dialysate contains high concentrations of glucose and absorption of this drives impairment of 
systemic glucose metabolism, demonstrated through a cross sectional analysis of GFS.  
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1 Aims 
Peritoneal Dialysis is a commonly used treatment for end stage renal failure, but its use is limited by 
the high complication rate, including issues related to peritoneal membrane damage. The aim of this 
thesis is to explore the relationship between local and systemic complications of peritoneal dialysis, 
with particular reference to inflammation and the role of this in peritoneal damage as demonstrated 
by changes in physiological measures. As a severe complication of PD, encapsulating peritoneal 
sclerosis will be investigated with particular attention, to explore the hypothesis that peritoneal 
inflammation and subsequent fibrosis drives the increase in risk of EPS associated with time on PD. 
This will be considered in several sections.  
1 –The interactions between peritoneal and systemic inflammation, patient survival and peritoneal 
solute transport rate (Chapter 4).  
2 –Changes in peritoneal solute transport rate and peritoneal and systemic inflammation over time 
(Chapter 5) 
3 –The role of peritoneal and systemic inflammation in driving encapsulating peritoneal sclerosis 
(Chapter 6) 
4 – Changes in the peritoneal membrane physiology preceding encapsulating peritoneal sclerosis 
(Chapter 7) 
5 –Describing the risk factors for encapsulating peritoneal sclerosis, in the context of the high 
mortality rate of patients on peritoneal dialysis (Chapter 8) 
6 – Investigating the effect of dialysate glucose on systemic metabolism (Chapter 9) 
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2 Background 
2.1.1 What are the main causes of peritoneal dialysis technique failure? 
Renal replacement therapy (RRT) is a very successful form of organ replacement therapy for end 
stage renal failure (ESRF), with a steadily increasing prevalence throughout the world. 
Transplantation is the form of RRT with the greatest impact on morbidity and mortality but, with a 
limited supply of donors, a significant transplant failure rate and with the difficulty of successfully 
transplanting older and more comorbid patients, there is still a need for dialytic forms of RRT. 
Haemodialysis is the most commonly used dialytic therapy, but there is still a significant number of 
patients on peritoneal dialysis (PD), and the use of this modality is increasing particularly in the 
developing world and in the United States due to the lower cost compared with haemodialysis. PD is 
where dialysate is instilled intra-peritoneally to use the peritoneal membrane as a semi-permeable 
membrane, allowing clearance of toxins by diffusion and clearance of water through convective 
flow. 
Unfortunately, PD remains limited by a high technique failure rate and a high mortality rate such 
that, by 3 years only 30% of patients remain on PD. The causes of technique failure change with time 
with catheter and abdominal problems, and psychosocial problems a significant problem in the first 
3 months and decreasing with time, while rates of infectious peritonitis stay relatively constant with 
time and the contribution of underdialysis or ultrafiltration failure increases with time.(1) Poor 
ultrafiltration rates are a risk for PD failure particularly in anuric patients (2) and with increasing 
technique survival rates, ultrafiltration failure is an increasing problem.  
Encapsulating peritoneal sclerosis (EPS) is an unusual complication of PD, initially described in Japan, 
but now recognised as a problem within the UK and throughout Europe. It is characterized by a 
cocoon of fibrotic material in the peritoneal membrane which constricts the bowel, leading to 
obstruction and a high mortality. The main risk factor appears to be time on PD, although peritonitis 
has also been reported as a risk factor. 
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2.1.2 What are the main causes of death on peritoneal dialysis? 
Both forms of dialysis have a very high mortality rate, with a massively elevated rate when compared 
with age, gender and ethnicity matched populations, (3) and a survival rate lower than that of many 
forms of cancer in the older population. Cardiovascular disease (CVD) is responsible for about 45% of 
the deaths in dialysis patients, although this risk increases with falling estimated glomerular filtration 
rate (eGFR) and is not specific to dialysis. (4) There is some evidence that PD is associated with an 
increased hazard of cardiovascular death compared with haemodialysis. (5) Infection is responsible 
for about 20% of deaths, withdrawal of dialysis 15% and malignancy 7%, although a significant 
number of patients have an unclear cause of death.  
Although Framingham risk factors are more prevalent in dialysis patients, including age, 
hypertension, diabetes, dyslipidaemia and physical inactivity, these do not account for all of the 
increased risk. Other factors identified as risk markers for CVD-related death include anaemia, 
hyperparathyroidism, hyperphosphataemia and vascular calcification, oxidative stress, inflammation 
and malnutrition, elevated asymmetric dimethylarginine, hyperhomocysteinaemia, endothelial 
dysfunction and accumulation of advanced glycation end products. 
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2.2  What is our current understanding of peritoneal membrane function? 
2.2.1 What is the structure of the peritoneal membrane? 
The peritoneum is a serous membrane that lines the abdominal cavity. The outer layer is known as 
the parietal peritoneum and the inner layer that wraps around the abdominal organs is the visceral 
peritoneum. Around 80% of the peritoneum is visceral and the blood supply is derived from the 
mesenteric arteries and drains into the portal veins, the other 20% is parietal which gets its vascular 
supply from the abdominal wall. Despite the visceral peritoneum having the larger proportion of the 
total surface area, rat models have suggested that the parietal peritoneum has more contact with 
dialysate, suggesting that it is the parietal peritoneum that is most important to peritoneal 
transport, (6) supported by studies of 15 patients post-omentectomy (7) and of dogs post-
evisceration, omentectomy or mesenterectomy (8) where no difference was found in solute 
transport.  
 
Table 2-1: Layers of Parietal Peritoneum from Superficial to Deep 
Layer Characteristics 
Mesothelium 
Flat, single cell layer around 0.5mm thick. Covered in 
microvilli. 
Basement Membrane Mostly type IV collagen. 25-40nm thick. 
Sub-mesothelial Compact 
Zone 
Fibrous tissue, collagen and scattered elastin fibres. 
Around 50mm thick in non-uraemic subjects 
Loose connective tissue zone 
Collagen, occasional fibroblast spindle cells, mononuclear 
phagocytes, mature lymphocytes and adipose tissue. Also 
contains blood vessels, lymphatics and nerves. 
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Milky spots are also found, being collections of macrophages with lymphocytes and occasional 
plasma cells supplied by blood and lymph vessels. They are found on other serosal surfaces, and 
within the peritoneal cavity particularly on omentum. Most authors agree that their function is that 
of a secondary lymphoid organ. 
 
2.2.2 What theoretical models describe the solute transport and fluid transport 
(ultrafiltration) characteristics of the peritoneal membrane?  
2.2.2.1 The three pore model 
There are several possible rate-limiting steps for peritoneal diffusive transport of low molecular 
weight solutes: peritoneal blood flow, capillary endothelium, interstitial space or mesothelium. 
There is indirect evidence that the blood flow to the peritoneum is several times that of the urea 
clearance suggesting that this is not limiting (9) and more animal model work also found no 
restriction at the level of the mesothelium (10) or in a normal interstitial space. (11) This leaves the 
capillary endothelium as the primary site of restriction to peritoneal diffusion i.e. this constitutes the 
‘semi-permeable membrane’.  
Evidence for diffusive solute transport across at least 2 pores came from studies of the transport of 
different sized molecules where the kinetics of transfer of large proteins, which are unable to pass 
through the small pore system responsible for the diffusion of low molecular weight solutes, 
indicated the presence of a smaller number of large pores. (12) This has then been adapted into a 3 
pore model (figure 1) to explain the phenomenon of sodium sieving, by including an ultrasmall, 
water selective, pore. (13) Supportive evidence for this theory came with the recognition of 
aquaporins (14) and mouse knock outs of AQP1 confirmed the role of AQP’s by preventing sodium 
sieving.(15)  The 3 pore model has also been used to successfully predict the success of the colloid 
osmotic agent Icodextrin separately or in combination with glucose. (16)  One of the limitations to 
this theory is the uncertainty over what exactly the theoretical small pores represent anatomically.  
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Figure 2-1: The 3 Pore Model of Transport Across the Peritoneal Capillary 
 
To explain fluid transport (ultrafiltration) across the peritoneum the equation  
Equation 2-1: Ultrafiltration Across  the Peritoneum 
Jv=Kf([Pc – Pi] – σ[πc – πi]) 
is used, where Jv is the net fluid flux across the capillary, Kf is a proportionality constant (a function of 
the liquid permeability of the membrane and its area), P is the hydrostatic pressure and π is the 
capillary and colloid osmotic pressure in capillary or interstitium, and σ is the reflection coefficient, 
This governs convection across capillaries and was devised by Ernest Starling in 1896.  
As osmotic pressure is one of the principal determinants of water flux across the peritoneal 
membrane, this is utilised in PD by varying the osmotic pressure of the dialysate (usually by adjusting 
the glucose concentration) to increase or decrease the water flux into the dialysate. Through this 
technique, the fluid balance of the patients can be controlled. However, according to the 3 pore 
theory, glucose should diffuse across the small pores down its concentration gradient so any 
increase in capillary endothelial area, and thereby an increase in the small pore area, will accelerate 
glucose absorption, diminishing the osmotic gradient, and therefore will limit the degree of 
ultrafiltration that can be achieved.  
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2.2.2.2  The fiber matrix/3 pore model 
A further development of the 3 pore model became necessary with the recognition that solute 
transport could become ‘uncoupled’ from ultrafiltration (17) i.e. that something other than solute 
transport affecting the osmotic gradient could adversely affect ultrafiltration in long term patients. 
Biopsies of peritoneal membrane from patients on PD demonstrated a substantial increase in the 
sub-mesothelial compact zone with time on PD. (18) This led to the development of a modification 
of the 3 pore model to include a fibrous matrix as another serial resistance, as shown in figure 2. By 
simulating an increased effective peritoneal surface area (i.e. perfused capillaries in contact with 
dialysate) in conjunction with an increased density of matrix and an increase in fiber size as would 
occur with the addition of collagen to proteoglycan, the uncoupling of solute transport, measured as 
the Mass Transfer Area Coefficient (MTAC) or the synonym Permeability-Surface Area product (PS), 
from hydraulic permeability (LpS) was reproduced. (19) This model has not yet been extended to 
predictions surrounding macromolecular transport due to the complexity of modeling this with serial 
resistances. By decreasing the LpS, the osmotic conductance to glucose (LpSσg) should also be 
adversely affected, as has been demonstrated in patients with UF failure on long term PD. (20) One 
study has demonstrated an association between a loosely defined group of impaired UF capacity 
patients on long term PD and an increased peritoneal thickness. (21) 
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Figure 2-2: Diagrammatic Representation of the Fiber Matrix/3 Pore Model 
          Normal    Ultrafiltration Failure 
Peritoneum  Capillary Peritoneum  Capillary 
     
The image on the left represents the peritoneal membrane at the start of PD with a loose matrix, 
having little impact upon the convective flow of water on the left. On the right the image 
demonstrates a dense matrix representing the increase in membrane fibrosis with time on PD, 
causing a resistance to the free flow of water, and subsequent UF failure. The dotted line in both 
images represents the capillary endothelium.   
2.2.2.3  The distributed model 
Another model has been developed to take account of the variable depth within the membrane of 
the peritoneal capillaries, with an osmotic gradient developing from the maximum at the 
mesothelium down to the lowest levels at the greatest depth within the membrane (figure 3). This is 
mathematically more complex, with the solution requiring partial differential equations with several 
variable parameters, (22) and because of this added complexity with no major clinical benefit, it has 
not been widely adopted but remains a research tool.  
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Figure 2-3: Diagrammatic Representation of the Distributed Model With a Variable Capillary Depth and 
Exponentially Decreasing Osmotic Pressure 
 
 
2.2.2.4  How do we measure peritoneal function? 
As PD is primarily trying to achieve both solute removal through diffusion into dialysate, and water 
removal through manipulation of the osmotic pressures, it is useful to measure the capacity of the 
membrane to deliver these. Several tests have been devised do this in a clinical setting, including the 
personal dialysis capacity (PDC) test, and the standard peritoneal permeability analysis (SPA), but the 
simplest and most widely used is the peritoneal equilibration test (PET). (23) 
The simplified PET consists of administration of a standard glucose based dialysate (either 2.27% or 
3.86%) and leaving in situ for 4 hours. The ratio of the dialysate to plasma creatinine concentrations 
(D/P Cr) at 4 hours is primarily a measure of how much diffusion has occurred. As diffusion is an 
inactive process, the ratio cannot rise above 1. Diffusion of solutes is mostly across the small pores, 
so a change in D/P Cr represents a change in small pore area, and thereby it is a measure of effective 
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peritoneal membrane area. D/P Cr is not a pure measure of diffusion, as solute drag will occur with 
convection, but the proportion is relatively small and the methods to measure diffusion only (Mass 
Transfer Area Coefficient - MTAC) are more complicated so D/P Cr is used as a close approximation. 
The original paper describing the PET divided the patients into groups (High, High-Average, Low 
Average and Low) based upon the D/P Cr, but this does change a continuous variable into a 
categorical variable.   
To measure the amount of ultrafiltration achieved, the volume of dialysate drained is measured, and 
the initial volume subtracted (with adjustments for bag overfill as necessary). This is called the 
ultrafiltration (UF) capacity, and it represents a composite measure, reflecting both the liquid 
permeability (Lp) and the surface area (S) of the membrane, the effective lymphatic reabsorption, and 
each of the 2 pressures determining the hydrostatic pressure gradient, the colloid osmotic pressure 
gradient and the crystalloid osmotic pressure gradient, itself partly determined by the reflection 
coefficient of glucose (σg).  
As UF capacity is a lumped parameter, newer tests, such as the double mini PET (24) or the sequential 
PET, (25) have been devised which allow calculation of the more specific osmotic conductance to 
glucose (LpSσg). The advantage of this calculation is that, as σ seems unlikely to change with time on 
PD, LpSσg should better reflect any changes that occur in the underlying liquid permeability to water 
(LpS) of the peritoneal membrane but as the protocol for this is more complicated that the simplified 
PET it has not yet been widely adopted.  
2.2.3 What do we know of the predictors of solute transport and ultrafiltration? 
2.2.3.1  Solute transport 
2.2.3.1.1 Early changes 
In the largest study of solute transport in incident (<6 months) patients, using 3,188 registry subjects 
from Australia and New Zealand, the independent predictors of faster solute transport were 
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diabetes, lower BMI, male gender, having received APD and ethnicity. (26) This study was 
confounded by incomplete reporting which was unlikely to be random as the groups with and 
without data were significantly different. As body surface area, and therefore presumably peritoneal 
surface area, is proportional to height (in different formulae, to different powers between 0 and 1), 
while BMI is inversely proportional to height squared, the association in this study seems likely to be 
due to a mathematical coupling with body surface area.  
Another study of the predictors of incident peritoneal transport was performed on data from the 
CANUSA study, where 14 centres providing 680 patients had 606 with details of the incident PET 
test. (27) Multivariable analysis was not used, but age, gender, diabetic status and serum albumin 
were significantly different amongst different categories of peritoneal transporter status. Neither of 
these two multicentre studies were analysed with techniques taking possible centre effects into 
account. 
The third large study of peritoneal transport at the start of dialysis was a single centre study with 
574 patients (17) where multivariable analysis established male gender, lower plasma albumin and a 
larger urine volume as predictors of faster transport, although with an R2 value of only 0.215. 
Comorbidity, according to the Stoke comorbidity index, and age were not significantly associated. 
Hypoalbuminaemia is predictably associated with solute transport as albumin will cross small pores 
as well as through large pores so a larger effective membrane area will increase dialysate albumin 
losses. A Danish study (28) confirmed the association between large pore flux (JvL from the Personal 
Dialysis Capacity test) and subsequent hypoalbuminaemia, but a study in Canada (29) found an 
association between the pre-dialysis albumin and the subsequent transport status (D/P Cr), 
suggesting there might be more than one cause for this association e.g. systemic inflammation 
increasing solute transport, and decreasing albumin levels through its role as a negative acute phase 
protein.  
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There is significant variability in incident solute transport only partially explained by the factors 
above, and these factors vary between studies. One explanation may lie in the timing of the PET test 
in the different studies. Johnson et al  found a significant increase in solute transport occurred 
between 1 and 4 weeks, but reasonable correlation between measurements at 4 weeks and 1 
year.(30) In this study some informative censoring did occur between 4 weeks and 1 year with those 
patients not surviving on PD to 1 year having a greater increase in solute transport within the first 
month. An apparently contradictory result was found by Struijk et al (31) where there was a 
decrease in solute transport from 1 month to 5 months. This could potentially be explained by an 
initial reaction to glucose exposure inducing vasodilation with an increase in perfused capillaries, 
followed by an adaptation to chronic glucose exposure although some longitudinal studies found 
either stability in solute transport over this time period, or a fall in solute transport occurring later. 
(32) These results are all prone to informative censoring as a fast solute transport predicted both 
technique and patient survival during the period when the majority of these studies were 
performed. 
The significance of these early alterations in solute transport is unclear as Davies found a lack of 
alteration in UF capacity. The study by Davies also examined the early changes, finding that a change 
in D/P Cr of <0.1 in the first 6 months was within normal test variation and not predictive of 
subsequent increases in solute transport, but a change of >0.1 was. This is potentially explained by 
the decrease in UF caused by an increase in absorption of dialysate glucose being matched by an 
increase in the osmotic conductance to glucose through an increase in surface area. 
Other factors may contribute to the variability in solute transport. La Milia et al conducted a non-
randomised study comparing pre-dialysis PET tests with those at 4 and 16 months, and they 
demonstrated an increase in D/P Cr in CAPD patients, not found in APD patients suggesting an effect 
of modality early on. (33) Furthermore, the definition of the commencement date of PD is not clear 
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in most studies, possibly interpreted as the start of training or at the end of a variable length of 
training with varying amounts of dialysate exposure. 
Another reason for the variability in predictors of solute transport between studies was suggested in 
an editorial by Davies. (34) Solute transport predictors can interact with each other e.g. BMI, age and 
diabetes,  and with other factors such as ethnicity, such that the case mix for each study, in 
combination with different statistical methods, may well contribute to the different findings.  
Several small studies have also found genetic associations with incident solute transport including 
polymorphisms in endothelial nitric oxide synthase (eNOS), (35)  in RAGE but not eNOS or VEGF, (36) 
in IL-6, but not VEGF or eNOS, in a European population (37) and in IL-6 in a Korean (38) population. 
As a genetic predisposition to IL-6 production is consistently associated with faster solute transport, 
this strongly suggests that inflammation partially determines solute transport. Interestingly, the level 
of change in PSTR at 12 months was found to be associated with VEGF (39) and IL-10 (40) 
polymorphisms, when these did not affect baseline values, adding weight to the theory that the 
drivers of PSTR change over time. 
2.2.3.1.2 Late changes 
The investigation of membrane function in prevalent patients is essentially the study of longitudinal 
changes with duration of PD and there are several potential drivers of change with time – peritonitis 
episodes, the presence of a catheter, bio-incompatible dialysate, and uraemia. Most studies have 
found a consistent increase in solute transport with time on PD, (31,41,42) although there were 
differences in when this rise commenced which could be linked with the differences between 
centres in early changes discussed above. The rise in solute transport indicates an increase in 
perfused capillaries. There does appear to be an increase in capillary area with solute transport 
[40]but there have been no longitudinal studies showing a clear relationship between capillary 
density and time. The largest biopsy study did find greater vessel density in patients with histological 
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fibrosis or ‘membrane failure’, (18) suggesting that increases in solute transport may reflect variable 
levels of vasodilatation and angiogenesis. 
2.2.3.1.3 Drivers of change 
Peritonitis does have an effect upon solute transport linked to the number of episodes, the organism 
involved, and the severity of the inflammation. (41) This effect becomes less significant with time as 
the patient group without peritonitis also has a long term increase in solute transport which ‘catches 
up’ with the peritonitis group.  This finding is consistent with a number of other studies, (43–45) 
although these studies are smaller and/or shorter.  
High osmolarity, high glucose concentrations, buffer composition, pH and glucose degradation 
products have all been identified as components in the well recognised bio-incompatibility of 
conventional dialysis fluids driving impaired immune function, angiogenesis and fibrosis in animal 
models and in in vitro work. (46,47) Newer solutions designed with a more optimal 
bicarbonate/lactate buffer, higher pH and lower GDP content have been shown to be beneficial in 
laboratory studies (48) although, until recently, no benefit had been consistently identified in human 
randomized controlled clinical trials. The BALANZ trial was a study of 185 incident patients, 
randomized to either standard or biocompatible dialysate fluid (both from Fresenius Medical Care). 
The primary outcome, the rate of decline in residual renal function, just failed to meet pre-specified 
statistical significance, (49) but numerous secondary outcomes were statistically significant, some 
highly. This included the D/P Cr which was significantly faster in the biocompatible group at 1 month 
into the trial but this measurement remained stable. This contrasted with the standard dialysate 
group where the D/P Cr increased significantly over the 24 months of the trial to end up significantly 
faster than the biocompatible group. (50) 
The effects of other dialysis solutions have not been so well studied. Icodextrin usage, which may be 
associated with greater intra-peritoneal inflammatory cytokine and fibrin production, (51–53) has 
been associated with less functional change in peritoneal membranes, albeit in an observational 
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study. (54) Unfortunately, none of the randomized controlled trials of Icodextrin alone have 
examined the effects on PSTR. One randomized controlled trial where patients were allocated to a 
regime of either Icodextrin for the overnight dwell with a biocompatible glucose solution and an 
amino acid solution (intervention group) during the day or a regime of standard glucose solutions for 
all dwells (control group) examined dialysate markers and PSTR changes. (55) Dialysate from the 
long dwell showed that the Icodextrin dwell was associated with higher IL-6 levels as well as CA125 
and adiponectin, whilst serum IL-6 and CRP were no different. The PSTR in this study was 
significantly faster in the intervention group by the end of the 12 month follow up (0.78 ± 0.13 vs 
0.68 ± 0.12, p=0.001) despite a much larger glucose load in the control group (33.7 grammes/day 
±9.9 vs 130.3 ± 34.7, p<0.001). 
The level of membrane exposure to glucose has also been linked with changes in the PSTR, (56) in an 
observational study where higher glucose exposure predated increased PSTR, even when RRF is not 
relevant as a confounder.(54) Whether higher glucose exposure still predicts increases in PSTR in 
biocompatible fluids is not known, but a study of this would help to identify the relative roles of 
osmolality and glucose versus GDPs, buffer composition and pH. 
There are several studies in rat models suggesting an inflammatory foreign body reaction to the 
implantation of a catheter with effects upon angiogenesis, fibrosis and solute transport, although 
the applicability to humans is unclear with a different ratio of catheter to peritoneum size, and 
therefore a different level of peritoneal ‘catheter exposure’. (57) Evidence supporting the concept of 
catheters causing chronic inflammation comes from observational data in haemodialysis patients 
showing that intravascular catheters and arteriovenous grafts are, even in fully adjusted models, 
associated with increased systemic IL-6 and CRP compared to arteriovenous fistulae, and that 
transitions from fistulae to catheters are associated with an increase, as well as vice versa. (58) 
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Uraemia also must have an effect upon membrane structure as evidenced by the peritoneal changes 
documented at the start of PD, (18) although the ongoing effect of this once PD has commenced is 
not known.  
2.2.3.2 Ultrafiltration 
2.2.3.2.1 Predictors of ultrafiltration capacity 
Assessment of the predictors of UF capacity is significantly more difficult as it is a lumped parameter, 
reflecting the effects of intraperitoneal pressure, sump volume, effective lymphatic absorption rate, 
hydraulic permeability, and glucose reflection coefficients, and the measurement itself has a 
significant coefficient of variability of 20 to 25%. (34) This complexity is demonstrated by studies 
where the initial rate of UF was shown to be independent of solute transport, while the 4 hour 
volume was decreased by a fast solute transport (59) and where UF through the ultrasmall pores 
was found to be dependent solely on osmotic gradient, whilst small pore UF had significantly more 
variation. (60) 
 Consequently, most studies have focused on studying the effect of these experimentally derived 
factors and there have been few studies of sufficient size to identify clinical predictors of initial UF 
capacity. One exception to this was a smaller study of 367 incident patients where age was identified 
as predictive of UF capacity, independently of glucose concentration and solute transport (61) 
although this was not found in a larger study. (42) There have been no studies investigating the 
correlation between age and the size of the sub-mesothelial compact zone.  
Intraperitoneal pressure is simply measured by examining the height of the column of dialysate 
within the dialysis catheter from the mid-axillary line, and an increase of 1cm has been shown to 
correlate with decrease in UF at 2 hours of 70mls. (62) A potentially important consequence of this 
association is that UF could be lower when upright compared with recumbency, but this effect 
seems to be small. (63) This effect on UF may be mediated by an increase in effective lymphatic 
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absorption, according to a study by Imholz et al (64) although theoretically it should have a direct 
effect opposing UF for a given osmotic gradient.  
There is considerable debate within the literature regarding the true significance of the effect of 
lymphatic absorption, (65,66) with results from the measurement of Dextran absorption suggesting 
an important effect, (20,60,67) but when radiolabelled albumin was used the effective lymphatic 
absorption rate appeared significantly less. (68) There is some evidence that a higher effective 
lymphatic absorption rate may be important in UF failure occurring early in the course of PD (20) and 
there are experimental reasons to suspect that abnormalities may exist (vide infra). 
One of the predictions of the 3 pore model was of the efficacy of colloids when trying to achieve 
sustained UF, borne out with studies of Icodextrin. (69) Colloids are only be absorbed through 
lymphatic channels thereby preserving the osmotic gradient for longer dwells, and their high 
reflection coefficient across small pores ensures efficient ultrafiltration for a relatively low 
concentration gradient. This prediction was extended to predictions for dialysates containing both 
Icodextrin and glucose, once again borne out with clinical studies, (16,70) where the effects of 
colloid, by counterbalancing the intracapillary oncotic pressure driving fluid reabsorption, combined 
with the crystalloid to produce a significant UF.  
2.2.3.2.2 Longitudinal changes in UF with time 
That UF capacity falls with time is consistently documented, and some of this fall could be explained 
by the increase in solute transport (and therefore glucose reabsorption) that also occurs with time 
but a report from 2004 (17) demonstrated that after 5 years of PD, there was a disproportionate fall 
in UF capacity linked to poorer residual renal function and greater glucose exposure. That an 
explanation other than solute transport is necessary to explain changes in UF capacity is also 
suggested by the absence of changes in UF capacity in conjunction with early changes in solute 
transport. Subsequent studies have suggested that some of the long term decline in UF capacity is 
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due to a fall in osmotic conductance of the peritoneal membrane (20) thereby causing ultrafiltration 
failure.  
2.2.3.3 Effect upon mortality of solute transport and ultrafiltration 
There is a well-established association between solute transport and mortality, with a meta-analysis 
by Brimble et al combining 19 prospective and retrospective studies with over 6,500 incident and 
prevalent patients demonstrating a relative mortality risk of 1.15 for 0.1 increase in D/P Cr. (71) 
Whilst a faster solute transport for a given volume of ultrafiltration should create a beneficially 
greater small solute clearance, it will also be associated with a greater protein loss and thereby 
hypoalbuminaemia, (28) a known risk factor for mortality, as well as creating faster glucose 
reabsorption with subsequent lower UF and greater glucose exposure. This increase in mortality 
with fast solute transport is consistent with several trials which have shown no benefit in greater 
peritoneal solute clearance, (72–74) but an increase in mortality with worse UF. (73,75,76)  
Studies that included patients on APD, a strategy which should preserve UF in fast transporters, 
showed a smaller increase in mortality with solute transport, (77) Furthermore, the studies included 
in the Brimble meta-analysis were mostly before the introduction of Icodextrin, a dialysate solution 
utilizing a colloid osmotic gradient, thereby avoiding the problem of reabsorption across small pores 
and preserving UF. A recent analysis of the ANZDATA registry actually demonstrated a mortality 
hazard ratio of 0.56 for patients with a fast transport status on APD, possibly due to the superior 
control of fluid balance in this group, whilst there was actually an increased mortality for APD use in 
patients with a slow transport status. (78)  
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2.3 What is the role of inflammation and fibrosis? 
2.3.1.1 How does the peritoneal membrane morphology change with time? 
As mentioned above, one of the predominant features of the peritoneal membrane change with 
time is the increase in the submesothelial compact zone. This change occurs before the start of PD, 
with uraemia responsible for an initial increase in fibrosis, but this fibrosis increases with time on PD 
such that the median thickness of the compact zone is 50μm, 140μm and 700μm in normal subjects, 
uraemic subjects and patients on PD for over 8 years respectively. This increase in fibrosis is 
predominantly in the parietal peritoneum with a median thickness of 505μm (normal subjects 50μm) 
compared with only 20μm in the visceral peritoneum in PD patients. (79)  
Figure 2-4: Sub-mesothelial compact zone thickness with time on PD 
 
Figure from Williams et al, JASN 2001 
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In PD patients, the main other change described in the peritoneal membrane is a hyalinising 
vasculopathy of venules, small veins and sometimes arterioles, with subendothelial accumulation 
that may progress to narrow or obliterate the vessel lumen. This vasculopathy increased with time 
on PD. There is a similarity between diabetic vasculopathy and that described in PD patients, but 
there was not an obvious interaction between PD and diabetes affecting the vasculopathy. (18) The 
vasculopathy was also found in 28% of uraemic, non-PD patients, although another study of post 
mortem samples from PD patients with severe hyalinising vasculopathy found no evidence of 
vasculopathy elsewhere. (80) Again, differences are found between peritoneal surfaces with the 
greatest vascular changes in the parietal peritoneum. (79) 
The vessel density did not increase with time on PD but it was greater in those with fibrosis (compact 
zone >150μm) and in samples from patients with membrane failure, although the definition of 
membrane failure was not clear in this study (18) 
The mesothelium undergoes epithelial-mesenchymal transition (EMT) (81) where it loses epithelial 
morphology, and cytokeratin and E-cadherin expression in conjunction with induction of the 
transcriptional repressor Snail. The mesenchymal phenotype was marked by α2-integrin expression 
and acquisition of a migratory phenotype and all of these EMT changes were induced by 
transforming growth factor β1 (TGF-β), potentiated by IL-1β. EMT is also linked with angiogenic 
stimuli (82) and solute transport. (83)  
2.3.1.2 Does uraemia affect other serosal surfaces? 
Fibrinous pleuritis has been described in a post mortem study of uraemic patients, (84) there have 
been a few reports of a fibrosing uraemic pleuritis requiring decortication for which the 
pathophysiology remains unclear, (85) and a retrospective review of haemodialysis patients in 2007 
found that the commonest cause of exudative pleural effusions was uraemic pleuritis. (86) Acute 
pericarditis is a well recognised complication of uraemia, but chronic constrictive pericarditis seems 
to be far less common, (87) with only 4.8% (2 of 42) of patients requiring surgery for constrictive 
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pericarditis having uraemia as a cause. (88) Uraemia does occasionally appear to cause significant 
pathology of serosal surfaces, whether inflammatory or fibrotic, although the exact prevalence of 
these changes has not been fully elucidated with histological studies.  
2.3.2 Is there local inflammation? 
2.3.2.1 Histology 
Histological evidence of inflammation in routine PD patients membranes is limited with the largest 
peritoneal biopsy study (18) finding only 12% of patients with inflammatory changes (75% of which 
were chronic inflammation).  Whilst there is no real evidence of overt inflammation, there is a little 
evidence for an increase in subtle inflammatory changes with uraemia and PD. Kihm et al found an 
increase in IL-6 and NF-κB staining but no increase in CD3 staining in uraemic patients, whilst 4 PD 
patients with before and after biopsies had an increase in CD3 staining. (89) Milky spots have also 
been shown to increase in either number or size in both animal and human studies. (90) Few other 
studies have looked for subtle changes.  
One of the strongest pieces of evidence for an association between inflammation and PSTR comes 
from study of 42 uraemic patients who had a peritoneal biopsy at the point of catheter insertion. 
The concentration of peritoneal macrophages correlated very strongly (r=0.61) with the PSTR 
measured within 6 months of starting PD. (91) 
2.3.2.2  Cellular profile 
Macrophages, lymphocytes and neutrophils have all been detected in dialysate (92) with 
macrophages up to 70% of all the leucocytes (93) although there are wide variations between 
individuals. (94) Mast cells are found within the peritoneum and increase with PD and peritonitis. 
Mast cell deficient rats had less peritoneal cell influx and omental changes, but no change in 
functional parameters or angiogenesis, fibrosis or mesothelial cell damage. (95) The intra-peritoneal 
lymphocyte population consists of 10-20% B lymphocytes with the remainder T cells, (94) which are 
mostly composed of effector memory T cells, probably resident within the peritoneum. (96)  
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Endothelial cells play an active role in inflammation and a local increase in rolling, adhesion and 
extravasation of leucocytes has been demonstrated in animal PD models. Mesothelial cells usual 
function is to provide a frictionless and protective layer, with this latter role responsible for the 
secretion of chemokines including IL-8 or MCP-1, as well as inflammatory cytokines like IL-6, in 
response to stimuli including AGE’s, GDPs, peritonitis and glucose. (97) There is also constitutive 
expression of Toll-like receptors (TLR) -1, 2, 3, 4, 5 and 6 by mesothelial cells. 
2.3.2.3 Cytokine profile 
Studies of cytokines are frequently hard to interpret for a number of reasons. First, as cytokines are 
usually small enough to diffuse across the peritoneal membrane, and would also arrive intra-
peritoneally by convection, intra-peritoneal levels may reflect this, rather than local production. 
Second, there is no ‘normal’ control group against whom comparisons can be made when examining 
dialysate, as dialysate by definition is not ‘normal’. Third, the concentrations of cytokines do not 
necessarily reflect activity as this is complicated by the presence of natural inhibitors e.g. IL-1β with 
IL-1RA, and the presence of cytokines with antagonistic activity e.g. pro-inflammatory TNF-α with 
anti-inflammatory IL-10.  Fourth, cytokine concentrations will be dependent on the dwell length so 
appearance rates must be calculated to take this into account. Fifth, some established 
immunoassays may not differentiate between active molecules and those bound to their specific 
inhibitor. Finally, the functional significance of differences in concentrations is often unclear as less 
inflammatory cytokine production may represent less inflammation and damage, but may also 
represent impaired cellular function and therefore defense against micro-organisms.  
IL-6 is a pleiotropic cytokine secreted by many cell types including T cells, macrophages, adipocytes, 
myocytes, vascular smooth muscle cells and osteoblasts with effects including immunoglobulin 
production, osteoclast activation, platelet production, fever, myeloma and mesangial cell 
proliferation, and the acute phase response by hepatocytes amongst many others. IL-6 acts through 
a signaling complex of IL-6 receptor (IL-6R), for which expression is limited to a few cell types, and 
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ubiquitously expressed gp130, but IL-6R can be alternatively spliced or shed to create soluble IL-6R. 
When bound to IL-6, soluble IL-6R, through gp130 (trans-signaling), has a different effect thought to 
mediate the transition from acute to chronic inflammation. (98)  
IL-6 is routinely detectable at higher concentrations in the dialysate than in the serum, implying local 
production, and there is significant correlation between dialysate IL-6 and solute transport, (99,100) 
including in multivariable modeling, (101) although how this correlates with inflammation and how 
much of this relationship could be due to filtration of plasma IL-6 remains unclear.  
Dialysate IL-1β, TNF-α, IFN-γ and IL-10 levels are usually low to undetectable, all rising sharply with 
peritonitis, (102–105) but in PD patients IL-8 has an elevated serum level and an approximately 
equivalent dialysate concentration IL-8 local production usually. (106,107) MCP-1 and VEGF are also 
usually detectable in dialysate. (101)  
2.3.3 Systemic inflammation 
2.3.3.1  Is systemic inflammation important in PD patients? 
As discussed below, there is a well described association of muscle wasting and cardiovascular 
disease with inflammation in ESRF patients, which has been described as the ‘MIA’ (malnutrition, 
inflammation, atherosclerosis) syndrome (108) and all 3 parts of this syndrome are associated with 
an increased mortality. 
2.3.3.1.1 Inflammation and cardiovascular disease 
Inflammation is now recognised as playing a role in CVD within the normal population (109) thought 
to occur through an endothelial effect, and inflammatory markers, particularly IL-6, are significantly 
associated with mortality in ESRF patients, (110) a group that have a high risk of CVD. Studies have 
subsequently confirmed the link within ESRF patients between inflammatory markers and 
cardiovascular death, (111) but CVD in ESRF is histologically different from classical occlusive 
atherosclerotic disease, being characterised by calcification of the arterial media, rather than the 
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intima.(112) Inflammatory markers in ESRF patients have been associated with typical 
atherosclerotic disease (113) but there are an increasing number of studies demonstrating a link 
with arterial calcification. (114–116) 
Fetuin-A is a negative acute phase protein that is also a calcification inhibitor and low levels of this 
are associated with malnutrition, atherosclerosis, inflammation and mortality in dialysis patients. 
(117) Osteoprotegerin (OPG), a member of the TNF-receptor superfamily, is an inhibitor of RANKL 
(Receptor activator of NF-κB Ligand), a member of the TNF superfamily which induces osteoclast 
differentiation and maturation, and elevated levels of OPG are associated with both CRP and 
calcification,(118) suggesting a protective response secondary to inflammation and calcification.  
2.3.3.1.2 Inflammation and body composition 
Muscle wasting is recognised in many inflammatory conditions and it has now been suggested that 
subclinical inflammation may be partially responsible even for wasting associated with aging. (119) 
IL-6 promotes muscle protein catabolism,(120) and cancer associated cachexia,(121) whilst high 
levels are associated with anorexia in dialysis patients. (122) 
TNF-α is also associated with cachexia,(123) with a variety of possible mechanisms including 
activation of the ubiquitin-proteasome system,(124) inhibition of MyoD transcription (125) and 
through anorexia. 
The functional significance of this interaction between inflammation and catabolism is illustrated by 
a study demonstrating that polymorphisms predicting high levels of TNF- α and IL-6 were all 
independently associated with higher comorbidity and lower functional status  and low IL-10 
producers predicted lower functional status (closely associated with muscle function and 
composition) in haemodialysis patients. (126) 
2.3.4 Fibrosis 
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As discussed above, there is clear evidence of an increase in peritoneal  fibrosis in uraemic patients 
which progresses dramatically with time on PD. The drivers for this must ultimately be the same as 
for inflammation i.e. uraemia, the presence of a catheter, peritonitis and bioincompatibility of 
dialysate. Which of these is most important is unclear due to the difficulties in collecting biopsies 
from patients, or in using indirect evidence such as the osmotic conductance to glucose, or trying to 
separate the effect of fibrosis on UF capacity from the other factors affecting this. Studies have 
focused on determining molecular mediators instead. 
2.3.4.1 Advanced glycation end products 
Advanced glycation end (AGE’s) products are irreversibly altered proteins including pentosidine and 
carboxymethyllysine, that are associated with uraemia, and one of the most potent inducers of 
AGE’s are the glucose degradation products (GDPs) such as methylglyoxal and 3-deoxyglucosone 
found in standard dialysate.(127) GDPs alter the structure and function of mesothelial cells (128) and 
AGE’s induce collagen synthesis through TGF-β,(129) accumulate in the peritoneal vasculature and 
interstitium, (130)and correlate with fibrosis, solute transport and ultrafiltration dysfunction.(131) 
2.3.4.2 Inflammation 
Inflammation has long been recognised as the precursor to the healing process, of which fibrosis is a 
necessary part, but there is now evidence that inflammation can both exacerbate and aid in the 
resolution of fibrosis.(132) Within the peritoneum there are several studies suggesting a link 
between inflammation and subsequent fibrosis but the complexity is demonstrated in a study of the 
effects of IL-1β or TNF-α expression where the subsequent fibrosis resolved by 21 days when 
induced by TNF-α but IL-1β induced fibrosis persisted, in association with greater inflammation and 
higher levels of TGF-β and TIMP-1.(133) Peritonitis has been studied clinically and found to 
upregulate IL-1β, IL-6, TGF-β and bFGF sharply on the first day but levels remained elevated for at 
least 6 weeks after, consistent with longer term effects upon fibrosis.(134)  
2.3.4.3 Renin-angiotensin-aldosterone system 
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As there is for renal fibrosis and cardiac hypertrophy, there is evidence of a pro-fibrotic role for the 
renin-angiotensin-aldosterone system (RAAS) within the peritoneum,. Components of the RAAS are 
expressed within mesothelial cells, and are upregulated in the presence of inflammation and 
exposure to peritoneal dialysate. The high glucose concentration, low pH, and the presence of GDPs 
in dialysate have all been implicated in modulation of this system.(135,136) Furthermore, activation 
of the RAAS, as well as the downstream production of transforming growth factor-beta, contributes 
to epithelial-to-mesenchymal transformation of mesothelial cells and to increased VEGF production. 
Several animal models have shown that fibrosis can be ameliorated by blocking the RAAS.(137) 
2.3.4.4 Transforming growth factor-β 
TGF-β has a central role in fibrosis in a wide variety of disease types and this was also suggested in 
peritoneal fibrosis by using adeno-virally mediated gene transfer in a rat model.(138) TGF-β has a 
wide variety of effects such as fibroblast activation, collagen deposition, inhibition of fibrinolysis 
through PAI-1, maintenance of fibrosis through inhibition of matrix metalloproteinases, 
angiogenesis, EMT and immunomodulatory effects including inhibition of T helper cell proliferation 
and increased Th17 and regulatory T cell production. Dialysate levels of TGF-β were higher than 
predicted by diffusion from serum,(139) and TGF-β1 mRNA was detectable in dialysate 
macrophages, suggesting local production. There have been conflicting results surrounding the 
association between dialysate levels of TGF-β and solute transport (100,139,140) although when 
TGF-β is expressed by adeno-virus vector in an animal model, there is an increase in solute 
transport.(138) Dialysate levels are particularly difficult to interpret for TGF-β as it is secreted as a 
complex with Latency –Associated Peptide and one of the Latent TGF Binding Proteins in an inactive 
form so it is unclear what the levels represent.  
2.3.4.5 Other mediators 
Other putative mediators of fibrosis include FGF-2, connective tissue growth factor (CTGF), TGF-β’s 2 
and 3, platelet derived growth factor (PDGF) and PAI-1. Molecules such as the MMP’s may also have 
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a role, partly through their role as collagenases and their balance with TIMP’s, but also in the 
induction of EMT (MMP-2) although this latter factor has mostly been studied within the kidney.  
2.3.5 Blood and lymph vessel changes 
The type of angiogenesis of relevance to peritoneal dialysis is sprouting angiogenesis, initiated by 
growth factors that stimulate the endothelial cells to degrade the basement membrane through 
protease production. Endothelial cells then proliferate to form sprouts and migrate through the use 
of integrins towards the angiogenic stimulus. Some of the main signaling molecules involved include 
the VEGF family, fibroblast growth factors (particularly 1 and 2), angiopoietins, ephrins, platelet 
derived growth factors, transforming growth factor-β and endothelial nitric oxide synthase.  
2.3.5.1 Angiogenesis and solute transport 
Angiogenesis is well established as occurring in experimental PD, and correlates with solute 
transport but using solute transport as a direct marker for angiogenesis does have some flaws as 
solute transport actually represents perfused capillaries in contact with dialysate, so could be 
influenced by vasodilation. Some direct studies of causation of peritoneal angiogenesis have been 
done and they mostly suggest that the same stimuli for faster solute transport induce angiogenesis. 
For instance, activation of  the receptor for advanced glycation end products (RAGE) induces VEGF 
and angiogenesis,(141) glucose degradation products (GDPs) induce mesothelial production of VEGF 
(142) whilst a GDP scavenger (aminoguanidine) reduced angiogenesis (143) and dialysate lactate 
increase angiogenesis.(144) EMT associated with more VEGF production and faster solute 
transport.(82) The direct relevance to solute transport is demonstrated by the fact that VEGF 
polymorphisms predicted a greater increase in solute transport at 1 year follow up of incident 
patients.(39)  
2.3.5.2 Angiogenesis and the link with inflammation 
Inflammation has a recognised association with angiogenesis, particularly from cancer research 
where inflammation is thought to adversely affect outcomes through blood vessel formation and 
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subsequent tumour growth. Of particular relevance to peritoneal dialysis is the fact that in a variety 
of situations IL-6 induces VEGF,(145) although IL-6 requires sIL-6R and angiogenesis is completely 
inhibited by VEGF inhibitors (146) or tocilizumab.(147) IL-1β and α, TNF-α, oncostatin M and IL-8 also 
induce VEGF. Specifically in PD, the linkage has been demonstrated in animal models where both IL-
1 and TNF-a administered intraperitoneally induced VEGF and angiogenesis in rats (133) and where 
LPS induced an increase in VEGF and solute transport.(148) Angiogenesis also develops in tandem 
with fibrosis,(149) and interventions to reduce angiogenesis also decrease fibrosis.(150)  
Conversely, angiogenesis can affect inflammation – Placental GF induced IL-6 and TNF-α by 
mononuclear cells,(151)  transgenic PlGF induced dermal inflammation (152) VEGF can increase TNF-
α and IL-6 production by peripheral blood mononuclear cells (153) and angiopoietin-2 may have a 
role in the widespread inflammation in critically ill patients, including prognostic significance.(154) 
Of relevance to PD is the observation that angiopoietin-2 deficient mice cannot mount an 
inflammatory response to Staphylococcus aureus peritonitis.(155) Together, these findings illustrate 
the difficulty of investigating inflammation, angiogenesis and fibrosis in isolation, given their 
interconnected nature. 
2.3.5.3 Lymphangiogenesis 
There has been a large increase recently in the investigation of lymphangiogenesis due to the 
identification of lymphatic vessel specific markers, which has started to allow the identification of 
some of the molecular mechanisms controlling this process. A central role has been established for 
VEGF-C through VEGFR-3 (156) as well as roles for VEGF-A and D and angiopoietin-2.(157) There is 
an association with inflammation, with evidence of lymphangiogenesis induction by TNFα,(158) Toll-
like receptor 4/Lipopolysaccharide,(159) and increased lymphangiogenesis in inflammatory 
joints.(160) TGF-β appears to inhibit lymphangiogenesis.(161,162) There is therefore good reason to 
suspect abnormalities in lymphangiogenesis will exist in peritoneal dialysis but there has been only 
one animal study (163) directly investigating lymphangiogenesis (in relation to celecoxib use) and 
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one study of VEGF-C levels in dialysate where they are related to faster solute transport and less 
UF.(164) Despite the prominence of oedema in renal failure, it is not known if there is any uraemic 
effect upon the regulation of lymphangiogenesis.  
2.3.6 Is there a link with Encapsulating Peritoneal Sclerosis? 
Encapsulating peritoneal sclerosis is an uncommon condition primarily occurring in patients with 
prolonged exposure to PD, where a cocoon forms around the intestine causing obstruction, 
malnutrition and a high mortality. Histological changes consist of increased membrane fibrosis, 
particularly in visceral peritoneum, inflammation, and vascular occlusion and calcification. This has 
been compared with patients with ‘simple sclerosis’ where, as with the Peritoneal Biopsy Registry, 
parietal fibrosis is more significant.(165)  
Studies to date have identified a fast solute transport with a low ultrafiltration capacity at the time 
of stopping PD in those patients who develop EPS.(166) As time on PD is associated with increased 
fibrosis and impaired ultrafiltration capacity, there is therefore circumstantial reason to suspect that 
a gradual increase in membrane fibrosis is a significant risk factor for EPS although it still remains 
unclear why certain patients with fibrosis would subsequently develop EPS whilst others do not. 
Possible ‘second hits’ include stopping PD, peritonitis or visceral involvement.  
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2.4 Conclusion 
At the start of PD there is variability in solute transport which remains mostly unexplained. During 
PD, the peritoneum undergoes histological changes characterised primarily by angiogenesis and 
fibrosis with the functional consequences of fast solute transport and impaired ultrafiltration 
capacity leading to increased mortality. The drivers of this change are peritonitis, loss of residual 
renal function and subsequent greater bioincompatible fluid exposure. The only molecule 
consistently linked with these processes is intra-peritoneal IL-6 with solute transport but the 
prognostic and diagnostic information this adds is unclear. The role of inflammation, whether 
systemic or local, is also unclear. The final result of these changes, if left unrecognised and 
unmanaged, is likely to be a high risk of EPS. A summary of this model is displayed below (Figure 
2-5). The purpose of this thesis is to investigate the roles that local and systemic inflammation are 
playing, whilst seeking to establish clinically useful biomarkers.  
Figure 2-5: Pattern of Cumulative Membrane Damage During Peritoneal Dialysis 
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3 Methods and Materials 
3.1 Studies 
3.1.1 Stoke PD study  
This is a single centre, prospective, cohort study commenced in 1990 by Professor Simon Davies. All 
patients commencing PD in University Hospital of North Staffordshire were included and 
demography recorded at this point. Routinely collected clinical data was also recorded 6 monthly, 
including blood tests, PET’s (D/P Cr and UF capacity), adequacy measurements (both renal and 
dialysis) and PD prescription including dialysate glucose exposure, as well as peritonitis events when 
they occurred. The outcome at the end of PD and the eventual date of death were also recorded. 
The Stoke comorbidity score was validated in this study (167) and this was subsequently available for 
all patients.  
The database started as a spreadsheet but iteratively evolved into a bespoke Access database 
(PDDB) which is used as both a clinical and research tool (see Section 3.2.1 below for details). The 
data has been validated through numerous previous studies on longitudinal change in peritoneal 
function, and its relationship to mortality, peritonitis and dialysate glucose exposure.(17,32,42,56) At 
the time of use in this thesis, there were 692 patients included. 
3.1.2 GLOBAL Fluid Study 
This is a multi-centre, multi-national, prospective, cohort study commenced in 2002 by Professors 
Simon Davies and Nick Topley and funded by Baxter Healthcare. The same clinical and demographic 
data as in the Stoke PD study was collected, including the Stoke comorbidity score, but a dialysate 
and plasma sample was also taken when clinical samples were being acquired (i.e. not during fasting 
conditions). As the study was a pragmatic, large study with a limited budget the timing of sample 
acquisition was not strictly mandated but occurred during either PET or occasionally adequacy 
testing.  
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The regularity of the data acquisition was allowed to vary according to the local centres practice 
pattern (e.g. in Stoke, data and samples were collected every 6 months). 16 centres from 6 countries 
recruited patients (see table Table 3-1)  
Table 3-1: List of GLOBAL Fluid Study Centres 
Country Centre 
Included in 
initial analysis 
Patient 
Numbers 
UK 
University Hospital of North Staffordshire, 
Stoke-on-Trent 
Yes 209 
Ipswich Hospital, Ipswich Yes 25 
Addenbrooke’s Hospital, Cambridge Yes 27 
Morriston Hospital, Swansea Yes 118 
Manchester Royal Infirmary, Manchester Yes 116 
University Hospital of Wales, Cardiff No 178 
Queen Elizabeth Hospital, Birmingham No 9 
Canada 
Dr. Georges L.Dumont Hospital, Moncton  Yes 41 
Edmonton General Hospital, Edmonton Yes 70 
Korea 
Yeungnam University Hospital, Daegu Yes 55 
Soon Chun Hyang University, Seoul Yes 
53 included 
(30 excluded 
due to 
missing 
batch of 
samples) 
Kyungpook National University Hospital, 
Daegu 
Yes 245 
Hong 
Kong 
Princess Margaret Hospital, Kowloon 
No 4 
Israel 
Carmel Hospital, Haifa No 18 
Assaf Harofeh Hospital, Zrifin No 18 
Belgium University Hopsital of Ghent, Ghent No 20 
 
The dialysate and plasma samples were kept locally then transferred in batches for storage at the 
central laboratory at Cardiff University School of Medicine, with all storage at -800C. Clinical data on 
CRF’s was also sent there for input onto the Global Database, unless the units used PDDB. 
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3.1.3 AnzData 
AnzData is a registry funded by Kidney Health Australia, the New Zealand government and the 
Commonwealth through the Organ and Tissue Authority which collects a limited dataset on all 
dialysis and transplant patients throughout Australia and New Zealand. Data is collected by a web 
based data form as events occur and by an annual paper-based survey, with data held at the Royal 
Adelaide Hospital. The data has been collected since dialysis commenced in these countries and has 
been extensively validated, with 22 publications in 2012 alone. 
Data is collected on basic demography, comorbidity and dialysis details. Comorbidity is collected 
through specific questions for chronic lung disease, coronary artery disease, peripheral vascular 
disease and cerebrovascular disease, diabetes and smoking, as well as a free text box to enter other 
comorbidities. PD specific data collected includes the initial PET D/P Cr result, adequacy results for 
dialysate and residual renal function and type of PD solutions used as well as a specific form to 
report instances of peritonitis. There is also a data dictionary specifying causes of dialysis modality 
switching and causes of death that are recorded. 
3.1.4 Scottish Renal Registry 
Data from Scottish renal units are available from 1960 with a small data set which was initially sent 
to the European Renal Association- European Dialysis Transplant Association (ERA-EDTA) registry. In 
1991 a computer based registry was established for patients receiving RRT for ESRD in Scotland, 
funded by the National Health Service in Scotland. 
Data collection is through a paper based form, with routine collection of demography and dialysis 
details but not comorbidity. PD details include peritonitis details and dialysate adequacy. EPS data 
was collected for a specific project (168) where all 10 renal units were contacted and asked to 
identify all EPS patients and the diagnosis was then independently validated by the study team. The 
data has been extensively validated by the Registry’s internal processes, with numerous publications 
resulting. 
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3.1.5 PD-CRAFT 
Data from this study was not used directly in this thesis but will be briefly described as it underpins 
the strategy described in Chapter 8, as well as providing some of the opportunities for further work 
described in Section 10.4.  
The primary aim of this National Institute for Health Research Research for Patient Benefit grant 
funded study is to validate a prognostic model for EPS, which is being developed with AnzData and 
SRR data. It is an observational cohort study, with all UK patients on PD eligible for inclusion but with 
a focus on prevalent PD patients. Standard demographic and clinical data, including peritoneal 
membrane function testing where it is routinely performed, will be collected and patients will be 
followed up until study end or death. Currently, 43 UK renal centres are recruiting and the target 
patient number is 1,600 with over 700 recruited to date. 
An ancillary study, funded by the Baxter Extra-mural Grant Programme, is collecting dialysate and 
plasma samples from 300 long term PD patients, providing a resource to check candidate biomarkers 
as predictors of EPS. A further ancillary study is collecting data to examine markers associated with 
glucose metabolism as well as abdominal circumference. 
 
3.2 Data Validation and Integrity 
3.2.1 Database design 
The study database (Peritoneal Dialysis DataBase, PDDB) is a bespoke database which evolved over 
time, building on the GFS database and the Stoke PD study database, which is designed specifically 
for clinical PD studies. A Microsoft Access database was originally developed by Dr Kieron Donovan1 
from Cardiff for the GFS, and functionality was added by Dr James Chess2 for the Swansea Prevalent 
                                                          
1 Consultant Nephrologist, University Hospital of Wales, Cardiff 
2 Consultant Nephrologist, Abertawe Bro Morgannwg University Health Board, Swansea 
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Study. This structure was then significantly reworked by Dr Christopher Huckvale3, incorporating a 
lot of the structure that Prof Simon Davies had developed for the research database for the Stoke PD 
study, into what is now PDDB. A PDDB copy is used for the ongoing Stoke PD study, with separate 
copies used for the Global Fluid Study (see study descriptions for description of data in these 
studies). 
PDDB has itself has evolved iteratively, with the latest version being 4.16 and now incorporating the 
functions in Table 3-2. 
Table 3-2: PDDB Functions 
Data type/range constraints 
Internal data consistency checks 
Extraction of anonymised encrypted consented data only 
Patient level graphical timeline display of data 
Automatic Backup 
 
3.2.2 Data entry and checking procedure 
Data was managed in different ways depending on the centre involved. For most centres data was 
recorded on paper based Case Report Forms, then transferred to Cardiff for entry into the study 
database, but for Stoke data was entered directly into PDDB as it is used for clinical management. 
For Ipswich, Manchester and Cambridge data was initially entered in Cardiff via CRF but 
subsequently a centre-specific version of the data was created and this was used for direct data 
entry at the centres. For the final analysis, all centre-specific versions were combined into an 
analysis spreadsheet. 
 
                                                          
3 Clinical Research Fellow, Dept of Primary Care and Public Health, University College London 
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Table 3-3: Data Checking Processes 
Validation on entry to database 
Database allowed ranges 
PDDB automatic checks 
Missing Data Check 
Data Values Check 
Data Sense Checking 
 
Data checking occurred at several stages as shown in Table 3-3. The missing data check, the data 
values check and the data sense checking were performed on centre-specific versions using 
Structured Query Language (SQL), and issues resolved with the individual units if possible. The data 
sense checking rules are illustrated in 11.4.  
3.3 Measurements 
3.3.1 Inflammatory Markers 
Enzyme-Linked Immuno-Sorbent Assays (ELISA) are a standard laboratory method used to detect a 
very wide range of antigens. An antibody specific to the antigen of interest is bound to a plate or 
well and the solution of interest is applied. The solution is washed off and a second ‘detection’ 
antibody is applied. An antibody to the detection antibody is then applied, but it is conjugated to an 
enzyme that will generate a signal.  
Electrochemiluminescence (ECL) is a modification of this process where an electrically generated 
charge triggers a chemical reaction that leads to luminescence. It has the benefit of using small 
volumes, rapidity and being suitable for use in a multi-array plate. It is also sensitive as the trigger 
(electrical) is separate from the detection method (luminescence).  
The technique used for analysis of the GFS samples (Sections 4, 5 and 6) was ECL, using a Multi-Array 
4-spot inflammatory plex from Meso-Scale Discovery (MSD). This assays for human interleukin-1β 
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(IL-1β), tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin-6 (IL-6) and they were 
run by Miss Ann Kift-Morgan and Mrs Charlotte James at Central Biotechnology Services, Cardiff 
University. 
3.3.2 Peritoneal Solute Transport Rate 
In all studies involved in this thesis, the method used for measuring PSTR was the D/P Cr derived 
from the 4 hour PET. All measurements were performed locally, and any correction for dialysate 
glucose concentrations was locally determined.  
3.3.3 Ultrafiltration Capacity 
As in the case of PSTR, all measurements of UF capacity were based on the 4 hour PET although the 
glucose concentration used was either 2.27% or 3.86%. Local corrections for bag overfilling were 
applied.  
3.4 Statistical Models 
3.4.1 Linear regression 
The basic technique of simple linear regression is to model the relationship between a response 
variable, y, and a predictor variable, x, using linear coefficients with values estimated from the 
dataset. An example of the use of this would be to model the relationship between PSTR and 
dialysate IL-6 levels, allowing quantification of the relationship and a test of whether this 
relationship is stronger than is likely to have occurred by chance. 
Equation 3-1: Simple Linear Regression 
 =  +    + 	 
Where y = response variable, x = predictor variable, i = individual within the dataset and ε = 
unexplained variation, or residual.  
3.4.1.1 Multivariable linear regression 
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Simple linear regression with one predictor variable is easily extended to multiple variables. Using 
the example of regressing dialysate IL-6 levels on PSTR, this could be extended to regressing a variety 
of other variables simultaneously. If the dialysate IL-6 was significantly associated on univariable 
regression but was no longer significant on multivariable testing, this would imply that the 
univariable association was most likely due to dialysate IL-6 correlating with another variable that 
had a ‘true’ underlying relationship with PSTR.  
Equation 3-2: Multivariable Linear Regression 
 =   +  
 ,


+ 	 
where there are n predictor variables. There are some important assumptions for these models. 
Firstly, observations have to be independent of each other e.g. if repeated observations are taken 
from one subject, they will be more closely correlated than others and therefore not independent. 
Deviation from this assumption results in correlated residuals. Secondly, for the most commonly 
used forms of this model, the residuals must be normally distributed which typically involves the 
dependent variable being normally distributed. Thirdly, homoscedasticity should hold, where the 
residuals have a constant variance plotted against the predicted dependent variables. Fourthly, the 
predictor variables should not demonstrate multicollinearity. This occurs when the predictor 
variables are highly correlated, causing the estimated variance in the predictor coefficient to be 
inflated. 
3.4.1.2 Analysis of clustered data 
If the dataset to be analysed contains data that is clustered, as is the case for chapters 4, 6, 7 and 9, 
this breaks the assumption of independence of errors. Clustered data commonly occurs when 
repeated measures are taken from one person, or if data on multiple individuals from several 
centres are collected. Data from different hospitals is one such source as different hospitals tend to 
serve populations that differ in many ways that are both measurable (e.g. ethnicity, socioeconomic 
deprivation) and unmeasured (e.g. genetic differences, unknown environmental factors). To assess 
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level of variance accounted for by clustering, the intra-cluster correlation coefficient (ICC) is used. If 
a model is developed 
Equation 3-3: Simple Random Effects Model 
 =   +   +  	 
for i level 1 units (or patients) and j level 2 units (or hospitals) such that yij represents the i’th subject 
from the j’th centre, with µ = level 2 residual and  ε = level 1 residual then the variance is partitioned 
into σµ2 and σε2. The ICC is then defined as 
Equation 3-4: Intra-cluster Correlation Coefficient 
 =  

( +  ) 
If the ICC is significant then estimates from standard linear regression will be biased and the 
standard error will be misleadingly low with an increased chance of a type I error. To get around this, 
multilevel models have been developed: 
Equation 3-5: Multilevel Linear Regression 
 =   + 
 ,


+  + 	 
for n covariates. This is a basic form with only a random intercept (intercept = α + ) but it can be 
adapted to include random slopes by replacing βk with (βk + γj) where γj is a random effects 
component varying between level 2 units. More levels can be created to allow, for example, 
grouping by country, and hospital and patient. When the residuals are normally distributed, these 
models are also referred to as linear mixed models, but they can incorporate continuous non-
normal, binary and categorical responses in generalised linear mixed models. These models were 
used to analyse: 
• determinants of dialysate and plasma IL-6 and PSTR (chapter 4) 
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• determinants of inflammatory cytokines and PSTR to establish whether they differed 
between patients with subsequent EPS and those without (chapter 6) 
• whether dialysate glucose load independently predicted random blood glucose levels 
(chapter 9) 
Other techniques are available to analyse clustered data. These include generalised estimating 
equations which, although more robust to misspecification, provides population-averaged 
coefficients, does not allow for analysis of the different levels of variation and requires careful 
handling of missing data. Repeated-measures analysis of variance has more restrictive assumptions 
including the same number of measures per cluster and sphericity, where there is constant variance 
and covariance. 
3.4.2 Survival Analysis 
3.4.2.1 Survival and hazard functions  
Longitudinal studies often measure events that may occur during follow up, most commonly death 
in the medical literature, and they require a particular analytic approach, as is the case for analyses 
in chapters 4, 8 and 9. A key principle for these survival analyses is the survival function, S, defined 
as the probability of the event of interest occurring after a given time: 
Equation 3-6: Survival Function 
() = Pr ( > ) 
where t is time, Pr = probability and T is a random variable denoting time of death. A Kaplan-Meier 
plot provides an estimate of this function. The cumulative incidence function of T, (F(t)), is given by  
Equation 3-7: Cumulative Incidence Function 
 () = 1 − () 
A further concept is the hazard function, λ, which represents the event rate at a given time: 
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Equation 3-8: Hazard Function 
#() =  lim'(→*  
Pr( ≤  <  + - |  ≥ )
-  
This is linked to the survival function through the cumulative hazard function, Λ, defined as the 
integral of the hazard function and therefore the accumulated hazard over time but which has no 
upper bound: 
Equation 3-9: Cumulative Hazard Function 
0() =  1 #(2)-2
(
*
=  −log () 
Censoring, where follow up is stopped before the event of interest (right censoring), is common in 
survival studies and any analysis must take this into account. 
3.4.2.2  Cox models 
One of the most widely used models is the Cox proportional hazards model, as this is a 
semiparametric model where the baseline hazard function is not specified: Multivariable Cox models 
were used to examine the relationships between patient survival and: inflammatory cytokines 
(chapter 4), variables available for a prognostic model of EPS (chapter 8) and random blood glucose 
levels (chapter 9). 
Equation 3-10: Cox Model 
#(|) = #*()5(67897:⋯: 6<89<) 
Results from the Cox model are typically given as a hazard ratio (i.e. the exponentiated value of the 
coefficient β). The Cox model also has the advantage of being able to incorporate time varying 
effects, whereby a predictor value can change over time, or the effect of the predictor can change. It 
is also possible to adjust for an effect without having to estimate the effect by performing a 
stratified analysis where the strata are incorporated into the baseline hazard. 
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The assumptions of the Cox model are: non-informative censoring (informative censoring occurring 
when cases are censored by a non-random method), and proportional hazards, whereby the effect 
of a unit change in predictor variable remains constant over time. The former issue is avoided by 
study design and the latter issue is tested for by a variety of methods, such as log-log plots or 
regressing Schoenfeld residuals on time. 
3.4.2.3 Competing Risks 
Cox models perform very well for single outcomes such as death but there are many situations in 
medical studies where more than one mutually exclusive outcomes are possible, as found in chapter 
8. If any of these multiple outcomes is non-random, then a Cox model of another outcome has the 
non-informative censoring assumption violated. Furthermore, if predictor variables associate with 
more than one outcome then a Cox model cannot provide estimates of the probability for an 
individual of experiencing an event, as this will be affected by the effect of the other events. One 
consequence of applying simple survival analysis techniques is that the Kaplan-Meier estimator of 
the survival function will overestimate the risk of an event. 
A common situation would be a study of an event other than death and a standard survival analysis 
would treat death as a censoring event and those subjects who die would be treated as remaining at 
risk of a further event. If age affected the event of interest, then the effect on the incidence of the 
event would also depend on the incidence of death but this would not be apparent from a Cox 
model. This is a particular concern for EPS as this is strongly associated with a prolonged duration of 
PD, but patients with a high risk of death are unlikely to survive for long enough to be at a significant 
risk of EPS. 
A better alternative is to use a competing risks (CR) analysis, although it is recommended that this is 
done in conjunction with a Cox model of a cause-specific hazard to aid interpretation. For a CR 
analysis, use is made of the cumulative incidence function (CIF) providing the probability of an event 
having occurred by a given time point, rather than the survival function referred to above as the 
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interpretation of S is more complicated in the CR scenario. The CIF for cause z, with a survival 
function S defined as survival free from any event, covariates represented by X and a cause specific 
hazard λ is defined as: 
Equation 3-11: Cumulative Incidence Function in Competing Risks 
 =() =  1 #=(2|>)(2)-2
(
*
  
This explicitly states that the risk of any event is dependent on other events not occurring. The sum 
of the CIF’s for all events are then equal to 1 – S(t). 
As can be seen from the equations above, for a Cox model the CIF can, with mathematical 
transformations, be linked directly to the hazard, but for a competing risks scenario, the CIF now 
depends on other events too so the effect of a covariate on the CIF is no longer clear. Because of this 
Fine and Gray (169) developed the subdistribution hazard, h, which links a covariate directly to the 
CIF:  
Equation 3-12: Subdistribution Hazard 
ℎ() =  lim'(→*
Pr ( ≤  <  + -, @ = 1| ≥  ∪ ( ≤  ∩ @ ≠ 1)
-  
Equation 3-13: Subdistribution Hazard and Cumulative Incidence Function 
ℎ(|) =  − log {1 −  (|)}-   
This models the effect of a covariate upon the overall risk of an event, taking into account the effect 
upon competing events. The CR model uses this in a very similar method to the Cox model: 
Equation 3-14: Competing Risks Model 
ℎ(|) =  ℎ,*()5(67897:⋯: 6<89<) 
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In this model, the proportionality assumption still holds, the baseline subhazard does not require 
specification and the results are reported as subdistribution hazard ratios.  
Because of the benefits of a competing risks model, this was used to establish independent 
predictors of EPS taking into account the risk of death as the first step to establishing a prognostic 
model for EPS (chapter 8).  
3.4.3 Fractional Polynomials 
One of the problems with normal linear regression is that relationships are assumed to take 
particular forms. Usually this will be a simple straight line relationship as demonstrated in Equation 
3-1 and Figure 3-1, but if the true relationship between them assumes a different form, as in Figure 
3-2, a linear relationship is at best inaccurate. The possibility that PSTR follows a non-linear path with 
time is explored in chapter 5. 
 
Figure 3-1: Linear Relationship Between 2 variables 
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Figure 3-2: Linear Regression of Polynomial Relationship 
 
With standard regression if a non-linear relationship is suspected, quadratic terms can be applied 
but there is a practical limit on the number of different forms that can be tried. To achieve a 
regression fit without assumptions being made about the shape of the true fit, fractional polynomial 
regression tries different combinations of different transformations of the predictor variable to 
achieve the best fit of the response variable. An example of the regression equations tried is shown 
in Equation 3-15. 
Equation 3-15: Example Fractional Polynomial Equation 
 =  F +  G + GGlog () 
For each equation tried, a measure of the fit of the model (deviance = -2*log likelihood) is calculated 
and the best model is used. The transformations tried are from the ladder of powers and typically a 
limited range is necessary to provide a very wide range of potential fits e.g. {-2, -1, -0.5, 0, 0.5, 1, 2, 
3} where 0 = logarithmic transformation. The number of terms in the model is variable but again, 
-
50
0
0
50
0
10
00
15
00
y
0 5 10 15 20
x
Dashed line - Linear Regression, Complete line - Quadratic Regression
Linear Regression of Polynomial Relationship
 46 
 
typically only 3 or 4 provide a very wide range of fits. Other options that do not assume specific 
forms exist, primarily including locally weighted scatterplot smoothing (lowess) regression but this 
does not provide a regression function easily represented by a mathematical function and is 
therefore less easily reproduced. 
3.4.4 Missing Data 
As with all studies, the issue of missing data had to be considered in all of the analyses. There are 
generally considered to be 3 types of missing data, as shown in Table 3-4. 
Table 3-4: Types of Missing Data 
Missing Completely At Random (MCAR) 
Missing At Random (MAR) 
Missing Not At Random MNAR) 
 
Missing Completely At Random (MCAR) comprises data missing by a random method unrelated to 
the observed or missing data, such as a sample being lost or smashed. A wide range of analyses 
remain valid in this situation. 
If data is Missing At Random (MAR), it is related to observed data. An example of this would be if a 
study records a history of dementia, and patients with dementia are more likely to forget to return a 
questionnaire. Data from the questionnaire would then be related to history of dementia i.e. 
observed data.  
The last type of missing data is Missing Not At Random (MNAR), where the missing data is only 
related to unobserved factors. An example of this might be a sample that is missing because the 
patient had become unwell since the last record in a study and therefore missed having the sample 
taken.  
A variety of techniques can be used for missing data, summarised in Table 3-5. A complete case 
analysis excludes subjects missing any data but this is inefficient and can lead to biased estimates if 
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data is not MCAR. The Last Observation Carried Forward replaces the missing data with the previous 
data, but this significantly distorts means, distorting inferences, and variance/covariance, distorting 
significance testing.  
Table 3-5: Techniques for Handling Missing Data 
Complete Case Analysis 
Last Observation Carried Forward 
Imputation Methods 
• Simple Mean Imputation 
• Regression Mean Imputation 
• Multiple Imputation 
Available Case Analysis 
• Likelihood Models 
 
Imputation methods involve substituting missing values with values derived from another method. 
Simple techniques include simple mean imputation where the mean of a variable is used, but this 
produces an underestimate of variance, and tends to dilute measures of association. An 
improvement on this is regression mean imputation where the variable with missing data is 
regressed on another, and the expected value of the missing data is calculated and imputed. This 
produces unbiased means, measures of association and regression coefficients, but the variance 
remains underestimated so significance testing can be biased.  
Multiple imputation is a further development where the variable with missing data is regressed on 
other variables, using the results to inform a probability distribution from which a random value is 
drawn. This is repeated a number of times and the final analysis will be performed on each imputed 
dataset, with pooled estimates drawn. Estimates are less biased, but results are dependent on the 
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assumptions made and all imputation methods still rely on invented data. This technique was 
considered for use in chapter 4, but discarded as the final variables selected contained sufficiently 
small amounts of missing data to proceed with an available case approach. 
For available case analysis, all data is retained in the analysis and if likelihood estimates of 
coefficients are used, the resulting parameters are unbiased in the case of MAR and MCAR.  
3.4.5 Statistical versus Biological or Clinical Significance 
As with all studies, it is important to distinguish between results that are statistically or biologically 
significant. This is particularly true when studies are large as the statistical power can be large, e.g. 
the correlations in chapter 5 (some of which are ‘statistically significant’ but quite weak correlations) 
and the multilevel analyses in chapter 4. The survival analyses in the thesis are less affected by this 
as the statistical power comes from the event number, and this is substantially less than total 
number of study participants.  
Conversely, there are many benefits to large studies as well. It is possible to perform meaningful 
mortality analyses on the same population as used for other analyses, as in chapter 4. This is despite 
the fact that statistical power for survival analyses relies on event numbers (i.e. deaths) which are 
inevitably smaller than the total number of study participants. With large studies there will be 
greater precision in estimates of effect sizes. The increase in statistical power with large studies can 
compensate for any decrease in power arising from regression dilution bias due to measurement 
error, (170) such as may occur when samples have been shipped then stored for long periods of 
time. With large sample sizes, regression models can adjust for a far wider range of covariates, 
thereby improving the chances of identifying ‘true’ independent predictors of a given outcome. 
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4  Local versus systemic inflammation in peritoneal dialysis 
4.1 Summary 
4.1.1 Background 
Systemic inflammation, as evidenced by elevated inflammatory cytokines, is a recognised feature of 
advanced renal failure and predicts worse survival. Dialysate IL-6 concentrations are associated with 
variability in peritoneal small solute transport rate (PSTR) which has also been linked to patient 
survival. The purpose of this analysis is to determine the link between systemic and intra-peritoneal 
inflammation and establish their relation to membrane function and patient survival. 
4.1.2 Methods and Materials 
The Global Fluid Study is a multi-national, multicentre, prospective, combined incident and prevalent 
(n=959 patients) cohort study with up to 8 years follow-up. Data collection included detailed 
demography, comorbidity, modality, prescription and membrane function. Dialysate and plasma 
cytokines were measured by electrochemiluminescence.  
4.1.3 Results 
426 survival endpoints occurred in 559 incident and 358 prevalent patients from 10 centres in Korea, 
Canada and the UK. On entry to the study there was dissociation between systemic and intra-
peritoneal cytokine networks with evidence of local production within the peritoneum. After 
adjustment for multiple covariates, systemic inflammation was associated with age and comorbidity 
and was an independent predictor of patient survival in both incident and prevalent cohorts. In 
contrast, intra-peritoneal inflammation was the most important determinant of PSTR but did not 
affect survival. In prevalent patients the relationship between local inflammation and membrane 
function persisted but did not account for an increased mortality associated with faster PSTR. 
4.1.4 Discussion 
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Systemic and local intra-peritoneal inflammation reflect distinct processes and consequences in 
patients treated with peritoneal dialysis, so their prevention may require different therapeutic 
approaches; the significance of intra-peritoneal inflammation requires further elucidation. 
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4.2 Introduction 
Individual differences in peritoneal membrane function have been shown to influence clinical 
outcomes in peritoneal dialysis (PD) patients. In particular a high peritoneal solute transport rate 
(PSTR) has been linked to worse survival. (32,71) This association has been considered to be due to 
one of two main mechanisms – less efficient ultrafiltration and excess fluid reabsorption as a 
consequence of early loss of the glucose gradient during the dialysis dwell (68) or because high PSTR 
is a manifestation of the systemic inflammation commonly seen in advanced kidney 
failure.(167,171)The picture is further complicated by changes in PSTR due to acquired membrane 
injury with time on PD, (41) where in addition to reducing ultrafiltration by the above mechanisms it 
can be associated with a reduction in membrane efficiency (reduced osmotic conductance).(20)  
More recently it was shown that PSTR is associated with the amount of IL-6 in drained dialysate, 
which is present in higher concentrations than can be explained by diffusion from plasma, implying 
its local production.(99,101) Furthermore, individuals with genetic polymorphisms associated with 
increased IL-6 production, both systemically and locally, have increased PSTR (37,38) and worse 
survival.(172) Against this association being the main link between PSTR and survival is the 
observation that it is confined to patients treated with continuous ambulatory PD (71) whereas in 
more recent cohorts where automated PD (APD) predominates the effect disappears (173,174) or 
even reverses. (78) 
To date there are no studies linking dialysate cytokine profiles to survival and only small studies 
suggesting that dialysate IL-6 appearance reflects a wider activation of the local cytokine 
network.(101,175) The purpose of this first major analysis of the Global Fluid Study was to test the 
following hypotheses    (a) that intra-peritoneal and systemic inflammation are distinct entities, (b) 
that it is local not systemic inflammation that associates with membrane function (PSTR), (c) that 
different clinical factors associate with local and systemic inflammation, and (d) that systemic but 
not local inflammation predicts patient survival.  
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4.3 Methods and Materials 
4.3.1 Study design 
The Global Fluid Study is an international, multi-centre, prospective, observational cohort study 
designed to answer a series of research questions seeking to relate peritoneal membrane function to 
local and systemic biomarkers as predictors of predefined clinical endpoints (e.g. patient survival, 
membrane injury). It was open to any centre worldwide as advertised at international meetings. 10 
centres from the UK, Korea and Canada were finally included (see table 1 in supplementary material) 
in this analysis. An additional 6 centres (comprising 247 patients) were excluded based on a pre-
analysis assessment indicating poor data quality (more than 10 variables were missing more than 
10% of data) and it was judged unlikely that this could be improved upon due to logistic issues. 
Recruiting incident (within first 90 days of PD) and prevalent patients, enrolment commenced in 
June 2002, and finished in December 2008 (with some centres stopping before then), with follow-up 
censored at centre-specific dates during December 2010. Any patient on peritoneal dialysis was 
eligible for inclusion provided they could give informed consent.  The sample size was the maximum 
logistically feasible, as determined by each centre. Dialysate sampling was from a 4 hour peritoneal 
equilibration test (PET), with some centres also collecting samples from an overnight dwell. 
Simultaneous clinical data were collected and stored in a purpose built Peritoneal Dialysis Access 
database (PDDB). Ethical approval was obtained from the Multi-Centre Research Ethics Committee 
for Wales covering the UK, whilst local country ethics were obtained for other contributing 
countries. 
4.3.2 Prospective collection of routine clinical measurements 
Routine demography was recorded and comorbidity documented using the validated Stoke 
Comorbidity Index that both categorises patients into low (score 0), intermediate (score 1-2), and 
high (score >2) risk groups, and enables analysis by individual comorbidities within the index. Patient 
level ethnicity was not available so this was recorded as non-Korean vs Korean based on centre. 
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Routine blood, urine and dialysate tests were performed locally and, if necessary, converted into 
standardised SI units. 
PD related measurements included residual renal function (mean of urea and creatinine clearances), 
dialysis regime and dose, and peritoneal membrane function using the peritoneal equilibration test 
(solute transport rate: dialysate to plasma creatinine ratio (PSTR) and net UF capacity at 4 hours with 
2.27% or 3.86% glucose, corrected for flush volume, if included in the measurement). The glucose 
exposure rate was calculated as total grams of glucose within the daily dialysate, and the average 
daily glucose concentration was the total daily dialysate glucose/total daily dialysate volume 
(grams/litre). 
4.3.3 Sample analysis 
Dialysate and plasma samples were stored locally at -800C, then transferred frozen to a central 
laboratory in the UK. Plasma and 4 hour dialysate samples were assayed for IL-1β, TNF-α, IFN-γ and 
IL-6 by electrochemiluminescence immune assay, using the commercially available Pro-Inflammatory 
I 4-plex (Meso-Scale Discovery, Gaithersburg, Maryland, USA). Triplicate measurements were made, 
the mean of which was used.  
4.3.4 Statistical analysis 
Demographic features were compared with independent sample t-tests, Mann-Whitney U tests or 
chi-squared tests, depending on whether the variable was normally distributed, skewed or 
categorical. Similarly for centre effects, one-way ANOVA or Kruskal-Wallis was used (table 1). 
Pearson’s R was used for cytokine correlations with Sidak’s adjustment for multiple comparisons and 
a p value of 0.05 for statistical significance. The 3 pore model was used to predict 4 hour cytokine 
D/P ratios based on the predicted molecular radius. (13) For plasma values of 0 with detectable 
dialysate cytokine, a ratio greater than 1 was assumed; if both dialysate and plasma cytokine were 
undetectable, a ratio of 0 was assumed. 
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3 multilevel linear models for predictors of the continuous variables PSTR, and log10 transformations 
of dialysate and plasma IL-6 concentrations in 3 separate models were run to account for the 
observed centre effects by introducing a centre level residual as well as the usual person level 
residual. As an exploratory analysis, no adjustment of significance levels was made for multiple 
hypotheses tested. Random intercept models were fitted, (random slopes models were attempted 
but did not converge). The variable selection method was to include all cytokine measures and all 
the important clinical and available demographic variables. Dialysate IL-1β was dropped and only 1 
measure of BP included due to multi-collinearity. Diabetes and comorbidity were included in 
separate models as existing literature suggests diabetic effects may be important independently of 
the comorbidity score, despite being highly correlated. (26) The duration of PD was included as 
either a linear or linear plus quadratic term in the incident group, as suggested by existing literature. 
(31) The Iterative Generalised Least Squares method was used for coefficient estimation and 
residuals were checked for normality. For clarity of interpretation, 23 patients with a previous 
episode of PD were excluded from the prevalent group multilevel modelling. 
We included cytokine results in the PSTR model as either concentrations (as shown) or appearance 
rates, and selected the type that provided the best goodness of fit as measured by -2LL values. The 
selected variable type was then used in all other analyses. 
Cox modelling, stratified by centre, was used for survival analysis, with robust standard errors. 
Hazard Ratios for cytokines quoted are for a log10 change in concentration. Proportional hazards 
were checked with log-log plots, scaled Schoenfeld residual plots and significance testing. Dialysate 
IL-1β was excluded due to high collinearity. 
MLWin v2.26 (Centre for Multilevel Modelling, Bristol University) was used for the multilevel 
modelling. All other analyses were run using Stata IC 12.1 (StataCorpLP, Texas). Missing data, which 
ranged between 0 to 4.8% for different variables, were considered missing at random and complete 
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case analysis was used. Loss to follow up was trivial (16 incident and 8 prevalent patients, with 22 
from one centre and all patients from that centre being dropped in a sensitivity analysis). 
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4.4 Results 
4.4.1 Description of incident and prevalent cohorts  
The clinical characteristics of the 959 patients included in the analyses are shown in Table 4-2. 
Comparing the incident and prevalent groups the latter used more icodextrin and APD, greater total 
dialysate volumes and had lower urine volume.  Although the use of APD was relatively low, this was 
much more likely to be prescribed in patients with faster PSTR (0.78 v 0.7, P=0.0005). 
For most patient characteristics and prescription practices there were highly significant centre 
effects (Table 4-1) and for this reason all linear regression models used multi-level methods. 
Table 4-1: Intra-cluster correlations for PSTR, dialysate and plasma IL-6 
Variable Incident Prevalent 
PSTR 
0.17 
(0.09, 0 – 0.34) 
0.17 
(0.09, 0 – 0.35) 
Dialysate IL-6 
0.18 
(0.09, 0 – 0.36) 
0.09 
(0.08, 0 – 0.32) 
Plasma IL-6 
0.08 
(0.05, 0 – 0.17) 
0.005 
(0.016, 0 – 0.037) 
Data presented = ICC (SE, 95% CI) 
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Table 4-2: Study Population Characteristics 
  
Incident 
N = 575 
Centre Effect  
(p value) 
Prevalent 
N=384 
Centre Effect  
(p value) 
Difference between incident 
and prevalent (p value) 
Age (years) 55.6 (15.3) 0.001 54.2 (15.2) 0.037 NS 
Female Gender 38.4% NS 46.4% NS 0.05 
Korean 37.2% By definition 36.2% By definition NS 
BMI (kg/height2) 25.2 (4.7) <0.001 25.3 (4.7) <0.001 NS 
Total dialysate volume (litres) 7.96 (1.29) <0.001 8.38 (1.87) <0.001 <0.001 
Blood pressure (mmHg) 136/80 (21/12) <0.001 135/81 (20/12) NS NS 
Duration of PD (days; median) 40 (28, 55) <0.001 360 (169, 609) <0.001 <0.001 
4 hour PSTR 0.71 (0.12) <0.001 0.71 (0.12) <0.001 NS 
UF capacity 431 (365) <0.001 439 (340) <0.001 NS 
Albumin 35.0 (5.2) <0.001 35.4 (4.8) 0.06 NS 
Haemoglobin 11.0 (2.2) <0.001 11.2 (1.8) <0.001 NS 
Urine volume (litres; median) 0.90 (0.46, 1.44) <0.001 0.60 (0.19, 1.21) 0.001 <0.001 
Biocompatible solution usage 19.3% <0.001 16.1% <0.001 NS 
Icodextrin solution usage 19.1% <0.001 28.0% <0.001 0.002 
Comorbidity 
(Low/Intermediate/High) 
35.6/56.8/7.6% <0.001 43.9/48.5/7.6% <0.001 NS 
Use of APD 6.0% <0.001 15.1% <0.001 <0.001 
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4.4.2 Demonstration that local peritoneal and systemic inflammation is partly 
uncoupled 
To establish that dialysate IL-6 is representative of a localised inflammatory process is it necessary to 
demonstrate both local production and an association with other pro-inflammatory cytokines that is 
independent of plasma. Taking molecular size into account, 87% of subjects had dialysate IL-6 
concentrations higher than predicted by diffusion across the peritoneal membrane (Figure 4-1). 
Values for IL-1, TNF-α and IFN-γ were 33.3%, 6.9% and 45.7% respectively. Within the peritoneal and 
circulatory compartments there were moderate to strong correlations between the measured 
cytokines reflecting localised activation of pro-inflammatory networks (Table 4-3). In contrast, 
correlations between dialysate and plasma were either absent or weaker than those seen within 
plasma or dialysate.  
Figure 4-1: Scatterplot of Dialysate/Plasma Concentration Ratio of IL-6 Against Duration of PD 
 
The line represents the ratio predicted by the 3 pore model (0.145) so all points above this line are 
predicted to represent local production.   
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Table 4-3: Correlation Coefficients Between Cytokine Concentrations 
Incident 
Dialysate Plasma 
IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ TNF-α 
Dialysate 
(n=563) 
IFN-γ 0.65             
IL-6 0.29 0.29           
TNF-α 0.82 0.74 0.42         
Plasma 
(n=557) 
IL-1β -0.004 0.005 -0.01 -0.07       
IFN-γ 0.0002 -0.01 0.11 -0.007 0.10     
TNF-α -0.05 -0.01 0.15* -0.03 0.08 0.51   
IL-6 0.05 0.09 0.28 0.04 0.13* 0.25 0.35 
Prevalent 
  
Dialysate 
(n=378) 
IFN-γ 0.61             
IL-6 0.21 0.32           
TNF-α 0.76 0.75 0.43         
Plasma 
(n=379) 
IL-1β 0.12 0.10 -0.02 0.09       
IFN-γ 0.04 0.05 -0.001 0.05 0.12     
TNF-α -0.07 -0.06 0.11 0.01 0.14 0.43   
IL-6 -0.02 0.11 0.27 0.07 0.15 0.24 0.29 
Sidak adjusted p values ≤0.001 in bold, * p 0.01-0.05, otherwise p>0.05. There were 548 and 374 
common observations between dialysate and plasma samples for incident and prevalent patients 
respectively. 
4.4.3 Local not systemic inflammation is the main determinant of PSTR 
Results of the multivariable, multilevel, linear regression models showing the associations with PSTR 
are displayed in table 3. Dialysate IL-6 concentration was the most significant association in both 
patient cohorts, a pattern observed in all of the participating centres. This was independent of 
patient factors (gender, race, BMI, BP, urine volume, diabetic status) and dialysis prescription, all of 
which had significant associations. For incident patients, the timing of the initial membrane function 
assessment had an effect that was not linear: tests done early, i.e. from baseline the PSTR rose for 2 
months, increasing by 0.08, then fell to a total gain of 0.06 by 3 months. In prevalent patients, higher 
PSTR was associated in a linear fashion with longer time on treatment. Cytokine concentrations 
produced a better model than appearance rates (Δ-2 LL = 36).  
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Table 4-4: Predictors of PSTR 
 Incident Prevalent 
 
Coefficient  
(95% CI) 
p value 
Coefficient 
(95% CI) 
p 
value 
Age 
(per decade) 
0.001 
(-0.005, 0.008) 
0.7 
-0.004 
(-0.012, 0.004) 
0.4 
BMI 
  -0.002 * 
(-0.005, -0.0001) 
0.04 
-0.0009 
(-0.004, 0.002) 
0.5 
APD usage 
-0.02 
(-0.06, 0.02) 
0.3 
-0.008 
(-0.04, 0.03) 
0.7 
Systolic BP 
(per 10mmHg) 
   0.005 * 
(0.0002, 0.009) 
0.04 
0.001 
(-0.004, 0.007) 
0.6 
Male Gender 
 0.02 * 
(0.003, 0.04) 
0.02 
 0.02 * 
(0.002, 0.05) 
0.04 
Duration of PD  
 
 0.08 x month ** 
(0.03, 0.13), 
 -0.02 x month2 * 
(-0.04, -0.003) 
<0.001 
  0.01 x year ** 
(0.004, 0.02) 
0.003 
Biocompatible Solution Usage 
-0.005 
(-0.02, 0.02) 
0.7 
 -0.04 * 
(-0.07, (-0.004) 
0.03 
Icodextrin Usage 
   0.06 ** 
(0.03, 0.09) 
<0.001 
 0.04 * 
(0.01, 0.07) 
0.01 
Average glucose concentration 
(per gramme/litre) 
   0.005 ** 
(0.002, 0.007) 
<0.001 
0.005 **  
(0.001, 0.008) 
0.004 
Dialysate IL-6  
  0.08 ** 
(0.06, 0.11) 
<0.001 
0.09 ** 
(0.07, 0.12) 
<0.001 
Dialysate TNF-α 
0.04 
(-0.03, 0.10) 
0.3 
-0.03 
(-0.1, 0.06) 
0.6 
Dialysate IFN-γ 
-0.009 
(-0.04, 0.02) 
0.6 
0.008 
(-0.03, 0.04) 
0.6 
Plasma IL-6 
-0.02 
(-0.06, 0.01) 
0.2 
0.006 
(-0.04, 0.05) 
0.8 
Plasma TNF-α 
0.02 
(-0.04, 0.09) 
0.5 
-0.05 
(-0.12, 0.02) 
0.2 
Plasma IFN-γ 
-0.009 
(-0.04, 0.02) 
0.6 
-0.02 
(-0.06, 0.03) 
0.4 
Plasma IL-1β 
0.02 
(-0.06, 0.11) 
0.6 
0.001 
(-0.09, 0.09) 
0.98 
Diabetic 
  0.02 * 
(0.001, 0.05) 
0.04 
0.004 
(-0.03, 0.03) 
0.8 
Comorbidity 
0.0005 
(-0.01, 0.01) 
0.9 
0.003 
(-0.01, 0.02) 
0.7 
Urine volume  
(per litre) 
   0.03 ** 
(0.01, 0.04) 
<0.001 
0.02 * 
(0.005, 0.04) 
0.01 
Korean 
0.08 * 
(0.01, 0.15) 
0.02 
0.05 
(-0.005, 0.11) 
0.07 
*p<0.05 **p<0.005 
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4.4.4 Determinants of local versus systemic inflammation 
Before proceeding to survival analyses it was necessary to determine, using the multilevel 
multivariable models, the clinical associations with local (Table 4-5) and systemic (Table 4-6) 
inflammation as defined by the dialysate and plasma IL-6 concentrations respectively. 
Local membrane inflammation was associated with older age, lower systolic blood pressure, use of 
icodextrin, local TNF-α and systemic IL-6 concentrations in incident and prevalent patients. Factors 
associated with systemic inflammation were similar where a reciprocal effect might be expected 
(e.g. the plasma and dialysate cytokines) but also included a relationship with comorbidity; in 
prevalent patients this was with the overall comorbid burden whereas in prevalent patients it was 
especially evident with diabetics (although the IL-6 levels were still different between the grades of 
comorbidity, one-way between subjects ANOVA, p=0.006).  
Sensitivity analyses excluding one centre with marginally less good data quality increased the 
significance of the association between plasma IL-6 and age (p=0.02) in prevalent patients. A 
supplementary analysis including PSTR as one of the covariates is included in Appendix A (Chapter 
11.1) 
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Table 4-5: Predictors of Dialysate IL-6 
 
 
Incident Prevalent 
Coefficient p value Coefficient p value 
Age  
(per decade) 
   0.04 ** 
(0.01, 0.06) 
0.002 
0.05 ** 
(0.01, 0.08) 
0.01 
BMI 
0.0009 
(-0.007, 0.009) 
0.8 
 0.008 
(-0.003, 0.02) 
0.2 
APD Usage 
-0.06 
(-0.21, 0.10) 
0.5 
0.2 
(-0.004. 0.3) 
0.06 
Systolic BP  
(per 10mmHg) 
 -0.02 * 
(-0.03, -0.002) 
0.03 
 -0.03 ** 
(-0.05, -0.002) 
0.03 
Male Gender 
0.04 
(-0.04, 0.11) 
0.3 
0.1 
(-0.0003, 0.2) 
0.051 
Duration of PD 
(per year) 
0.1 
(-0.6, 0.8) 
0.7 
0.02 
(-0.02, 0.05) 
0.4 
Biocompatible solution usage 
0.0007 
(-0.09, 0.09) 
0.99 
0.1 
(-0.04, 0.3) 
0.1 
Icodextrin Use 
  0.3 ** 
(0.2, 0.4) 
<0.001 
 0.2 ** 
(0.07, 0.3) 
0.003 
Average Glucose Concentration  
(per gramme/litre) 
  0.01 ** 
(0.004, 0.02) 
0.006 
-0.004 
(-0.02, 0.01) 
0.5 
Dialysate TNF-α  
  0.8 ** 
(0.6, 1.0) 
<0.001 
0.7 ** 
(0.3, 1.0) 
0.001 
Dialysate IFN-γ 
0.006 
(-0.1, 0.1) 
0.9 
0.02 
(-0.1, 0.2) 
0.8 
Plasma IL-6  
  0.3 ** 
(0.2, 0.4) 
<0.001 
0.3 ** 
(0.1, 0.5) 
0.001 
Plasma TNF-α  
-0.2 
(-0.4, 0.06) 
0.1 
0.2 
(-0.1, 0.5) 
0.2 
Plasma IFN-γ 
0.06 
(-0.06, 0.19) 
0.3 
-0.1 
(-0.3, 0.03) 
0.1 
Plasma IL-1β 
-0.1 
(-0.3, 0.3) 
0.9 
-0.05 
(-0.5, 0.4) 
0.8 
Diabetic 
0.01 
(-0.08, 0.10) 
0.8 
0.05 
(-0.08, 0.2) 
0.4 
Comorbidity 
0.02 
(-0.03, 0.06) 
0.5 
-0.004 
(-0.06, 0.05) 
0.9 
Urine volume  
(per litre) 
0.03 
(-0.02, 0.08) 
0.2 
-0.1 * 
(-0.2, -0.02) 
0.01 
Korean 
-0.02 
(-0.2, 0.2) 
0.8 
-0.2 
(-0.5, 0.1) 
0.3 
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Table 4-6: Predictors of Plasma IL-6 
 
 
Incident Prevalent 
Coefficient p value Coefficient p value 
Age 
(per decade) 
  0.02 ** 
(0.007, 0.04) 
0.004 
0.01 
(-0.009, 0.03) 
0.3 
BMI 
0.0001 
(-0.005, 0.005) 
0.96 
0.004 
(-0.002, 0.01) 
0.2 
APD Usage 
0.04 
(-0.06, 0.14) 
0.4 
0.003 
(-0.08, 0.09) 
0.9 
Systolic BP  
(per 10mmHg) 
0.003 
(-0.007, 0.014) 
0.5 
-0.009 
(-0.02, 0.004) 
0.2 
Male Gender 
0.05 
(-0.001, 0.09) 
0.06 
0.02 
(-0.03, 0.07) 
0.5 
Duration of PD 
(per year) 
-0.2 
(-0.6, 0.2) 
0.4 
0.02 * 
(0.0008, 0.03) 
0.04 
Biocompatible solution usage 
0.003 
(-0.05, 0.06) 
0.9 
-0.02 
(-0.10, 0.06) 
0.6 
Icodextrin usage 
0.04 
(-0.02, 0.11) 
0.3 
-0.02 
(-0.09, 0.05) 
0.6 
Average Glucose Concentration 
(per gramme/litre) 
0.003 
(-0.004, 0.009) 
0.4 
-0.002 
(-0.01, 0.005) 
0.5 
Dialysate IL-6  
  0.13 ** 
(0.07, 0.18) 
<0.001 
0.09 ** 
(0.03, 0.15) 
0.002 
Dialysate IFN-γ 
0.07  
(-0.003, 0.15) 
0.06 
0.04 
(-0.04, 0.1) 
0.3 
Dialysate TNF-α 
-0.2 * 
(-0.3, -0.005) 
0.04 
-0.1 
(-0.4, 0.06) 
0.2 
Plasma TNF-α 
  0.4 ** 
(0.2, 0.5) 
<0.001 
0.4 ** 
(0.2, 0.5) 
<0.001 
Plasma IFN-γ 
0.05 
(-0.03, 0.13) 
0.2 
0.2 ** 
(0.07, 0.3) 
0.001 
Plasma IL-1β 
0.2 * 
(0.001, 0.4) 
0.049 
0.3 * 
(0.07, 0.5) 
0.01 
Diabetic 
-0.05 
(-0.1, 0.007) 
0.09 
0.07 * 
(0.002, 0.15) 
0.045 
Comorbidity 
  0.05 ** 
(0.02, 0.08) 
0.001 
0.02  
(-0.01, 0.05) 
0.2 
Urine Volume 
(per litre) 
-0.02 
(-0.05, 0.01) 
0.3 
-0.009 
(-0.05, 0.03) 
0.7 
Korean 
0.03 
(-0.05, 0.11) 
0.4 
-0.04 
(-0.1, 0.1) 
0.4 
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4.4.5 Systemic not local inflammation predicts patient survival 
A total of 427 deaths occurred in the two cohorts (241 and 186 in the incident and prevalent groups 
respectively during median follow up times of 5.25 and 5.06 years) during the 8 year follow-up 
period. Using Cox modelling, survival of incident patients was independently predicted by age, 
cumulative comorbidity, plasma albumin, and systemic inflammation (IL-6 and TNF-α), whereas 
dialysate cytokines levels and PSTR had no effect (Table 4-7). Survival analysis in the prevalent group 
also found age, comorbidity, systemic IL-6 but not peritoneal inflammation, to predict death, with 
some additional differences. Plasma albumin did not predict survival whereas residual renal function 
was protective and a faster PSTR was associated with increased mortality. Sensitivity analyses 
excluding one centre with higher levels of missing data increased the significance of PSTR in 
prevalent patients (p=0.02) and excluding patients with previous episodes of PD treatment from the 
prevalent group made no difference. 
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Table 4-7: Predictors of Survival 
 
Incident Prevalent 
Hazard Ratio 
(95% CI) 
p value 
Hazard Ratio 
(95% CI) 
p value 
Dialysate TNF-α 
0.96 
(0.33, 2.82) 
0.95 
0.91 
(0.23, 3.63) 
0.9 
Dialysate IL-6 
 0.93 
(0.66, 1.31) 
0.7 
0.96 
(0.64, 1.43) 
0.8 
Dialysate IFN-γ 
1.19 
(0.70, 2.02) 
0.5 
1.20 
(0.65, 2.20) 
0.6 
Plasma IL-1β 
0.58 
(0.15, 2.19) 
0.4 
0.54 
(0.16, 1.77) 
0.3 
Plasma TNF-α 
3.41 * 
(1.26-9.24) 
0.02 
2.03 
(0.52, 7.93) 
0.3 
Plasma IL-6 
2.16 ** 
(1.23, 3.80) 
0.007 
2.69 ** 
(1.29, 5.59) 
0.008 
Plasma IFN-γ 
0.86 
(0.49, 1.50) 
0.6 
1.20 
(0.65, 2.21) 
0.6 
Age                    
(per year) 
1.06 ** 
(1.05, 1.08) 
<0.001 
1.06 ** 
(1.04, 1.07) 
<0.001 
Male Gender 
0.93 
(0.69, 1.27) 
0.7 
1.28 
(0.92, 1.79) 
0.1 
Comorbidity    
(per disease) 
1.68 ** 
(1.44, 1.97) 
<0.001 
1.37 ** 
(1.18, 1.58) 
<0.001 
Urine volume   
(per litre) 
0.95 
(0.76, 1.19) 
0.7 
0.65 ** 
(0.48, 0.87) 
0.004 
Duration of PD 
(per month incident) 
(per year prevalent) 
1.05 
(0.80, 1.19) 
0.7 
1.14 ** 
(1.04, 1.24) 
0.005 
Albumin            
(per 1 g/dl) 
0.94 ** 
(0.91, 0.97) 
<0.001 
0.99 
(0.95, 1.03) 
0.6 
PSTR                  
(per 0.1 increase 
in D/P Cr) 
1.09 
(0.98, 1.23) 
0.1 
1.18 * 
(1.003, 1.41) 
0.046 
BMI 
1.01 
(0.97, 1.05) 
0.6 
1.01 
(0.98, 1.04) 
0.6 
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4.5 Discussion 
This analysis of the Global Fluid Study clearly shows that systemic and local peritoneal inflammatory 
cytokine networks are to some extent uncoupled and that they have different consequences for 
patient survival. Local, subclinical peritoneal inflammation is demonstrated to be the strongest 
known factor associated with between patient variability in PSTR, independent of centre effects, and 
the lack of an association with survival refutes the prior hypothesis that fast PSTR increases mortality 
through its association with systemic inflammation. If anything, evidence points to intra-peritoneal 
inflammation being a contributor to systemic inflammation without influencing its association with 
mortality. 
Although the association between local inflammation and PSTR has been found in prior studies 
(99,101,175) none of these has had either the power or the degree of detailed clinical data to show 
its relative importance compared to previously demonstrated, much weaker, clinical associations. As 
with CANUSA,(176) ANZDATA(26) and the Stoke PD Study, (17,41) diabetics and males were found to 
have higher PSTR, whereas the association with increasing age, overall comorbidity and inverse 
relationship to BMI were not seen. This is also the first study to identify important centre effects and 
include adjustment for these in the analytic approach. These centre effects will reflect differences 
such as case mix and race, practice patterns related to dialysis and EPO prescription which could 
largely be adjusted for, but also differences in PSTR that are likely to reflect local variations in exactly 
how the peritoneal equilibration test (PET) is performed or biochemically analysed, as well as 
unknown factors. Timing of the initial PET showed a complex relationship from which it is possible to 
infer that there is an early increase in PSTR within the first four weeks of treatment with a 
subsequent fall before a longer term increase in keeping with previous reports.(17,30,31) Given the 
ANZDATA’s finding that race influenced PSTR (26) it is interesting that this was found to be higher in 
Korean patients, independent of IL-6 levels, suggesting that other genetic factors might be 
important. 
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It is difficult to disentangle the observed association between use of either icodextrin or higher 
glucose concentration solutions with higher dialysate IL-6 concentrations given that they also 
associate with PSTR and thus there may be some confounding by indication. However, icodextrin in 
combination with other solutions has been associated with increased solute transport, (55,177)  as 
have other biocompatible solutions at the commencement of treatment with PD.(50) One possible 
explanation is that more biocompatible dialysate improves local cell viability and thus facilitates the 
local production of  cytokines or vaso-active mediators.(53,178) In light of the recently published 
balANZ study in which use of a biocompatible solution was associated with disappearance of the 
increase in solute transport with time on PD,(50) it is interesting to note in this study that prevalent 
patients using these solutions had lower PSTR. 
The associations between plasma IL-6, other systemic inflammatory cytokines and comorbidity were 
to be expected and are in keeping with the previously described relationship between IL-6 
polymorphisms, comorbidity and survival in haemodialysis and PD patients.(111,172) More 
surprising is the association between plasma and dialysate IL-6. This could reflect the fact that 
genetically high IL-6 producers more readily synthesise more of this cytokine in any of the body 
compartments.(37) Alternatively, the high concentrations in dialysate, which in some of these 
patients was >1000 times that of plasma despite the diluting effects of two litres of instilled solution, 
reflects peritoneal membrane concentrations that could spill over into plasma. 
The relationship between systemic inflammation and survival, independent of age and comorbidity 
was as anticipated, although previous studies have not reported independent effects of TNF-α and 
IL-6 as observed here in incident patients.(179,180) There were other potentially important 
differences between the incident and prevalent cohorts, partly because prevalent patients are by 
definition a self-selected cohort. As would be expected, longer duration of PD was a risk factor for 
worse survival. Relative preservation of residual urine volume, in keeping with prior studies, is more 
important than for incident patients whereas it’s likely that the patients with the lowest plasma 
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albumin concentrations will have already died explaining the lack of association with survival. It is 
interesting to note that in these prevalent patients increased solute transport was associated with 
reduced survival; this may be because the relative importance of membrane function would be 
expected to increase as residual function becomes more critical. Although the use of APD at the start 
of PD in the GFS cohort is relatively low, it was used preferentially in patients with high PSTR and 
with double the frequency in prevalent compared to incident patients. In contrast to most published 
cohorts, icodextrin use was high.  
This study has a number of limitations. Despite the depth and completeness of the clinical data 
collected and attempts to account for important observed centre effects, it must be acknowledged 
that there are likely to be practice patterns and local factors that remain poorly understood and/or 
unmeasured along with other residual confounders. Whilst the study used 10 centres from 3 
countries a degree of selection bias might be present as the selected centres had better data quality. 
As with any observational study, direction of causality must always be questioned. The genetic 
associations between high producing IL-6 polymorphisms and membrane function, effectively 
Mendelian randomisation experiments, strongly suggest that activation of local cytokine networks 
are the cause rather than the consequence of increased PSTR, which is also biologically plausible. 
However there were a number of statistical associations demonstrated that do not have clear 
biological explanations. For example, a lower systolic blood pressure was associated with higher 
dialysate but not plasma IL-6 concentration. These require reproducing in separate cohorts and 
further investigation. Despite clear evidence of local production in some patients, average dialysate 
TNF-α levels were less than predicted by the 3 pore model, but the results were biologically plausible 
and compatible with previous studies.(103) Cost and feasibility dictated that we limit our 
inflammatory cytokine profiles to just four; other studies using larger panels of biomarkers confirm 
that these are representative of activation of the inflammatory pathway in general. (101,175,181) 
Controversy exists as to whether dialysate biomarkers should be expressed as absolute 
concentrations or appearance rates. In our multivariable analysis, dialysate IL-6 concentrations 
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produced better models than appearance rates suggesting biological effects are determined by 
concentration, mediated by changes over log orders. Correcting for appearance rates produced 
worse models, probably because the dialysate samples were all standardised to 4 hour dwells and a 
recent study has shown a linear increase in IL-6 concentrations with time. (182) 
In conclusion, dialysate IL-6 concentration, representing local subclinical intra-peritoneal 
inflammation is the most significant known predictor of PSTR, but does not determine patient 
survival. Intra-peritoneal and systemic inflammation are independent, except for an association in 
the case of IL-6. Independent of inflammation, higher PSTR may still be associated with worse 
survival in prevalent patients. The clinical implications of these findings are that attention to 
membrane function in dialysis prescription rather than switching off membrane inflammation per se 
is important for patient survival. The relevance of membrane inflammation is yet to be determined. 
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5 Longitudinal changes in inflammation and peritoneal solute 
transport 
5.1 Summary 
5.1.1 Background 
The current literature on the longitudinal changes in PSTR, and peritoneal and systemic 
inflammation is confused, with studies sampling at different time points producing apparently 
contradictory results. The GLOBAL Fluid Study had samples from many time points, allowing an 
analysis without pre-supposed hypotheses about the nature of these changes. 
5.1.2 Methods and Materials 
We used the GFS, a multi-national, multicentre, prospective, combined incident and prevalent 
(n=959 patients) cohort study with up to 8 years follow-up. Data collection included demography 
and membrane function, with dialysate and plasma cytokines measured by 
electrochemiluminescence. PSTR and inflammatory cytokines were plotted against duration of PD 
with fractional polynomials and based on this, time was divided into 0-2, 2-18 and >18 months. 
Correlations were used to test the significance of these apparent changes over time. 
5.1.3 Results 
PSTR, systemic inflammatory cytokines and dialysate IL-6 increased between 0 and 2 months, 
dialysate inflammatory cytokines all fell between 2 and 18 months, and >18 months PSTR increased 
and plasma TNF-α fell. 
5.1.4 Conclusions 
The start of PD appears to be associated with an increase in systemic inflammation, possibly 
mediated by absorption of dialysate IL-6 and in the medium term, there appears to be a fall in 
peritoneal inflammation. These results are hypothesis generating. 
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5.2 Introduction 
As discussed in the Introduction (Chapter 2.2.3.1) there are changes in PSTR with time on PD, and as 
we have confirmed with the GFS, dialysate IL-6, which is indicative of peritoneal inflammation, is the 
strongest predictor of PSTR but whether there are temporal changes in dialysate IL-6 to explain the 
changes in PSTR is not known.  
PSTR increases from the first to the fourth week of PD, (30) but there may, (31) or not may not, (41) 
be a fall in PSTR from the first to the fifth or sixth months. Dialysate IL-6 has been examined at 
baseline and at 1 year by Pecoits-Filho et al (99) and at 1, 6 and 12 months by Cho et al, (100) but 
both studies found increases over these time frames, an apparently contradictory result given that 
dialysate IL-6 is the strongest known predictor of PSTR (Chapter 4). The Pecoits-Filho et al and Cho et 
al studies also analysed systemic IL-6 levels at these time points, finding a rise with time and stable 
levels respectively. 
As the GFS did not specify when PET’s with dialysate and plasma samples were to be taken, it 
represented an opportunity to study changes in both PSTR and inflammatory markers over time 
without examining them at arbitrary time points as has been done previously. This allows us to look 
for changes between these time points to try and reconcile the different findings. 
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5.3 Materials and Methods 
All patients from the Global Fluid Study were included and the study design, routine clinical 
measurements and sample analysis are the same as in sections 3.3.1, 3.3.2 and 3.3.3 respectively. 
Patients were not divided into incident and prevalent cohorts but analysed together. 
In an exploratory analysis, logarithmically transformed dialysate and plasma cytokines and D/P Cr 
were separately included in a fractional polynomial regression against the duration of PD using 3 
polynomial terms. This allows modelling of the relationship without assuming a particular form (e.g. 
linear). Because of the scarcity of data at longer time points, this was restricted to the first 5 years of 
PD.   
The patients were then divided into early (0-2 months), medium (2-18 months) and late (>18 
months) groups, these divisions having been selected as representative of the nadirs and peaks in 
the apparent trends over time visible in the graphs, with the exact timing of the changes calculated 
from the polynomial regression equation. Pearson correlation coefficients were calculated for 
cytokine measurements and D/P Cr with the duration of PD based on these divisions. As this was an 
exploratory analysis, no correction was made for multiple tests.  
To investigate an unexpected finding for plasma TNF-α, a multilevel multivariable model of log-
transformed plasma TNF-α with centre for the level 2 and person for the level 1 residual was run, 
utilising MLwiN v2.26 (Centre for Multilevel Modelling, Bristol University) via runmlwin. 
To further investigate a discrepancy between regression results and correlation coefficient for 
plasma IL-1β, both a fractional polynomial regression with 4 polynomial terms and a lowess 
regression were run. 
All analyses were performed with Stata IC v12.1 (College Station, Texas).  
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5.4 Results 
960 patients were included with demographic and clinical details shown in Table 5-1. 
Table 5-1: Patient Details 
Results of the fractional 
poloynomial regression with 95% 
confidence intervals for PSTR, 
dialysate cytokines and plasma 
cytokines against duration of PD are 
shown in Figure 5-1, Figure 5-2, 
Figure 5-3, Figure 5-4, Figure 5-5, 
Figure 5-6, Figure 5-7, Figure 5-8 
and Figure 5-9.  
For both plasma TNF-α and IFN-γ, 
there was an initial apparent fall, 
but this was based solely on the 
first 2 slightly higher values. 
Otherwise the trends with time are shown in Table 5-2. To test the significance of these apparent 
trends, we split the duration of PD into early, middle and late time periods based on the data in 
Table 5-2, and calculated correlation coefficients as shown in Table 5-3. The correlations are not 
strong, with the largest value being 0.36 for the association of solute transport with time over 18 
months. 
The correlations based on these scatterplots are shown in Table 5-3, demonstrating an increase in 
systemic inflammation over the first two months of PD, along with dialysate IL-6 and PSTR, followed 
by a fall in dialysate cytokines over the next 16 months. In the longer term PSTR increases whilst 
 n=960 
Age 55.0 (15.3) 
BMI 25.3 (4.7) 
BP 
135.7/80.3 
(20.8/12.2) 
Albumin 35.1 (5.0) 
Urine Volume (mls) 800 (309-1320) 
Duration of PD (days) 63 (36-212) 
Biocompatible Usage 18.10% 
Icodextrin Usage 22.70% 
APD Usage 9.70% 
Comorbidity 
(Low/Intermediate/High) 
38.9/53.5/7.6% 
Korean 36.80% 
Female 41.70% 
 74 
 
plasma TNF-α levels fall. Because plasma IL-6 did not fit the apparent pattern in systemic cytokines 
over the first 2 months despite the significant appearance of the regression, one further correlation 
of plasma IL-6 with duration of PD was performed limited to the first 45 days of PD (r=0.17, 
p=0.002). 
Figure 5-1: Peritoneal Solute Transport Rate with Duration of PD  
 
Black line represents fitted line, with grey area the 95% confidence interval for this, for Figure 5-1, 
Figure 5-2, Figure 5-3, Figure 5-4, Figure 5-5, Figure 5-6, Figure 5-7, Figure 5-8 and Figure 5-9. 
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Figure 5-2: Dialysate IL-6 By Duration of PD  
 
Black line represents fitted line, with grey area the 95% confidence interval for this. 
Figure 5-3: Dialysate IL-1β By Duration of PD 
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Figure 5-4: Dialysate IFN-γ By Duration of PD 
 
 
Figure 5-5: Dialysate TNF-α By Duration of PD 
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Figure 5-6: Plasma IL-6 By Duration of PD 
 
 
Figure 5-7: Plasma IFN-γ By Duration of PD  
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Figure 5-8: Plasma IL-1β By Duration of PD  
 
 
Figure 5-9: Plasma TNF-α By Duration of PD 
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Because of inconsistency between the correlation coefficient and the apparent flat line of the 
regression slope for plasma IL-1, the regression was examined in further detail with both a quartic 
fractional polynomial plot and a lowess regression, both of which did show some evidence of an 
early increase in plasma IL-1 levels. 
Table 5-2: Timing in Months of Peaks and Nadirs of PSTR and Cytokine Concentrations During PD  
 
PSTR Dialysate Plasma 
D/PCr IL-6 TNF-α IFN-γ IL1-β IL-6 TNF-α IFN-γ IL1-β 
Initial peak 2.1 3.9 2.4 4.8 0.5 1.4 2.0 1.9 N/A 
Subsequent 
nadir 
17.3 21.9 32.4 33.9 30.7 13.0 N/A N/A 9.1 
 
Table 5-3: Correlations of Cytokines and PSTR with Duration of PD 
 
From PD Start to 2 
Months 
From 2 to 18 months 
of PD 
From 18 months of PD 
onwards 
Correlation 
Coefficient 
p value 
Correlation 
Coefficient 
p value 
Correlation 
Coefficient 
p value 
Dialysate 
IL-6 0.10 0.04 -0.13 0.02 0.10 0.3 
IFN-γ -0.08 0.10 -0.14 0.009 0.09 0.4 
IL-1β -0.08 0.11 -0.17 0.0009 0.09 0.3 
TNF-α -0.09 0.07 -0.20 0.0001 0.05 0.6 
Plasma 
IL-6 0.09 0.06 -0.06 0.3 0.07 0.4 
IFN-γ 0.16 0.001 -0.01 0.8 -0.09 0.4 
IL-1β 0.10 0.03 0.08 0.1 0.05 0.6 
TNF-α 0.24 <0.0001 0.02 0.6 -0.19 0.04 
PSTR D/P Cr 0.19 0.0001 -0.06 0.3 0.36 0.0001 
 
To further explore the unexpected selective fall in plasma TNF-α levels, a multilevel, multivariable 
model examining the effect of duration of PD on plasma TNF-α was run, adjusting for the same 
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covariates as used in chapter 4 (see supplementary results in 11.5.2)  The duration of PD had no 
effect (coefficient -0.0015, 95% CI -0.0095, 0.0065, p=0.71). 
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5.5 Discussion 
This is the first large, multi-centre study examining trends with time in PSTR and inflammation, both 
systemic and peritoneal. Through this, we have demonstrated an increase in systemic inflammation 
during the first 6 to 8 weeks of PD and a fall in peritoneal inflammation from 2 to 18 months of PD. 
PSTR and dialysate IL-6 also had an initial rise but we could not confirm a significant fall in PSTR 
subsequently despite the trend apparent from the regression.  
The initial sharp rise in systemic inflammation reconciles the 2 previous contradictory studies that 
found an increase, (99)and no increase,(100) in systemic IL-6  as the increase occurred after the 
baseline measurement in the first study, and mostly before the first measurement at one month in 
the second study. We have also extended the findings in Pecoits-Filho to show that the rise in 
systemic IL-6 is paralleled by a rise in other inflammatory markers. 
If the early increase in systemic inflammation represents a true biological phenomenon, there are 2 
main possible explanations – firstly, that there is a local inflammatory response to dialysate 
exposure which ‘spills over’ into the systemic circulation, and secondly that dialysate components 
capable of inducing an inflammatory response are absorbed into the systemic circulation.  
As demonstrated in chapter 4, the peritoneal cavity during dialysis is an inflammatory environment 
and cytokines can have a steep diffusion gradient from the peritoneal cavity to the circulating blood. 
This was particularly marked for IL-6 in both our study (see Figure 4-1), and another study with a 
wider variety of cytokines. (183) Also, dialysate IL-6 concentrations rise during the first 2 months of 
PD, mirroring the changes in plasma inflammatory cytokines. Taken together, these findings support 
the hypothesis that peritoneal IL-6 production induces an increase in systemic inflammation during 
PD. Other dialysate cytokines tended not to have such a steep diffusion gradient, and the temporal 
changes did not match the systemic changes. 
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The only components of dialysate known to be absorbed in significant amounts are glucose, GDPs 
and the buffer, either lactate or bicarbonate. Glucose absorption during PD is associated with 
hyperinsulinaemia (184) and the metabolic syndrome, (185) which are themselves associated with 
systemic inflammation (186) although inflammation is generally considered to cause insulin 
resistance rather than vice versa. One small randomised study failed to find either a significant 
difference, or a trend to a difference, in systemic inflammation between biocompatible or standard 
solutions although this does not disprove the possibility of either GDPs or the buffer causing 
inflammation as it was a trial between different levels of GDPs and different buffers rather than a 
comparison against no GDPs or buffer. (187)  
The rise in PSTR over the first few weeks of PD replicates previous studies, (30) and it is notable that 
dialysate IL-6, one of the strongest known predictors of PSTR, rises over this timescale, as does 
plasma IL-6 and systemic inflammation with it. The increase in PSTR is likely to be driven by intra-
peritoneal IL-6, which may drive the systemic inflammation too. 
We failed to show a statistically significant fall in PSTR after the initial rise, during the time period 
that previous data suggested there was a fall during. (31) D/P Cr levels are known to differ between 
centres, possibly through different effluent creatinine assays or glucose correction factors and this 
analysis could not take this, or differential sampling by centres, into account. This will limit the 
power of our study to detect significant changes in PSTR, although there was an apparent fall in the 
PSTR regression slope during the time period that there was also a demonstrable fall in effluent 
inflammatory cytokine levels. PSTR is increased, through IL-6, by peritoneal inflammation so the 
decrease in peritoneal inflammation provides a mechanism to explain the falls in PSTR described by 
Struijk et al, (31) although the correlation was quite weak. 
Potential explanations for the fall in peritoneal inflammation include a loss or change in phenotype 
of viable inflammatory cells within the peritoneum through repeated exposure to bio-incompatible 
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dialysate or, if peritoneal inflammation predicts technique failure or death over the relevant 
timescale, informative censoring. 
The longer term rise in PSTR is well documented, (41) and thought to be due to angiogenesis (188) 
but the molecular mechanisms driving this are not known. IL-6 is a strong predictor of PSTR but the 
mechanism behind this is not known, with possible explanations including angiogenesis, increased 
vascular permeability and vasodilatation. IL-6 does not induce angiogenesis directly although it 
might affect this through mediators such as VEGF or angiopoietin 1 and 2. (189) If IL-6 drives the long 
term rise in PSTR through angiogenesis, a long term rise in dialysate IL-6 would be expected, as was 
found in the regression but this effect was not statistically significant.  
A selective long term fall in plasma TNF-α during PD has not been described previously, but the 
significance of this is doubtful as the duration of PD had no effect when controlled for other 
covariates in a multivariable regression. 
The biggest limitation to this analysis is the use of cross-sectional data to infer longitudinal change. 
Informative censoring can occur with this technique, through particular groups having an increased 
risk of stopping PD and being underrepresented later on. The early changes are less likely to be 
affected by this, both because fewer patients will have stopped PD and because inflammation rises 
rather than falls with time as would be expected with informative censoring. The longer term 
changes will be more susceptible to informative censoring; also, there was a scarcity of data at 
longer time points.  
Another limitation of the study is also a strength in that there was not a pre-formed hypothesis of 
when important changes in PSTR and inflammation occur, such as there are in other studies with 
pre-defined time points for sampling. This study was therefore not driven by a specific hypothesis 
other than that changes can occur between previously studied time points.  
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The multi-centre nature of the data could not be accounted for in the analysis, so centre effects 
remain a potential confounder. Because of these limitations none of the findings described can be 
regarded as definitively demonstrated but await confirmation in a study specifically designed to 
measure these changes.  
In conclusion, we have demonstrated that there is highly likely to be a significant increase in 
systemic inflammation at the start of PD, possibly linked to a significant rise in dialysate IL-6, and a 
medium term fall in peritoneal inflammation following this that provides a mechanism for the fall in 
PSTR previously described. 
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6 The role of inflammation in Encapsulating Peritoneal Sclerosis 
6.1 Summary 
6.1.1 Background 
EPS is an uncommon condition, strongly associated with a long duration of PD which is associated 
with increased fibrosis in the peritoneal membrane. The peritoneal membrane is inflamed during 
PD, and inflammation is often associated with fibrosis. We hypothesised that patients who 
subsequently develop EPS have a more inflamed peritoneal membrane during PD.  
6.1.2 Methods and Materials 
We performed a nested, case control study, identifying all EPS cases in the UK limb of the Global 
Fluid Study and matching them on centre and duration of PD with 2 to 3 controls. Dialysate and 
plasma samples taken during repeated peritoneal equilibration tests prior to EPS/stopping PD from 
cases and controls were assayed by electrochemiluminescence for IL-1β, TNF-α, IFN-γ and IL-6. 
Results were analysed by linear mixed models adjusted for age and time on PD.  
6.1.3 Results 
11 cases were matched with 26 controls. Dialysate TNF-α, 0.64 (0.23, 1.05), and IL-6, 0.79 (0.03, 
1.56), were significantly higher in EPS cases, whilst IL-1β, 1.06 (-0.11, 2.23), and IFN-γ, 0.62 (-0.06, 
1.29), showed a similar trend. Only IL-6 was significantly higher in the plasma, 0.42 (0.07, 0.78). 
Solute transport was not significantly different between cases and controls but did increase with 
duration of PD. 
6.1.4 Discussion 
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The peritoneal membrane is more inflamed during PD in patients who subsequently develop EPS, a 
change not apparent if peritoneal solute transport is used as a surrogate measure for peritoneal 
inflammation. 
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6.2 Introduction 
EPS is an uncommon but serious condition, primarily associated with a prolonged duration of PD. It 
is characterised by marked fibrosis ‘cocooning’ the gut, leading to functional impairment with 
malnutrition and obstruction. Histological studies have confirmed that after diagnosis there is a 
significant inflammatory component intra-peritoneally in EPS patients. As shown in chapter 4, PD 
induces intra-peritoneal inflammation during routine PD but it is not certain if this inflammatory 
response is greater in those patients with subsequent EPS.  
It is also now clear that increased intra-peritoneal inflammation is a strong predictor of PSTR through 
higher levels of IL-6. Faster solute transport in patients who develop EPS is a consistent finding in 
most case series published (190,191) which suggests increased inflammation but neoangiogenesis 
could equally explain this difference. One case-control study has shown that dialysate effluent IL-6 
was significantly higher in the EPS group 2 years prior to EPS diagnosis but it was not different at 
other time points. (192)  
EPS is also associated with an increase in systemic inflammatory markers both before and after 
diagnosis (193) but how this relates to intra-peritoneal inflammation is unclear. As the GFS collected 
dialysate and plasma samples on large numbers of routine PD patients, including prevalent patients 
with a prolonged duration of PD, we sought to explore the roles of intra-peritoneal and systemic 
inflammation prior to the onset of EPS.  
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6.3 Methods and Materials 
Study design 
This is a matched, nested, case-control study. The parent study has been described in detail 
elsewhere (Chapter 3.1.2)  but in brief, the Global Fluid Study is an international, multicentre, 
prospective cohort study of incident and prevalent patients commenced in 2002. Eligible patients 
were any PD patients over the age of 16 providing informed consent. Incident patients were defined 
as first data collection time point within the first 90 days of PD. Follow up was censored in December 
2011. Ten centres were included in the primary analysis, and for this analysis the 5 UK centres were 
selected for identification of all patients who developed EPS. These cases were then assigned 2 to 3 
controls who had finished PD and not developed EPS, matched on centre and duration of completed 
PD episode. 
Data collection 
All clinical data was recorded on a custom built database (PDDB). Demography was recorded and 
comorbidity was assessed with the validated Stoke comorbidity index. Routine blood tests, including 
albumin and random blood glucose, were performed locally and, if necessary, converted into the 
same units. All samples of dialysate and plasma from the cases and controls were assayed for TNF-α, 
IFN-γ, IL-1β and IL-6 by electrochemiluminescence. 
PD related measurements included residual renal function, dialysis regime and dose, and peritoneal 
membrane function using the peritoneal equilibration test (solute transport rate: dialysate to plasma 
creatinine ratio (PSTR) and net UF capacity at 4 hours with 2.27% or 3.86% glucose).  
Predicted dialysate concentrations 
We used the 3 pore model to predict dialysate cytokine concentrations based on molecular radius as 
calculated from molecular weight, and assuming diffusion only. (13) 
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Statistical analysis 
Missing data, ranging from 0 to 4.8% for different variables, were considered missing at random and 
complete case analysis was used. Descriptive data was compared with chi-squared tests, t-tests or 
Mann-Whitney U tests depending on whether variables were categorical or continuous variables, 
and if continuous, whether they were normally distributed or not. 
Multivariable, 3-level, random intercept linear mixed models, accounting for measurements 
clustering within person and person clustering within case-control groups, were used to explore 
determinants of log-transformed cytokine levels. Normal probability distributions were checked for 
level 1 residuals. Because IL-1β had a highly skewed distribution, a logistic model was used with IL-1β 
concentrations as a binary variable (detectable/undetectable). Models included age, as it is known 
to affect inflammatory cytokine concentrations, and time from sample acquisition to the end of the 
PD episode to account for temporal changes. Further covariates were not included as models 
included 3 residuals and 3 covariates with a limited number of samples although interactions were 
tested for. Significance testing was by the Wald test and the Iterative Generalised Least Squares 
method was used for coefficient estimation.  
MLWin 2.26 (194) was used via runmlwin for multilevel regression and StataIC 12 (StataCorp LP, 
College Station, TX) for the other calculations. 
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6.4 Results 
Demographic and basic clinical details are shown in Table 6-1. The EPS group had 41 samples and the 
control group had 106 samples. There were no statistically significant differences in any of the 
measured variables although there was a statistically insignificant but potentially clinically relevant 
lower age, worse residual renal function and faster PSTR at the time of first sample acquisition in the 
EPS group.  
Table 6-1: Descriptive Data for Cases and Controls 
  EPS (11) Control (26) p value 
Time 
Invariant 
Age 53.6 (15.5) 63.0 (14.8) 0.091 
Male Gender 50% 57.5% 0.86 
Comorbidity 
(Low/Intermediate/High) 
45.5/54.5/0% 32.0/48.0/20.0% 0.45 
Completed PD Episode 
(months) 
69.0 (35.4) 69.9 (34.4) 0.95 
Number of Samples 4 (1-7) 4 (2-6) 0.58 
Reason for stopping PD 
- Transplant 
- Peritonitis 
- Other technique failure 
- Death 
- Exit site infection 
- EPS 
- UF Failure 
- Patient choice 
 
18% 
0 
18% 
0 
0 
36% 
18% 
9% 
 
35% 
30% 
17% 
13% 
4% 
0 
0 
0 
 
At First 
Sample 
Months Till PD End 33.2 (21.8) 31.7 (18.9) 0.84 
Urine volume (mls) 501 (0-987) 838 (169-1432) 0.27 
Icodextrin Usage 45.5% 28.0% 0.31 
Dialysate Glucose Exposure 165.0 (74.9) 138.9 (42.6) 0.36 
APD usage 18.2% 20.0% 0.90 
Dialysate IL-6 10.67 (8.04-21.53) 6.05 (1.54-14.89) 0.18 
Plasma IL-6 0.95 (0.85-1.76) 1.30 (0.71-2.63) 0.61 
Serum Albumin 37.3 (5.0) 36.8 (5.8) 0.91 
D/P Cr 0.81 (0.15) 0.72 (0.16) 0.13 
Blood Pressure - 
Systolic/Diastolic 
142/83 (24/16) 146/83 (26/11) 0.64/0.77 
Figures are proportions, mean (SD) or median (IQR) depending on variable type and skewness. 
 
Determinants of dialysate and plasma cytokine concentrations, as found with multilevel 
multivariable models, are shown in Table 6-2. All dialysate cytokine concentrations tended to be 
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higher in EPS cases but the difference was only statistically significant for IL-6 and TNF-α. Of the 
plasma cytokines, only IL-6 was significantly higher in EPS cases although the average difference was 
only 0.42 log10 concentrations, compared to 0.79 log10 concentrations in dialysate IL-6. An increase 
with time was apparent for both dialysate and plasma IL-6 as well as for plasma IFN-γ. PSTR rose 
with time but PSTR was not statistically significantly different between EPS cases and controls 
(Figure 6-1). If the D/P Cr at the time of the last sample was compared, there was still no significant 
difference in PSTR between groups (EPS 0.820, Control 0.818, p=0.98). Age was associated with 
higher plasma cytokines except for IL-1β but out of the dialysate cytokines it was only associated 
with TNF-α. There were no significant interactions between EPS status, age and time to PD finish 
although the power to detect them would have been weak. 
Table 6-2: Determinants of Inflammatory Cytokine Levels by EPS Status 
Dependent 
Variable 
EPS Age Time Till PD End 
Coefficient 
(95% CI) 
p 
value 
Coefficient 
(95% CI) 
p 
value 
Coefficient 
(95% CI) 
p 
value 
Dialysate 
IL-6 
0.79  (0.03, 
1.56)* 
0.043 
0.009 (-0.014, 
0.033) 
0.43 0.27 (0.13, 0.42)* <0.001 
IL-1β 1.06 (-0.11, 2.23) 0.075 
0.022 (-0.012, 
0.056) 
0.20 0.19 (-0.08, 0.47) 0.17 
IFN-γ 0.62 (-0.06, 1.29) 0.073 
0.016 (-0.005, 
0.036) 
0.14 
0.085 (-0.045, 
0.215) 
0.20 
TNF-α 
0.64 (0.23, 
1.05)* 
0.002 
0.019 (0.007, 
0.031)* 
0.001 
0.048 (-0.026, 
0.123) 
0.20 
Plasma 
IL-6 
0.42 (0.07, 
0.78)* 
0.020 
0.016 (0.005, 
0.026)* 
0.003 0.13 (0.05, 0.21)* 0.001 
IL-1β 0.66 (-0.65, 1.97) 0.33 
-0.023 (-0.064, 
0.017) 
0.26 -0.21 (-0.55, 0.13) 0.23 
IFN-γ 
-0.30 (-0.69, 
0.09) 
0.14 
0.014 (0.001, 
0.027)* 
0.036 0.12 (0.02, 0.22)* 0.017 
TNF-α 0.13 (-0.13, 0.39) 0.31 
0.010 (0.002, 
0.017)* 
0.011 0.45 (-0.007, 0.098) 0.090 
Solute 
Transport 
D/P Cr 
0.024 
(-0.054, 0.102) 
0.55 
-0.0017 
(-0.0039, 0.0006) 
0.14 
0.035  
(0.023, 0.047) * 
<0.001 
 *p<0.05. Results from models with continuous dependent variables (log transformed if cytokine) 
except for dialysate and plasma IL-1 models which were logistic models for detectable vs 
undetectable. 
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34.4% of dialysate samples had a concentration of TNF-α greater than predicted by diffusion 
according to the 3 pore model, assuming plasma TNF-α exists as a homotrimer. If plasma TNF-α was 
assumed to be monomeric the proportion was 31.9%. 
Figure 6-1: Peritoneal Solute Transport Rate With Time to PD Finish By EPS Status 
 
Circles represent individual measurements, with lines identifying different patients 
 
The increase in dialysate IL-6 is demonstrated in Figure 6-2 , but there is no apparent change in the 
ratio of dialysate to plasma IL-6 (Figure 6-3). A univariable, multilevel regression model for dialysate 
to plasma IL-6 ratios confirmed that time had no effect (coefficient 0.98, 95% CI -2.65 to 4.60, p=0.6). 
The dialysate TNF-α results are demonstrated in Figure 6-4. 
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Figure 6-2: Dialysate IL-6 With Time to PD Finish By EPS Status 
 
Circles represent individual measurements, with lines identifying different patients 
Figure 6-3: Dialysate to Plasma IL-6 Ratio With Time to PD Finish By EPS Status 
 
Circles represent individual measurements, with lines identifying different patients 
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Figure 6-4: Dialysate TNF-α With Time to PD Finish By EPS Status 
 
Circles represent individual measurements, with lines identifying different patientsAll values are TNF 
concentration +0.1 to allow a logarithmic scale (i.e. 0.1 = 0) 
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6.5 Discussion 
We have demonstrated for the first time that intra-peritoneal inflammation, compared to controls 
who do not develop EPS, is increased for several years prior to EPS and this difference in intra-
peritoneal inflammation is more readily apparent than the associated difference in PSTR. There is 
also an increase in plasma IL-6, although the magnitude of this difference is less marked, and none of 
the other plasma cytokines are elevated. 
One of the unexpected findings was the lack of difference in solute transport which is frequently 
reported as a risk for EPS. Some of the other studies of solute transport in EPS have not been able to 
accurately match for time on PD because the strong association of EPS with long periods of PD makes 
finding controls with solute transport measured after the same duration of PD difficult (190,191)  
whilst another study found no difference in PSTR between EPS and UF failure.(195) Our study has 
matched very effectively for time on PD such that there is no significant difference in the total duration 
of PD, or in PD duration at the time of first sampling. The importance of this is highlighted by the 
significant independent effect that time had on solute transport in our study. Chapter 5 compared 9 
EPS cases, matched such that the control patients average time on PD was only an average of 3.7 
months less, found no difference in solute transport until the last year prior to EPS/PD finishing 
(although 6 patients from that study are included in this one). This suggests that PSTR is not a good 
method for identifying patients who subsequently develop EPS. 
We have replicated a previous finding of a raised dialysate effluent IL-6 in patients who subsequently 
develop EPS, (192) but extended the finding as that study only found a difference at 2 years prior to 
the development of EPS and not at 1 or 3 years prior. Our study had more samples, but also used all 
samples available in a single model, demonstrating that dialysate IL-6 concentrations are higher in 
EPS patients at all time points covered (from 6 years prior to stopping PD up to PD cessation). As 
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samples are only available from one EPS patient between 5 and 6 years prior to stopping PD, the 
certainty in the conclusions fall at this point, but the separation between EPS and control patients 
did not change over the duration of the study period (i.e. no significant interaction between EPS 
status and time to PD cessation).  
We have also shown for the first time that dialysate effluent TNF-α is significantly higher in patients 
who subsequently develop EPS and appears to be more promising as a biomarker for EPS risk than 
IL-6. As increased fibrosis manifesting as decreased osmotic conductance to glucose increases the 
risk of EPS (195,196) any biomarker for EPS is likely to be associated with fibrosis. TNF-α has 
previously been considered an antifibrotic molecule based on in vitro work, but there is some 
preliminary evidence in rheumatological conditions suggesting that TNF-α  inhibitors may reduce 
fibrosis. (197) Whether TNF-α is directly implicated may depend on whether the fibrosis associated 
with EPS is driven by inflammation or through another mechanism. 
Any dialysate biomarker predictive of EPS is likely to reflect local pathophysiology and therefore will 
be produced locally however previous studies of dialysate TNF-α have found low levels compatible 
with its presence being due to diffusion from the systemic circulation. (103,198) These studies have 
used a molecular weight based on TNF-α being a monomer to calculate the predicted dialysate 
concentration due to diffusion but TNF-α is reported to predominantly exist as a homotrimer. We used 
predictions based on both a monomeric and a homotrimer form of TNF-α and found little difference 
between the two but we did find that more samples than reported previously had evidence of local 
production. Furthermore, TNF-α has previously been shown to significantly correlate with other intra-
peritoneal cytokine levels for which there was clear evidence of local production.(198) This would be 
compatible with intra-peritoneal TNF-α, as part of an inflammatory cascade, inducing fibrosis and 
thereby predisposing patients to EPS. TNF-α has previously been linked with anti-fibrotic effects based 
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primarily on in vitro data, however there is some clinical data based on the effects of anti-TNF-α agents 
in rheumatological diseases suggesting that it might have a pro-fibrotic role. (197) 
Both IFN-γ and IL-1β showed a trend towards higher levels in the EPS group. Neither of these 
findings quite met the pre-set p value for statistical significance of 0.05, but the findings were 
certainly supportive of the hypothesis that patients who develop EPS have a more inflamed 
peritoneal membrane during PD.  
We have also examined changes in plasma levels of inflammatory cytokines preceding EPS, 
demonstrating an isolated increase in plasma IL-6. Previous studies have only examined CRP before 
the diagnosis of EPS, showing either no difference (199) or a difference one year prior to diagnosis 
(193). We have therefore extended this by showing changes evident systemically well before the 
diagnosis of EPS is made, but also provided a potential mechanism for this. There is a clear diffusion 
gradient from dialysate to plasma for IL-6 that is not present for most inflammatory cytokines 
suggesting that clearance of IL-6 from the peritoneum contributes to systemic levels. Further 
suggestive evidence comes from the greater difference in dialysate compared to plasma IL-6 
concentrations between EPS cases and controls as, if this theory is correct, a doubling in dialysate 
concentrations would be unlikely to lead to a doubling in plasma concentrations. 
Limitations of this study include a relatively small number of EPS cases, although it is an uncommon 
condition so this still represents the largest collection of dialysate effluent samples pre-diagnosis. As 
an observational study, cause and effect cannot be proven so it is not definite that inflammation is 
pathophysiologically involved in driving EPS.   
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7 Changes in the peritoneal membrane preceding Encapsulating 
Peritoneal Sclerosis 
 
See also Appendix C – Note on Statistical Tests in Chapter 7 
 
7.1 Summary 
 
Encapsulating peritoneal sclerosis (EPS) is a serious condition occurring with increasing frequency 
the longer the duration of peritoneal dialysis. We report the longitudinal changes in peritoneal 
membrane function of patients who develop EPS compared with controls who had completed their 
dialysis episode. All patients starting peritoneal dialysis since 1990 with an unequivocal diagnosis of 
EPS in our unit were identified, and each matched for dialysis duration and age with four controls. All 
prospectively collected clinical measures were retrieved and compared. The dialysate/plasma 
creatinine ratio increased with time in both groups but was only significantly higher in EPS patients 
at the time of stopping dialysis (0.89 vs 0.78, p=0.007), whereas the ultrafiltration capacity was 
significantly worse from at least 2 years prior to stopping dialysis, diverging further till dialysis 
finished (345mls vs 137mls, p=0.006) suggesting reduced osmotic conductance. Both the glucose 
exposure rate for the 5 years preceding stopping dialysis and the Icodextrin exposure was 
significantly higher, with a worse residual renal function, in the EPS group, but there was no 
significant difference in peritonitis rates. 24 hour peritoneal protein clearance was not significantly 
different in EPS cases, possibly due to a greater fibrous matrix. This study shows that regular 
peritoneal membrane function tests can identify most patients at high risk of developing EPS. 
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7.2 Introduction  
Encapsulating peritoneal sclerosis (EPS) is an increasingly recognised complication of peritoneal 
dialysis(PD), characterised by development of a diffuse ‘cocoon’ over the small bowel causing 
gastrointestinal symptoms and bowel obstruction, leading to weight loss, under-nutrition and in 
some cases death. The incidence increases with time on PD, ranging from 0% during the first 3 years 
to 5.9% for patients on PD between 8 and 10 years in Japan, (200) and from 0% during the first year 
to 8% for patients on PD for 5 or more years in Scotland.(168) Several treatment-related risk factors 
have been suggested including severe peritonitis, glucose exposure, lack of residual renal function 
and the development of ultrafiltration failure associated with high rates of membrane solute 
transport.  Paradoxically, discontinuation of PD appears to be a trigger factor for developing the 
condition resulting in a therapeutic dilemma for the clinician as to when and if patients should be 
switched to haemodialysis (HD). Although EPS is rarely seen in patients not exposed to PD, other 
precipitants such as cirrhosis with ascites, post-surgical, peritoneal shunts, autoimmune conditions 
and intraperitoneal chemotherapy (201,202) are described and the underlying pathophysiology 
remains obscure. This is compounded by the lack of a good animal model, the rarity of the disease 
and the lack of stringent diagnostic criteria. 
The ability to identify patients at high risk, thereby prompting consideration of switching to HD or 
transplantation might be facilitated by identifying changes in peritoneal membrane function that 
precede or predispose to the development of EPS. It is well established that time on PD is associated 
with increases in peritoneal solute transport rate (PSTR) associated with a fall in the ultrafiltration 
(UF) capacity of the membrane. In a proportion of patients there is uncoupling of these two 
processes due to a decrease in the osmotic conductance of the membrane that may well reflect the 
progressive fibrosis associated with longer time on treatment. These changes in membrane function 
are associated with more rapid loss in residual renal function and higher glucose exposure, which 
may contribute to further fibrosis and subsequent EPS. To date, most studies of EPS patients have 
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reported only the results of the most recent peritoneal membrane function tests prior to diagnosis.  
We report the first controlled longitudinal cohort study of peritoneal membrane function with 
associated detailed clinical measurement including RRF and peritoneal glucose exposure in patients 
who subsequently develop definite EPS. 
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7.3 Methods 
For further statistical comments, see Appendix C – Note on Statistical Tests in Chapter 7 
7.3.1 Study Design 
This was a nested case control study. We identified all patients from the well-defined Stoke PD 
patient cohort with probable EPS, and reviewed their clinical records including nursing 
documentation and radiological reports. To avoid some of the uncertainty surrounding early EPS, 
only patients with definite EPS (surgically or radiologically confirmed peritoneal membrane 
thickening and cocooning, in conjunction with weight loss and features of bowel obstruction) were 
selected. Two patients in whom EPS was associated with persisting poorly controlled peritonitis 
were excluded.  Each of these patients was then matched by time on PD, and age where possible, 
with 4 controls from the same cohort by identifying adjacent patients from the whole database who 
had completed their treatment episode on PD, neither deliberately including nor excluding controls 
with UF failure. 4 controls were selected to maximise statistical power whilst retaining efficiency. 
(203) 
7.3.2 Prospective collection of routine clinical measurements 
Baseline demography and PD measurements for cases and controls were retrieved from the 
database, along with the total number of peritonitis episodes per patient, and comorbidity, as 
assessed by the validated Stoke comorbidity index which categorises patients into low (score 0), 
intermediate (score 1-2), and high (score >2) risk groups.  
Routine 6 monthly measurements included residual renal function, dialysis regime and dose, and 
peritoneal membrane function using the peritoneal equilibration test (solute transport rate: 
dialysate to plasma creatinine ratio (D/P Cr) at 4 hours and net UF capacity with 2.27% glucose) were 
obtained from the database. The ‘overfill’ included in the bags was not subtracted from the 4 hour 
ultrafiltration capacity, but consistently measures 200mls in our unit. Adequacy was expressed as 
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weekly Kt/Vurea for the peritoneal component, whereas the urine volume and mean weekly urea 
and creatinine clearance (litres/week/1.73m2) were used to determine residual renal function. 
Glucose exposure was calculated by summing the grammes of anhydrous glucose within the daily 
dialysate used for each regime the patient had, multiplying this by the number of days they were on 
that regime, and combining the results for each regime for the annual total glucose exposure 
(grammes) of the peritoneal membrane. Icodextrin use was recorded as a categorical value for 
whether it was used at any point in the year in question. 
Peritoneal protein losses were measured from the 24 hour total dialysate collection assayed by the 
Biuret method. A validated correction factor (204) was then used in the equation: PCl = 24 hour 
dialysate protein loss/(serum albumin/0.4783), with PCl representing the peritoneal protein 
clearance expressed as mls of plasma per day. Regular dialysate protein concentrations were 
measured from 1999, providing data on 8 EPS cases (46 samples) and 28 controls (107 samples) 
within the last 4 years of PD. 
7.3.3 Statistical Analysis 
To compare the evolution of clinical measurements prior to the study endpoint (diagnosis of EPS for 
cases and completion of PD episode for controls), measurements were aligned from the point of 
stopping PD backwards, such that cessation of PD counted as time 0, with one year prior to this 
counting as -1, and so on until year -8. This method was used for UF capacity, solute transport and 
glucose exposure and the data is all expressed as the yearly mean value for each group. As 
measurements were taken 6 monthly, this usually represents the mean of two readings per patient.  
As residual renal function declines with time on treatment, the measurements of urine volume were 
aligned from starting PD forward to year +8. Comparisons between EPS cases and controls were 
made with all values obtained within yearly intervals, and all values from the first 4 years of PD.  
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Between-group comparisons used the 2-tailed unpaired t-test, the Mann-Whitney U test or the chi-
squared test depending on the data type and distribution. The paired t-test was used for longitudinal 
comparisons, using all measurements between 4.5 and 5.5 years before PD finished and comparing 
them with readings taken in the last year of PD. These figures were chosen to include measurements 
from as many patients as possible whilst maintaining a meaningful difference in time.  
The risk of developing EPS with time on treatment for the whole PD cohort was determined from a 
Kaplan Meier survival analysis of all patients commencing PD after 1/1/1990, with the definition of 
EPS for the study extended to include cases associated with severe and prolonged peritonitis. A 
linear mixed model was used to examine the PCl data as well as t-tests. These analyses were with 
SPSS v17.  
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7.4 Results  
9 patients with definite EPS were identified from a total cohort of 692 patients treated with 
peritoneal dialysis since 1990. The diagnosis of EPS was confirmed surgically in 5 out of 9 patients, 
and radiologically in 7 out of 9, (Table 7-1). 3 patients were on PD at the time of diagnosis, while the 
other 6 were on haemodialysis, a mean of 7.3 months after stopping PD (range 1-18 months). 
Constipation was unusual, while diarrhoea occurred in only 3 out of 9. Frank obstruction was only 
diagnosed formally in 4 out of 9 although vomiting occurred in 6 out of 9.  
EPS free survival is demonstrated in Figure 7-1. The 2 early cases of EPS (6 and 23 months) were both 
related to severe, prolonged peritonitis episodes. Of the EPS not associated with severe and 
prolonged peritonitis, there were no early cases, with the first case occurring at 32 months. The risk 
rose substantially after five years such that the probability of EPS free survival after 93 months on PD 
was 0.85. The confidence intervals for this are wide with small numbers of patients at risk but they 
follow a pattern of an increasing gradient with time in the Kaplan-Meier plot. 
 The demographics of the cases and 36 matched controls are shown in Table 7-2 with no significant 
difference between the groups. One EPS case had 2 significant sessions of PD which, whilst 
separated by a 9 year period, were combined into one for the analysis.  The cohorts were reasonably 
matched in time with a median date of stopping PD of 26/3/04 in EPS cases and 9/4/02 in the 
controls. Predictably, the outcome of the two groups was significantly different. 
The mean number of peritonitis episodes was greater in the control group, although this did not 
reach statistical significance (1.78 vs 4.19, p=0.061). 2 EPS cases had no peritonitis at all, only one 
EPS case had their catheter temporarily removed for peritonitis and only 2 of the EPS cases had 
peritonitis within the 6 months preceding stopping PD.
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Table 7-1: Clinical Features of EPS Cases 
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2 34.6 F 130 0 33 Multi-organ failure Peritonitis Y Y Y Y N Y N N N 
3 39.5 M 93 36 >729 Alive EPS Y Y Y Y Y Y Y Y Y 
4 71.5 M 65 0 2 Bowel obstruction EPS/died Y N Y N Y N N N N 
5 54.7 M 69 101 2 Sudden death after vomiting++ UF failure Y Y Y Y N Y N N N 
6 65.6 M 65 560 120 Malnutrition, withdrawal of HD Drainage problems Y Y Y Y Y N N Y N 
7 44.3 F 55 320 221 Sudden cardiac death UF failure N Y N Y Y N N Y N 
8 26.8 F 93 47 >344 Alive UF failure Y Y Y Y Y Y Y N Y 
9 60.0 M 32 296 48 Malnutrition Patient choice Y Y Y Y Y N N Y Y 
 106 
 
Figure 7-1: Kaplan-Meier Plot of EPS Free Survival 
 
  
The probability of remaining free of EPS with duration of time on PD. This includes 2 early cases 
associated with severe, prolonged peritonitis. The number of patients at risk at the time of each case 
of EPS is shown at the top. 
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Table 7-2: Demographics of EPS Cases and Controls 
 EPS 
(9 patients) 
Controls 
(36 patients) 
p value 
Duration of PD  in months (months; mean) 84.7 
 
81.0 
 
0.27 
Age at PD cessation (years; mean) 48.8 
 
54.7 
 
0.32 
Male Gender (%) 55.6 50 0.77 
Ethnicity 
- White European (%) 
- South Asian (%) 
 
88.9 
11.1 
 
97.2 
2.8 
 
0.28 
Stoke comorbidity index (mean) 
- Low (%) 
- Intermediate (%) 
- High (%) 
0.78 
55.6 
44.4 
0 
0.78 
50.0 
44.4 
5.6 
0.98 
0.76 
Diabetic (%) 0 16.7 0.19 
Adequacy at treatment start  
- Renal Kt/V (median) 
- Renal Cr clearance (median) 
- Peritoneal Kt/V  (mean) 
 
0.19 
9.86 
1.60 
 
0.98 
48.4 
1.60 
 
0.24 
0.27 
0.61 
PET test at treatment start 
- D/P Cr (mean) 
- UF capacity (mean) 
 
0.71 
402 
 
0.66 
423 
 
0.18 
0.82 
Modality immediately post PD 
- Haemodialysis (%) 
- Transplant (%) 
- Died (%) 
 
88.9 
0 
11.1 
 
30.6 
33.3 
36.1 
 
 
Both EPS and control groups demonstrated a gradual rise in solute transport rate with time on 
treatment (p=0.003 and 0.001 respectively), (Figure 7-2). The change with time of UF capacity in the 
EPS group (Figure 7-3) was significant (p=0.02) but not in the control group (p=0.34). Only 2 of the 
control group of patients had a consistently low UF capacity suggestive of UF failure. 
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Figure 7-2: Change in Membrane Solute Transport with Time on PD 
 
Solute transport is measured as the mean annual D/P Creatinine measured at 4 hours in standard 
peritoneal equilibration tests with standard error. The star indicates a difference between groups 
with p=0.007. 
Figure 7-3: Change in Ultrafiltration Capacity with Time on PD 
 
The UF capacity is the annual mean measured by a 4 hour peritoneal equilibration test with 2.27% 
glucose, including approximately 200mls overfill. Bars represent standard error. The stars indicate a 
difference between groups with p<0.05, un-paired t-test.  
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When D/P Cr and UF capacity are plotted together (Figure 7-4), the decline in UF capacity with 
increasing D/P Cr is disproportionately worse for the EPS group such that, for the same D/P Cr ratio 
in both groups, there is a statistically significant difference in UF (345mls at 0.781 for control group 
vs 194mls at 0.784 for EPS group, p=0.015).  
Figure 7-4: Change in Membrane Solute Transport with Change in Ultrafiltration 
 
Membrane solute transport and ultrafiltration are measured as the annual mean of measurements 
of UF capacity and D/P Creatinine in a 4 hour PET with 2.27% glucose, including approximately 
200mls overfill. Bars represent standard error. 
 
5 EPS cases had been on APD, giving a mean duration on APD usage of 20.2 months within EPS cases, 
and 19 controls had been on APD, giving a mean duration of 13.1 months within controls. This 
difference was not significant (p=0.35). The mean annual glucose exposure rates (Figure 7-5) were 
not statistically significantly different for the last 3 readings due to an increase in variance but the 
mean values still showed a clear difference. The last year’s glucose exposure was 66,494 and 96,241 
grammes per year in control and EPS groups respectively; 4 two litre 1.36% or 2.27% exchanges per 
day correspond to a yearly glucose exposure of 39,712 or 66,284 grammes per year respectively. 
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Icodextrin use was greater in the EPS cases, but the difference was only significant for between 1 
and 2 years prior to stopping PD (7/9 vs 12/36, p=0.016). 
Figure 7-5: Glucose Exposure with Time on PD 
 
Glucose exposure is measured as the mean of the total number of grammes of glucose in the 
dialysate used by each patient in that year. Bars represent standard error. The stars indicate a 
difference between groups with p<0.05, un-paired t-test. 
 
Over the first 4 years of PD residual renal function was significantly better preserved in controls  with 
a mean urine volume for EPS 339.6mls vs controls 572mls, p=0.001 (Figure 7-6). Peritoneal protein 
clearances (PCl) were not significantly lower in the EPS cases than the controls by independent 
samples t-test (Figure 7-7). The EPS group did have a lower PCl than controls in a linear mixed model 
with EPS/controls and time to PD finish as predictor variables using fixed effects but the model 
improved and the difference became insignificant when a random effect was added for EPS/controls 
or intercept. Although there were insufficient samples to make meaningful comparisons on a time 
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matched basis, there was no significant longitudinal change from the last year of PD to between 3 
and 4 years before stopping PD (94.50 vs 84.99 mls plasma per day, p=0.46).  
Figure 7-6: Residual Renal Function with Time on PD 
 
The residual renal function is measured as the median of the urine volume within each group 
assessed every 6 months from the start of PD. 
Figure 7-7: Peritoneal Protein Clearance with Time on PD 
 
Peritoneal protein clearance is measured in mls of plasma per day and the bars represent standard 
errors. There were no significant differences between the groups when applying mixed linear 
modelling.  
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7.5 Discussion 
 
This is the first controlled analysis describing the longitudinal changes of a number of treatment 
related measures of PD patients developing EPS. The characteristics of patients destined to develop 
EPS were early loss of residual renal function, and increased glucose exposure associated with 
reduced ultrafiltration capacity of the peritoneal membrane. In contrast baseline characteristics such 
as age, gender and comorbidity or subsequent frequency of peritonitis were not different. These 
observations have important implications for the longitudinal monitoring, prevention and risk 
assessment of patients on long-term PD. 
A higher risk of EPS has consistently been associated with a longer duration of PD. (200,205) The 
incidence in this study is in line with this, with a lifetime risk of 8.75% for patients on PD for more 
than 5 years, a finding in keeping with the incidence reported by the Scottish Renal Registry. (168) 
One of the strengths of this study is follow up data over a long period of time (19 years) allowing us 
to examine EPS risk after long periods on PD, and the Kaplan Meier gradient continues to worsen 
with longer PD exposure, a similar pattern to that published by Kawaguchi et al (206) although in our 
centre the decline in EPS free survival is shorter.  
It has been suggested that transplantation is a particular risk for the development of EPS, (207,208) 
although this does not seem to be the case for our cohort (12 out of 36 controls vs 0 out of 9 EPS 
cases had a transplant) nor was it the case in the Pan-Thames EPS study where 14 out of 65 patients 
had a transplant. (209) The majority of our patients developed the condition after stopping PD (6 out 
of 9) suggesting that, as has been documented previously, (206,210) cessation of PD may be the 
main trigger.  
The original reports of EPS linked it with an increased rate and/or severity of peritonitis, (205,211–
213) although this is not the case in our study. This might be explained by case selection as, to 
ensure there was uniformity in the diagnosis of EPS, we excluded 2 cases characterised by an early 
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diagnosis after severe and prolonged peritonitis. However, there have also been other recent case 
series where the rate of peritonitis was unremarkable such as that from Kawanishi et al (210) where 
16 of 50 cases of EPS had no peritonitis, and Summers et al (214) and Hendriks et al (215) where the 
rate of peritonitis was no different to the entire PD population and control group respectively. These 
case series suggest infectious peritonitis is no longer such an important feature. Changes in PSTR and 
UF capacity have been documented with peritonitis, particularly multiple and severe episodes, (41) 
so there may be a subset of patients in whom severe, non-resolving or recurrent peritonitis is still 
important in the development of EPS (216) such as the 2 patients we excluded from this analysis. 
The PSTR might reflect intraperitoneal inflammation through its association with local IL-6 levels (99) 
and previous studies have demonstrated a faster PSTR in most patients who develop EPS. 
(190,215,217) This association with EPS is usually reported in the context of a single measurement at 
differing time points on dialysis so how this related to the evolution of EPS was unclear until now. 
Our study confirms previous observations that PSTR tends to increase with time on treatment and 
shows this was not obviously different between EPS patients and controls, with the exception of the 
last measurements taken within a year of diagnosis. This is in keeping with previous observations 
suggesting that the early stages of EPS are inflammatory in nature with evidence of local 
inflammatory changes in biopsies compared with samples taken from patients with simple 
peritoneal sclerosis. (165) 
Whilst a previous uncontrolled study failed to show an increase in PSTR measured in 4 Standardised 
Permeability Analyses’ prior to the development of peritoneal sclerosis, our controlled study of EPS 
included measurements from within the final year of PD, the only time point at which there was a 
significant difference in PSTR. (218) The only previous report of peritoneal protein loss (albumin and 
IgG) in EPS was in 4 patients with no control group, (217) where 3 had an increase over time and one 
a decrease. By using a case control design with more cases we have demonstrated that EPS patients 
actually have a slightly smaller peritoneal protein clearance than time matched controls.   
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UF failure at the time of PD cessation has been documented as a risk factor for the development of 
EPS, (215,219)  including the same uncontrolled longitudinal study of peritoneal sclerosis mentioned 
above which demonstrated a decline in UF capacity over 4 years. (218) This EPS study extends these 
findings in time and by using time matched controls, a clear difference is apparent at least 2 years 
prior to PD cessation. Our study has also demonstrated for the first time uncoupling of PSTR and UF 
capacity, with less UF capacity for the same PSTR, in patients who subsequently develop EPS, also a 
recognised phenomenon in long term PD patients without EPS. (17)  A possible explanation for this 
fall in osmotic conductance is increased fibrosis reducing hydraulic permeability.  
Glucose exposure has previously been documented as greater in a group of peritoneal sclerosis 
patients compared with controls  (215) but this study again extends this to a longitudinal description 
finding a clear separation between cases and controls 4 years prior to stopping PD. Glucose exposure 
might be a reflection of greater use of APD, but in our study cases and controls had similar rates of 
APD. Unsurprisingly Icodextrin use was also greater in EPS cases given its known benefits in 
maintaining PD in patients with ultrafiltration failure, although this was only significant between 1 
and 2 years before PD cessation. That glucose exposure is statistically significantly different prior to 
the divergence in the UF capacity does not necessarily imply that it precedes the deterioration in UF 
capacity, as there is a small difference in UF capacity at 4 years prior to PD cessation which is almost 
significantly different (p=0.07) and UF capacity in the peritoneal equilibration test is recognised as 
having a large coefficient of variation, limiting the ability to detect true differences. The pattern of 
glucose exposure and UF capacity is strikingly similar with the plots in both graphs diverging 
between 4 and 5 years prior to stopping PD and separating further with time.  
The longitudinal evolution of residual renal function has not been studied previously, but this study 
demonstrated that those patients who go on to develop EPS pass a smaller urinary volume within 
the first 4 years. This is likely to be another contributory factor, along with declining UF capacity, in 
explaining the EPS patients’ greater and earlier glucose exposure. 
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The ISPD position paper on PD duration (220) emphasised the desirability of a method of identifying 
those patients at risk of EPS, not fulfilled by CT scanning, (221) and there is as yet no study on the 
use of biomarkers in predicting EPS. Patients who lose their residual renal function quickly and have 
a declining UF capacity, particularly a low UF capacity relative to their PSTR, are the group at highest 
risk of EPS, and consideration must be given to changing dialysis modality although other important 
factors must also be considered when discussing this. (220) The glucose exposure may be a more 
reliable marker than UF capacity as the glucose requirements are likely to be set by the osmotic 
conductance to glucose of the peritoneal membrane, whilst the measured UF capacity is affected by 
other issues (e.g. catheter position and drainage) and is thus more variable. This study has partially 
overcome this issue by using the mean value of twice yearly peritoneal membrane function tests.  
From previous studies the PSTR appeared to be an independent predictor of EPS that could be 
monitored for the purpose of identifying patients at risk. Our data suggests that it would be of less 
use than glucose exposure or UF capacity as clear separation between EPS cases and controls only 
appeared in the last year of PD, by which point stopping PD may well be too late, although a rapid 
increase in PSTR could help identify patients who are already at high risk of EPS at the point of 
modality switch and therefore require close follow up afterwards.  
Conventional glucose-based PD fluid contains glucose degradation products, is acidic, and, 
particularly for 3.86% bags, possesses an unphysiologically high osmolality, all of which are thought 
to contribute to membrane damage with an increase in PSTR in conjunction with a worse residual 
renal function. (42) This study has provided a further rationale to systematically minimise glucose 
exposure across all PD patients to minimise EPS risk.  
There is a growing literature to suggest that ultrafiltration failure in long term PD patients is caused 
by an increase in fibrosis decreasing osmotic conductance, including evidence from biopsies, (18) 
from computer modeling (19) and from peritoneal membrane testing. (20) We speculate that this 
fibrosis explains the changes we have demonstrated in patients who develop EPS, although patients 
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with these findings have yet to develop EPS suggesting that there is a difference between simple 
sclerosis and EPS. (165) The PCl data would support this view as, according to the standard 3 pore 
model, PCl should increase with membrane size and inflammation but the lack of effect we found 
might be explained by the fiber matrix/3 pore model with fibrosis restricting protein flux across the 
membrane. 
There are some limitations to this study. We could not be certain that all of the patients used as 
controls would not have gone on to develop EPS as, whilst there was long term follow up data post 
PD in the majority of the patients in this group, some patients stopped PD as a result of dying of 
other causes. This would tend to reduce differences between cases and controls but despite this 
there were still clear differences between the two groups. As with all studies of EPS, it is not helped 
by the lack of firm diagnostic criteria although the EPS group was carefully limited to those with 
characteristic CT or operative findings (often both) with typical clinical features and no other 
apparent cause. It is a single centre study so it is not necessarily widely generalisable, particularly 
with growing evidence of centre differences, (222) although our data was consistent with the 
existing literature. There is also the possibility that cases were not diagnosed, although this should 
only significantly affect the incidence and this was similar to that found in the most comparable 
population studied. (168) 
In summary, we report in detail the longitudinal changes in peritoneal membrane characteristics in 
the majority of patients who subsequently develop EPS (not associated with severe or prolonged 
peritonitis), demonstrating that loss of UF capacity is the predominant early change noted 
associated with lower initial residual renal function and higher glucose and Icodextrin exposure. 
Patients with these features are at high risk of EPS and consideration should be given to stopping PD, 
while these features and a rapid PSTR at the time of PD cessation should prompt close monitoring 
for EPS post-PD.   
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8 Competing Risks of Encapsulating Peritoneal Sclerosis 
8.1 Summary 
8.1.1 Introduction 
Encapsulating peritoneal sclerosis (EPS) is an uncommon complication of peritoneal dialysis (PD), 
where the risk increases significantly with increasing time on therapy. As risk factors for the 
competing event of death seemed likely to decrease the risk of developing EPS, we performed a 
competing risks analysis prior to developing a prognostic model from this..  
8.1.2 Methods and Materials 
We combined 3 large datasets (AnzData, Global Fluid Study, Scottish Renal Registry (SRR)) with 
complete data on EPS occurrence and the denominator population. All incident patients aged ≥15 
years were included and a competing risks survival analysis used with outcomes of censored, EPS 
(prior to death) or death and robust standard errors. Comorbidity data was classified by either 
primary renal diagnosis (low comorbidity = glomerulonephritis, polycystic kidney disease, chronic 
pyelonephritis, high comorbidity = other) and diabetic status (all 3 datasets) or by Stoke comorbidity 
score (AnzData and Global).  
8.1.3 Results 
There were 112 cases of EPS out of 17,912 patients. The cumulative incidence at 10 years varied 
from 0.04 in AnzData, to 0.25 in SRR. Competing risks models showed age (SHR 0.79 per decade, 
95% CI 0.5-0.83) and high comorbidity renal disease (SHR 0.54, 95% CI 0.41-0.73) decreased the risk 
of EPS which Cox models failed to demonstrate. The SRR had a SHR of 5.62 (95% CI 5.28-6.21) 
relative to AnzData but this was not through a decreased mortality (HR for mortality in SRR vs 
AnzData in adjusted Cox model 1.14, 95% CI 1.05-1.42) or through longer periods of PD (median 
months on PD, SRR 22.6, AnzData 21.1, p=0.2). The Global dataset had an intermediate risk (SHR 
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relative to AnzData 2.11, 95% CI 1.78-2.49) but the numbers were small so no further analysis was 
performed on this. 
8.1.4 Discussion 
For patients commencing PD, factors that increase the risk of death decrease the risk of developing 
EPS. Competing risks regression is an appropriate model for analysis of dialysis outcomes. The 
Scottish Renal Registry has a significantly higher rate of EPS than found in AnzData, possibly due to 
ascertainment bias or genetic factors. 
 
8.2 Introduction 
EPS is a severe complication of PD, with a significant impact on morbidity and mortality. It is most 
strongly associated with a prolonged period of time on PD (205,223) so tends to affect younger and 
‘fitter’ patients who survive on PD for a sufficient length of time to be at significant risk of EPS. There 
is a concern that a large proportion of patients, to avoid the perceived risk of EPS, will be transferred 
from PD, their preferred dialysis modality, to HD, when only a very small proportion of those 
patients would have gone on to develop EPS. A prognostic model informing physicians of a patient’s 
risks of death and EPS would help discussions of switching to HD with patients likely to develop EPS, 
and of staying on PD for patients likely to die (whether or not they switch) rather than get EPS. 
Commonly used survival analyses have relied on the assumptions behind the Cox model and the 
Kaplan-Meier estimator, where the event of interest is treated as inevitable and any cases who have 
not experienced the event of interest at the time of the study ending are treated as censored. This 
means that censored cases are removed from the risk set, which falsely increases the predicted risk 
of the event of interest at any one time. In the case of EPS, patients who have died are removed 
from the risk set so the estimated risk of EPS is then directly related to the relative numbers of EPS 
cases at any time point compared to patients still on PD who have not been censored, rather than 
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the proportion of cases compared to a larger population. All previous studies of EPS have used these 
survival analyses so will tend to overestimate the true risk of EPS.  
Competing risks analysis has been developed as a partial solution to these problems, where there is 
more than one possible outcome and these outcomes are mutually exclusive. (224) By keeping 
patients with competing outcomes in the risk set, the estimated probability of an event is more 
realistic, although the estimates are usually under the ‘true’ probability. It can also provide the 
overall effect on an outcome of interest of a variable, where it may change the rate of both the 
event of interest and the competing event. For EPS, death is a strong competing risk. We sought to 
perform a competing risks analysis, with the intention of subsequently creating a prognostic model. 
  
8.3 Methods and Materials 
8.3.1 Study Design 
This chapter describes a competing risks regression analysis for the events of death prior to EPS and 
EPS prior to death, using data from AnzData and the SRR with variables that could be included in a 
prognostic model.  
Only variables common to both datasets were included, these being age, diabetes gender and 
primary renal disease. Primary renal disease is known to predict mortality so adult polycystic kidney 
disease, glomerulonephritis and chronic pyelonephritis were categorised into a low mortality risk 
group and all other causes were considered high risk. The standard ethical and governance 
processes for each data source were followed. 
8.3.2 Data sources 
The AnzData registry includes all patients who have ever had RRT in Australia or New Zealand and 
they supplied data on all patients commencing PD. Cases of EPS were identifiable from 3 sources in 
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the routinely returned registry data: new comorbid conditions, causes of death and reasons for 
stopping PD, the latter 2 of which contain EPS specific codes. Primary renal disease, age, gender, 
comorbidity data and dates of PD start and cessation were all available. Only patients commencing 
RRT from 1/1/1990 were included in this study. 
The Scottish Renal Registry includes all patients on RRT in Scotland from 1991. EPS cases from a 
cohort of patients commencing PD between 1/1/2000 and 31/12/2007 were identified for a previous 
study (220). 35 cases were identified from follow up of this cohort until 30/6/2011. Registry data 
included age, gender, primary renal disease and dates of PD start and cessation.  
The GFS was an observational cohort study of incident and prevalent patients with 11 identified 
cases of EPS from 5 UK centres with complete PD patient data but this was considered too few cases 
to justify including a further dataset. 
8.3.3 Competing risks analysis 
For the initial analysis, we included all patients at the point of starting PD. Competing risks models 
according to Fine and Gray were developed with covariates included as above as well as a dataset 
identifier. The primary outcome was EPS occurring prior to death, with death prior to EPS the 
competing event. The covariates used were primary renal disease as a binary variable, age, dataset 
(AnzData/SRR), gender and the presence of diabetes. 
To compare the effects, standard Cox models for EPS and for death were also run. StataIC 12.1 
(College Station, Texas) was used for all analyses. Proportional hazards were checked with 
Schoenfeld residual plots and DFBetas were calculated to check for influential points (these checks 
were performed by Lucy Riley). 
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8.4 Results 
The study populations are described in Table 8-1. The populations were broadly similar although the 
AnzData patients were slightly older, with a slightly shorter mean follow up period. The rate of 
diabetes was significantly higher which may have contributed to the small difference in rates of ‘high 
comorbidity’ primary renal disease. The rates of EPS, not corrected for duration of PD or follow up 
period, were significantly different: AnzData 0.47% (77/16,274) and SRR 2.7% (34/1,237).  
Table 8-1: Characteristics of Study Populations 
Variable SRR AnzData p value 
Number of Patients 1,237 16,274  
EPS Cases 34 77  
Age 55.1 58.8 <0.001 
Male Gender 55.0% 54.8% 0.98 
Mean follow up period 64.5 60.7 <0.001 
Median (IQR) Duration of PD 22.6 (9.2-37.7) 21.1 (9.5-38.6) 0.2 
Median (IQR) Days on RRT prior to PD 0 (0-27) 0 (0-41) <0.001 
High comorbidity primary renal disease 59.9% 62.8% 0.04 
Diabetes 26.6% 40.3% <0.001 
 
Table 8-2: Competing Risks Model for Predictors of EPS 
Variable Sub-Distribution Hazard Ratio (95% CI) p value 
Age 0.976 (0.967-0.986) <0.001 
Male Gender (vs female) 0.95 (0.65-1.38) 0.8 
High Risk Primary Renal Disease (vs 
low risk) 
0.52 (0.32-0.84) 0.008 
Diabetes (vs no diabetes) 0.84 (0.48-1.47) 0.5 
Scottish Renal Registry (vs AnzData) 5.63 (3.78-8.38) <0.001 
 
The results from the competing risks analysis of EPS are shown in Table 8-2. As expected, gender was 
not significant, whilst increased age and high risk primary renal disease decreased the risk of EPS. 
Diabetes had no significant effect on risk of EPS but the risk of EPS between datasets was greatly 
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different, as demonstrated in Figure 8-1. A sensitivity analysis to check for a period effect was 
performed, restricting the AnzData patients to those starting PD from 1/1/2000 onwards. The same 
pattern was observed. No interactions between variables were observed. 
The Cox models with cause-specific hazards are shown in Table 8-3. For EPS, the effect of age 
disappears and that of high risk primary renal disease becomes statistically insignificant, but the 
dataset effect remains highly significant. The model for death showed that high risk primary renal 
disease, diabetes, increased age, female gender and being in the Scottish dataset were associated 
with increased risk of mortality.  
Table 8-3: Cox Models for Predictors of EPS and Death 
 EPS Death 
Variable 
Hazard Ratio 
(95% CI) 
p value 
Hazard Ratio 
(95% CI) 
p value 
Age (per year) 1.00 (0.99-1.01) 0.98 1.046 (1.044-1.048) <0.001 
Male Gender (vs female) 0.98 (0.67-1.43) 0.92 0.94 (0.91-0.98) 0.004 
Scottish Dataset (vs AnzData) 6.19 (4.06-9.42) <0.001 1.14 (1.05-1.24) 0.001 
Diabetes (vs no diabetes) 1.10 (0.65-1.88) 0.71 1.45 (1.39-1.52) <0.001 
High risk primary renal disease 
(vs low risk) 
0.68 (0.43-1.07) 0.092 1.55 (1.47-1.63) <0.001 
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Figure 8-1: Cumulative Incidence of EPS By Dataset 
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8.5 Discussion 
This analysis has proven the basic premise behind the intended prognostic model, that the risk of 
EPS can be predicted by factors associated with increased mortality. We have also demonstrated for 
the first time a significant difference in apparent risk of EPS by geographic region.  
That a competing risks analysis is appropriate for EPS in certain situations is demonstrated by the 
differences between the results of the competing risks and Cox analyses. Physicians and patients are 
interested in ‘real world’ risk factors, which include the effect of variables acting via alternative 
outcomes as provided by the competing risks analysis here. Cox models describe variables acting 
directly upon the outcome of interest, which may be of more interest if seeking pathophysiological 
insights.  
When comparing our results to existing literature, there is a significant problem in that we have not 
included the strongest known predictor of EPS, duration of PD, in our model. This is because 
inclusion of time varying covariates in a competing risks model requires knowledge of the covariate 
values after occurrence of the competing event that lead up to the eventual primary outcome. (225) 
In our case, this would require knowledge of what duration of time on PD leads to EPS after death 
has occurred, which is clearly impossible.  
The effect of age is compatible with previous findings as evidenced by relatively young mean ages 
(42 and 43.4 years old at diagnosis) in published case series (191,214) compared with typical ages for 
commencing dialysis, as well as a younger age in a case-control study from the AnzData registry. 
(226) It is also consistent with the multivariable analysis conducted with SRR data where age was not 
significant as logistic rather than competing risks regression was used. (168) Measures of 
comorbidity, including surrogates like the ‘high risk primary renal diagnosis’ in this study, have not 
been assessed in previous reports.  
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The lack of effect of diabetes is not surprising. The majority of diabetics in renal registries have 
diabetic nephropathy listed as their primary renal disease, (227) and would therefore be coded as 
‘high risk primary renal disease’ in this study. An independent effect of diabetes on EPS would be 
difficult to ascertain, given that it does not directly increase the risk of EPS. The sub-distribution 
hazard ratio for diabetes was below one but even using the largest study of EPS to date, the 
confidence intervals around diabetes remain wide.  
We have demonstrated the effect of time on the incidence of EPS (Figure 8-1), and the effect 
appears to differ from previously published reports in that the slope is approximately linear 
compared to slopes that increase with time. (168,205,206) This could be due to the use of the 
competing risks cumulative incidence function, rather than Kaplan-Meier estimators, or it could be 
due to the use of time, rather than time on PD. The relative roles of these explanations will require 
formal modelling of time on PD whilst taking account of the competing risk of death. 
The marked difference in risk between AnzData and SRR datasets is pronounced, which requires 
further investigation as these 2 datasets have led to some of the main publications that inform our 
current estimates of the magnitude of the problem of EPS. The difference could have several 
explanations. Firstly, a genetic difference cannot be excluded by this study.  Secondly, a difference in 
time on PD is possible although there was no difference in median time on PD between datasets. A 
more subtle effect such as better recognition of patients at risk of EPS in the AnzData region cannot 
be excluded and would require formal modelling of the effect of time on PD (e.g. in a multistate 
model). This explanation seems unlikely as there was limited recognition of EPS outside of Japan in 
the 1990’s.  
Thirdly, if patients in the AnzData region were significantly more likely to die, their risk of EPS would 
be lower but the Cox model demonstrates that patients from Scotland have a significantly higher risk 
of death. Finally, ascertainment bias may explain the difference completely. AnzData rely on 
routinely returned data with EPS coded as either the reason for stopping PD, the cause of death or 
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as a new comorbid condition whereas the SRR data identified EPS cases by specifically contacting 
each of the 10 units to ask for all cases of possible EPS. Aside from potential problems with the 
accuracy of routine registry data, EPS may well have milder forms that lead to diagnostic uncertainty 
and under-reporting in units less familiar with an unusual condition. (228)  
Limitations of this study include those discussed above to explain the differences between datasets, 
as well as the limited number of variables shared between datasets. The number of EPS cases is still 
relatively small, despite this study including the largest number of EPS cases in published studies to 
date, which will decrease the power to detect true associations. We have so far not included the 
effect of time on PD in the statistical model. Due to some of these limitations we have not yet 
established the ‘true’ baseline risk of EPS, which will require validation with other data sources. 
In summary, we have established the validity behind the concept of a prognostic model of EPS risk 
based on a competing risks methodology and uncovered important differences in apparent risk 
between 2 of the datasets used to inform current estimates of EPS risk. 
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9 Systemic effects of peritoneal dialysis 
9.1 Summary 
9.1.1 Background 
Glucose control is a significant predictor of mortality in diabetic peritoneal dialysis (PD) patients. 
During PD, the local toxic effects of intra-peritoneal glucose are well recognized, but despite large 
amounts of glucose being absorbed, the systemic effects of this in non-diabetic patients are not 
clear. 
9.1.2 Methods and Materials 
We analysed the Global Fluid Study, a prospective, observational cohort study initiated in 2002. A 
subset of 10 centres from 3 countries with high data quality were selected (368 incident and 272 
prevalent non-diabetic patients), with multilevel, multivariable analysis of the reciprocal of random 
blood glucose levels, and survival analysis by stratified-by-centre Cox regression model. 
9.1.3 Results 
The median follow up was 5.6 and 6.4 years respectively in incident and prevalent patients. Levels 
suggested undiagnosed diabetes in 3.7% and 5.4% of incident and prevalent patients respectively. 
On multivariable analysis glucose levels decreased with higher plasma sodium (β=0.002, 95%CI 
0.0005, 0.003) in incident patients, increased with age in incident (β=-0.007, 95%CI -0.01, -0.004, 
p<0.001) and prevalent (β=-0.004, 95%CI -0.008, -0.002, p=0.04) groups and increased with total 24 
hour dialysate glucose load (β=-0.0003, 95%CI -0.0005, -0.00001, p<0.001) in prevalent patients. For 
prevalent patients on Icodextrin a U-shaped association between random blood glucose and 
dialysate glucose was significant. Glucose levels predicted death in unadjusted analyses of both 
incident and prevalent groups but in an adjusted survival analysis they did not (for random blood 
glucose 6-10 compared with <6, Incident group HR 0.92, 95%CI 0.58, 1.46, Prevalent group HR 1.42, 
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95%CI 0.86, 2.34). 
9.1.4 Discussion 
In prevalent patients, random blood glucose levels are higher with increased total dialysate glucose 
load, and levels compatible with diabetes are under-recognised. Random blood glucose levels 
predict mortality in unadjusted analyses, but this association has not been proven in adjusted 
analyses. 
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9.2 Introduction 
There is a large amount of laboratory and clinical evidence of glucose-based peritoneal dialysate 
causing significant damage to the peritoneal membrane (56,229) but there have been far fewer 
studies documenting the systemic consequences of glucose-based dialysate. Significant glucose 
absorption from the peritoneum occurs during PD, such that glucose induced hyperosmolarity 
prevented the use of higher dialysate glucose concentrations. (230)   
Insulin resistance, along with hypertriglyceridaemia, high HDL/low LDL-cholesterol, hypertension and 
abdominal obesity, are defined as metabolic syndrome (MetS), (231,232) a condition thought to be 
related to sustained high sugar intake in the general population (233) and which predicts 
cardiovascular mortality. (232) Impaired fasting glucose predicts mortality, although not as well as 
impaired glucose tolerance, (234) and impaired fasting glucose increases during PD by up to 49.8%, 
along with other features of MetS.(185) These changes are all associated with glucose exposure, 
apart from impaired fasting glucose but this negative association was of glucose levels with historical 
glucose exposure, rather than a contemporaneous measure of glucose exposure. High glucose levels 
in PD patients are associated with mortality on univariable analysis (235) so whether a reduction in 
dialysate glucose exposure can mitigate the increase in hyperglycaemia is an important clinical 
question. 
We hypothesised that a contemporaneous measure of dialysate glucose loading would be associated 
with systemic glucose levels, and that impaired glucose homeostasis would independently predict 
mortality in non-diabetic patients. We used the GLOBAL Fluid Study to address these questions. 
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9.3 Methods and Materials 
Study design 
The study has been described in detail elsewhere but in brief, the Global Fluid Study is an 
international, multicentre, prospective cohort study of incident and prevalent patients commenced 
in 2002. Eligible patients were any PD patients over the age of 18 providing informed consent. 
Incident patients were defined as first data collection time point within the first 90 days of PD. 
Follow up was censored in December 2011. Ten centres were selected based on the highest quality 
existing data then iteratively checked to optimise final data completeness, and a cross-section of all 
non-diabetic patients from these units was used for this analysis at the point of study entry. Despite 
this process, one centre had significantly worse data quality in the final analysis, so sensitivity 
analyses excluding this centre were pre-specified. 
Data collection 
All clinical data was recorded on a custom built database (PDDB). Demography was recorded and 
comorbidity was assessed with the validated Stoke comorbidity index. Routine blood tests, including 
albumin and random blood glucose, were performed locally and, if necessary, converted into the 
same units. The timing of the plasma samples was not specified during the study so most were taken 
during peritoneal equilibration testing, but a few were taken during adequacy sampling, and none of 
them were specifically fasted samples. The samples of dialysate and plasma taken at the first 
assessment within the study were assayed for IL-6 by electrochemiluminescence. 
PD related measurements included residual renal function, dialysis regime and dose, and peritoneal 
membrane function using the peritoneal equilibration test (solute transport rate: dialysate to plasma 
creatinine ratio (PSTR) and net UF capacity at 4 hours with 2.27% or 3.86% glucose). The Daily 
Dialysate Glucose (DDG) exposure was calculated as total grammes of unhydrated glucose within the 
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24 hour dialysate regime as recorded on the day of assessment (e.g. 2 litres of 1.36% glucose based 
dialysate = 2 x 13.6 grammes = 27.2 grammes) 
Statistical analysis 
Comparisons between glucose categories were made with one-way ANOVA, Kruskal-Wallis or chi-
squared tests depending on the variable. 
Missing data, ranging from 0 to 4.8% for different variables, were considered missing at random and 
complete case analysis was used. Pre-specified sensitivity analyses excluding one centre with the 
highest level of missing data were performed.  
Multivariable multilevel, random intercept models, which account for centre effects, were used to 
explore determinants of random blood glucose. To achieve normally distributed level 1 residuals, the 
reciprocal of glucose was used as the dependent variable. Significance testing was by the Wald test. 
The Iterative Generalised Least Squares method was used for coefficient estimation.  
Log-rank tests were used for univariable, and Cox models stratified by centre with robust standard 
errors were used for multivariable, survival analysis. To allow for non-linearity glucose levels were 
categorised into <6 mmol/l, 6-10mmol/l and >10 mmol/l, the levels chosen to aid biological 
interpretability whilst maintaining group size.  A secondary analysis with glucose included as a 
continuous variable in the same adjusted Cox model was also performed. 
MLWin 2.26 was used via runmlwin for multilevel regression and StataIC 12 (StataCorp LP, College 
Station, TX) for the other calculations. 
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9.4 Results 
9.4.1 Patient Details 
Demographic and clinical data are shown in Table 9-1. There were 576 incident patients, with 
glucose available in 548, of whom 327 were non-diabetic with 116 deaths during a median follow up 
of 5.93 years. There were 384 prevalent patients, with glucose available in 360, of whom 242 were 
non-diabetic with 96 deaths during a median follow up of 7.29 years.  In incident patients, glucose 
levels were ≥6.2 mmol/l in 29.8%, 7.0-11.1mmol/l in 15.3% and >11.1mmol/l in 3.7%, and in 
prevalent patients they were ≥6.2 mmol/l in 32.6%, 7.0-11.1mmol/l in 14.0% and >11.1mmol/l in 
5.4%. Outcome data was unavailable for 8 prevalent patients from one centre and 16 incident 
patients (15 from the same centre), but sensitivity analyses excluding this centre entirely made no 
difference. 
9.4.2 Factors affecting systemic glucose levels 
Using multilevel multivariable models, in incident patients DDG load did not predict glucose levels on 
unadjusted or adjusted analysis (Figure 9-1 and Table 9-2). On both unadjusted (β=-0.003, 95% CI (-
0.005,-0.001), p=0.001) and on adjusted analysis (Figure 9-1 and Table 9-2), the DDG load predicted 
random blood glucose levels in prevalent patients. Sensitivity analyses excluding one centre with 
higher levels of missing data slightly altered the results in prevalent patients, by strengthening the 
association with DDG and weakening it with albumin. We also tested for 3 specific interactions - 
between DDG and peritoneal solute transport rate, DDG and the type of PD (automated PD versus 
continuous ambulatory PD), and DDG and Icodextrin usage. The first 2 had no significant effect, but a 
linear interaction with Icodextrin usage did and this improved with the addition of a quadratic term. 
Predicted values from the regression model on or off Icodextrin are    
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Table 9-1: Patient Details 
  
Incident Prevalent 
All Glucose <6 Glucose 6-10 
Glucose 
>10 
p 
value  
All Glucose <6 
Glucose 6-
10 
Glucose 
>10 
p 
value 
Number 327 219 95 13   242 151 74 17  
Age (years) 55.1 (17.0) 52.7 (17.4) 59.9 (15.6) 59.7 (12.2) 0.002 53.3 (15.8) 52.0 (16.2) 55.3 (15.5) 56.5 (12.8) 0.1 
Female Gender 34.3% 36.2% 40.6% 46.2% 0.4 47.9% 49.7% 47.3% 35.9% 0.5 
Korean 37.4% 33.0% 42.6% 76.9% 0.002 34.7% 29.1% 41.9% 52.9% 0.1 
Duration of PD  
(median, days) 
38 
36  
(22-52) 
42  
(29.5-51.5) 
36  
(28.5-51) 
0.1  
369  
(177-819) 
377  
(193-818) 
358  
(162-716) 
371  
(167-605) 
0.7 
BMI (kg/height2) 24.8 (4.8) 24.6 (4.9) 25.3 (4.7) 23.9 (3.8) 0.4 24.6 (4.4) 24.4 (4.0) 25.3 (4.9) 22.9 (3.9) 0.1 
Blood pressure (mmHg) 
135/81  
(20/12) 
135/82  
(20/12) 
136/79  
(22/13) 
137/80  
(24/14) 
0.6/0.3 
134/82  
(21/13) 
135/82  
(22/14) 
132/81  
(17/10) 
136/83  
(23/13) 
0.6/0.7 
4 hour PSTR (D/P Cr) 0.69 (0.12) 0.69 (0.13) 0.69 (0.10) 0.71 (0.13) 0.9 0.70 (0.11) 0.71 (0.12) 0.70 (0.11) 0.73 (0.13) 0.5 
Albumin (g/l) 36.1 (5.0) 36.5 (5.0) 35.5 (4.7) 34.2 (5.7) 0.1 36.1 (4.7) 36.7 (4.4) 35.1 (4.7) 33.9 (5.6) 0.005 
Urine volume 
 (median, litres) 
0.9 
(0.48-1.52) 
0.99 
(0.50-1.70) 
0.85 
(0.49-1.21) 
0.6 
(0.20-1.24) 
0.2 
0.52 
(0.15-1.13) 
0.57 
(0.20-1.21) 
0.55 
(0.14-1.15) 
0.3 
(0.02-0.93) 
0.3 
Comorbidity 
(Low/Intermediate/High) 
56.8, 31.0, 
12.3% 
57.3, 39.9, 
2.8% 
56.4, 41.5, 
2.1% 
53.8, 38.5, 
7.7% 
0.95 
62.8, 34.3, 
2.9% 
64.9, 32.5, 
2.6% 
60.8, 35.1, 
4.1% 
52.9, 47.1, 
0% 
0.8 
Plasma IL-6  
(median, pg/ml) 
1.27 
(0.55-2.75) 
1.2 
(0.50-2.55) 
1.73 
(0.66-3.13) 
1.75 
(0.74-2.74) 
0.1 
1.1 
(0.58-2.00) 
0.94 
(0.54-1.62) 
1.51 
(0.82-2.71) 
0.95 
(0.71-1.51) 
0.004 
Total Daily Dialysate 
Glucose (grammes/day) 
120.8 
(36.8) 
123.8 
(41.2) 
114.5 (25.9) 
117.6 
(20.4) 
0.2 132.0 (45.8) 
128.7 
(38.9) 
136.2 (50.0) 
142.7 
(74.4) 
0.3 
Total dialysate volume 
(litres) 
7.98 (1.28) 7.97 (1.47) 8.02 (0.86) 7.93 (0.25) 0.8 8.35 (1.95) 8.37 (2.06) 8.32 (1.83) 8.29 (1.57) 0.98 
Biocompatible solution 
usage 
23.8% 25.3% 18.1% 38.5% 0.2 16.2% 16.7% 13.5% 23.5% 0.6 
Icodextrin solution usage 14.8% 15.2% 16.0% 0% 0.3 23.8% 25.5% 23.0% 11.8%  0.5 
Use of APD 6.5% 8.4% 3.2% 0% 0.09 15.8% 16.7% 15.1% 11.8% 0.9 
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Figure 9-1: Scatterplot of Plasma Glucose vs. Total Daily Dialysate Glucose in Prevalent Patients 
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Table 9-2: Predictors of the Reciprocal of Random Blood Glucose Levels 
 Incident Prevalent 
Coefficient (95% CI) p value Coefficient (95% CI) p value 
Daily Dialysate 
Glucose 
0.0001 
(-0.00002, 0.0003) 
0.09 -0.0003 
(-0.0005, -0.00001) 
<0.001 
Korean -0.03 
(-0.05, -0.001) 
0.04 -0.01 
(-0.05, 0.03) 
0.6 
BMI -0.0008 
(-0.0020, 0.0003) 
0.1 -0.0006 
(-0.002, 0.0007) 
0.4 
Age 
(per year) 
-0.0007 
(-0.0010, -0.0004) 
<0.001 -0.0004 
(-0.0008, 0.0002) 
0.04 
Systolic BP  
(per 10) 
-0.001 
(-0.004, 0.001) 
0.3 0.002  
(-0.006, 0.005) 
0.1 
Peritoneal Solute 
Transport Rate 
0.04 
(-0.01, 0.09) 
0.2 -0.03 
(-0.08, 0.03) 
0.4 
Duration of PD -0.006 
(-0.14, 0.002) 
0.2 -0.0002 
(-0.004, 0.003) 
0.9 
Albumin 0.0001 
(-0.001, 0.001) 
0.8 0.001 
(-0.0003, 0.002) 
0.1 
Plasma Sodium 0.002 
(0.0006, 0.003) 
0.005 0.002 
(-0.0002, 0.003) 
0.08 
Plasma IL-6 
(per log10 order) 
-0.003 
(-0.02, 0.01) 
0.8 -0.01 
(-0.04, 0.01) 
0.4 
Urine Volume 0.002 
(-0.006, 0.009) 
0.6 -0.001 
(-0.01, 0.01) 
0.8 
Comorbidity -0.00006 
(-0.007, 0.007) 
0.99 0.004 
(-0.003, 0.01) 
0.3 
Icodextrin 0.008 
(-0.007, 0.023) 
0.3 -0.15 
(-0.24, -0.06) 
0.01 
Icodextrin*Dialysate 
Glucose 
Icodextrin*Dialysate 
Glucose^2 
  0.002 
(0.0007, 0.003) 
-0.000005 
(-0.000009, -0.000001) 
0.002 
 
0.01 
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Figure 9-2: Icodextrin Effect on Plasma Glucose Interacting with Dialysate Glucose 
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9.4.3 Effect of glucose on mortality 
Kaplan-Meier plots of survival in non-diabetic patients by random blood glucose categories are 
shown in Figure 9-3 and Figure 9-4, and they both demonstrated a significant difference on 
unadjusted analysis. Table 9-3 shows the results of adjusted Cox models for the same groups, 
whereby the effect of glucose on mortality is completely removed by adjustment in incident 
patients. In prevalent patients there is still a trend towards higher mortality but it is not statistically 
significant. 
In a secondary analysis, glucose was included as a continuous variable in the same adjusted model 
and it was not statistically significant for incident patients (HR 1.0002 for 1mmol/l increase, 95% CI 
(0.97, 1.03), p=0.993) or for prevalent patients (HR = 1.035 for 1mmol/l increase, 95% CI (0.96, 1.11), 
p=0.4).  
Figure 9-3: Survival by random blood glucose in Incident non-diabetic PD patients 
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Figure 9-4: Survival by Random Blood Glucose in Prevalent Non-Diabetic PD Patients 
 
 
Table 9-3: Predictors of Mortality 
 Incident Patients Prevalent Patients 
 Hazard Ratio (95% CI) p value Hazard Ratio (95% CI) 
p 
value 
Age  
(per decade) 
1.92 (1.51-2.41) ** <0.001 1.78 (1.48-2.14)** <0.001 
Plasma IL-6  
(per log order) 
3.07 (1.70-5.54)** <0.001 3.08 (1.22-7.79)* 0.02 
Albumin 0.96 (0.92-0.999)* 0.049 0.97 (0.93-1.02) 0.3 
PSTR  
(per 0.1 increased D/P Cr) 
1.05 (0.91-1.21) 0.5 1.24 (1.02-1.50)* 0.03 
Duration of PD  
(per month) 
1.14 (0.70-1.85) 0.6 1.013 (1.003-1.023)* 0.01 
RRF  
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9.5 Discussion 
This is the first study to demonstrate an effect of dialysate prescription on systemic glucose 
metabolism in non-diabetic patients, with higher random blood glucose levels correlating with 
increasing dialysate glucose exposure. We have also replicated the finding of unadjusted higher 
mortality rates with higher plasma glucose levels in a more widely generalisable population than 
shown previously, (235) although this association was not statistically significant in a more fully 
adjusted analysis than has been possible previously. 
The American Diabetic Association (ADA) defines impaired glucose metabolism as either impaired 
fasting glucose or impaired glucose tolerance (236). This makes the interpretation of all studies on 
this subject in PD patients limited by the glucose absorption which occurs during PD because, as the 
level of absorption is not usually known at the point of sample acquisition, it cannot be truly 
considered fasting unless PD is withheld, and a glucose tolerance test requires a defined dose 
supplied enterally. However the large studies necessary to detect subtle effects require 
straightforward tests. Our study used a pragmatic solution of completely random blood glucose 
levels and other studies opted for orally but not peritoneally fasted glucose levels although the 
diagnostic criteria for impaired fasting glucose or impaired glucose tolerance in the general 
population cannot be assumed to hold for either of these options in PD patients. 
Previous studies of abnormal glucose metabolism have shown that transplant wait-listed PD patients 
in the US had a similar but lower incidence of diabetes than haemodialysis patients (237) however a 
study of 195 non-diabetic Chinese patients found an increase from 12.8% to 62.6% in impaired 
fasting glucose (>6.2mmol/l) during 34 months of PD (185) and a study of 252 non-diabetic Chinese 
patients found new onset impaired fasting glucose (7.0-11.1mmol/l) in 19.0% after 1 month of PD. 
(235) Our study had a much lower rate of glucose levels >6.2mmol/l compared to 62.6%. (185) This 
was despite our patients not orally fasting although our study sampled the patients after only 12 
months of PD. Our results in incident patients are similar to, but lower than, those from Szeto et al. 
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(235) These rates in conjunction imply that oral fasting does not have a large impact on the glucose 
levels in PD patients. 
Both our study and that of Szeto et al suggest that undiagnosed diabetes is an issue in PD patients. 
The ADA diagnostic criteria (236) use casual glucose levels >11.1mmol/l with suggestive symptoms 
to diagnose diabetes and neither of these 2 studies had details of symptoms but Szeto found 8.3% in 
an incident group (235) and we found 3.7% and 5.4% in incident and prevalent groups respectively 
to have levels compatible with diabetes.  
In line with results from Szeto, (235) age was predictive of glucose levels in patients after 1 month of 
PD but using a multivariable model we also found plasma sodium to have a strong negative 
association with glucose. An association between hyponatraemia and hyperglycaemia is well 
recognised in other patient groups, and is thought to be due primarily to glucose-associated osmotic 
pressure causing a dilutional effect.(238) This might explain some of the association with 
comorbidity, inflammation and albumin found by Szeto. (235) 
Ethnicity is a strong risk factor for the development of type II diabetes, with white Caucasians having 
a lower risk than Asians, Hispanics and Afro-Caribbeans. (239) This is commensurate with our 
observation in the incident group of Koreans having higher glucose levels than the predominantly 
white Caucasian reference population and may partly explain the higher glucose levels in the study 
by Szeto et al. (235) 
The peritoneal solute transport rate is one of the potential determinants of the systemic effects of 
dialysate glucose, through modification of glucose absorption. We found no effect, possibly because 
the difference in absorption was relatively minor in comparison to the total amount absorbed 
however this study used a dialysate/plasma creatinine ratio as the measure of peritoneal solute 
transport rate. The D/D0 glucose may be a better measure for this analysis but was not available. 
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Another important clinical question is whether it matters how the dialysate is prescribed. We tested 
for this by including the type of PD (APD vs CAPD) both as a main effect and an interaction and found 
no effect.  This suggests that how the dialysate glucose is prescribed matters less than the amount 
that is prescribed. 
Icodextrin does not affect glucose levels in diabetic PD patients (240) so, although the main effect of 
Icodextrin on glucose levels was not significant, we also tested for an interaction which was highly 
significant. For patients on Icodextrin the predicted glucose initially declined with increased DDG but 
subsequently rose. Indication bias could explain this, if an abnormality of glucose metabolism not 
formally diagnosed as diabetes was recognised and treated with Icodextrin usage and glucose 
minimisation. The same relationship between increased DDG and glucose levels found in patients 
not on Icodextrin could explain the subsequent rise in glucose levels with increased DDG for patients 
on Icodextrin. 
The survival analysis has confirmed the results from Szeto et al, (235) with a significant unadjusted 
effect on mortality of plasma glucose levels, but we extended this into an adjusted analysis. In 
incident patients there is no significant independent effect on mortality but it remains unclear 
whether there is an effect in prevalent patients, when dialysate glucose has its greatest effect. That 
two studies have now shown an association between plasma glucose levels and unadjusted 
mortality rates appears to contradict a more recent finding from Szeto et al where MetS, no matter 
which definition was used, was not associated with mortality. (241) This apparent inconsistency may 
be explained by the limitations of applying diagnostic criteria used in the general population for 
MetS to the PD population. 
That ethnically Chinese patients develop aspects of MetS during PD, and that this is associated with 
prolonged glucose exposure, was established in 2008 by Jiang et al, (185) but they found no 
association between glucose exposure and systemic levels. This was possibly as they correlated the 
most common dialysate glucose prescription during PD with subsequent glucose levels rather than 
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measuring the prescription in use at the time of glucose measurement. Our study used simultaneous 
measurements of dialysate glucose exposure and systemic levels to successfully demonstrate this 
association in a mix of British, Canadian and Korean prevalent patients. The difference in this 
association between incident and prevalent patients may be due to the sustained glucose loading 
prevalent patients have undergone but informative censoring could also theoretically explain this 
difference. 
In the absence of larger studies using better markers of glucose metabolism, clear guidance on the 
safe dose of dialysate glucose is not possible, but this study provides more evidence in support of 
minimising dialysate glucose exposure and suggests that, particularly if larger glucose doses are 
being used, systemic glucose metabolism should be monitored. 
Limitations of this study include evidence of digit preference in blood pressure measures and 
incomplete information on the presence of metabolic syndrome as the study was not primarily 
designed to investigate glucose metabolism. Glucose levels were measured locally although use of a 
multilevel model should account for this. The study did not contain sufficiently reliable information 
on automated PD regimes to investigate the effect of different regimes rather than total dialysate 
glucose exposure. Whilst the study used 10 centres from 3 countries a degree of selection bias might 
be present as the selected centres had better data quality. As an observational study, causality 
cannot be proven although the association between dialysate glucose and systemic levels would 
fulfil most of the Bradford-Hill criteria for causality.  
Dialysate glucose load appears to have a major effect on systemic glucose levels and the effects are 
under-recognised. This should be factored in when prescribing peritoneal dialysate and increased 
awareness of the potential problems are necessary.  
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10 Conclusion 
10.1 Findings So Far 
10.1.1 Chapter 4 
The previous literature did not contain clarity on the relative roles of peritoneal and systemic 
inflammation, both in relation to each other, and in relation to PSTR and patient survival. In Chapter 
4 we have shown that the peritoneal membrane is inflamed, that this is mostly independent of 
systemic inflammation and that peritoneal inflammation is the strongest determinant of PSTR 
through IL-6. We have further shown that patient survival is directly affected by systemic and not 
peritoneal inflammation, although PSTR is still a determinant of patient survival, so peritoneal 
inflammation may have an indirect effect on patient survival. One important qualification to the 
above paragraph lies in the relationship between peritoneal and plasma IL-6, which was a consistent 
finding in all analyses.  
10.1.2 Chapter 5 
This chapter needs to be regarded as an exploratory analysis, partly as it was driven by the 
hypothesis that analysing changes with time in biological variables by using pre-specified arbitrary 
time points can lead to misleading results, and partly because it was using cross-sectional data to 
infer longitudinal change. Despite these misgivings, we replicated the previous finding of a sharp 
increase in PSTR in the first few weeks of PD, suggesting that, as a minimum, the early changes do 
reflect those of the PD population and are not due to informative censoring. This change was 
accompanied by an increase in systemic inflammation and in peritoneal IL-6. There was also an 
unexpected, but very consistent, finding of a fall in peritoneal inflammation over the subsequent 16 
months.  
10.1.3 Chapter 6 
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We have demonstrated that PD patients with subsequent EPS have a more inflamed peritoneum, 
that this is not evident when measuring the PSTR and that plasma IL-6 levels are also higher in this 
group 
10.1.4 Chapter 7 
In this chapter we replicated the finding that PSTR is not significantly different between EPS patients 
and time matched controls, but EPS patients do have a significantly poorer UF capacity and higher 
dialysate glucose requirements, which is likely to be due to increased fibrosis. 
10.1.5 Chapter 8 
Managing PD patients to minimise the risk of EPS, whilst optimising the length of time they can stay 
on their chosen modality is an important clinical principle, and this chapter describes the 
development of a prognostic model to aid in this.  
10.1.6 Chapter 9 
Whilst the preceding 3 chapters dealt with a local complication of PD, this chapter describes a novel 
feature of the systemic complications of PD where increased dialysate glucose loading impairs 
systemic glucose metabolism in non-diabetic patients.  
10.2 Discussion 
Having established in chapter 4 that the peritoneal membrane is inflamed, one of the key questions 
is ‘what is the significance of peritoneal inflammation’. There are a number of ways in which it could 
be significant described in the following hypotheses: 
1 - Peritoneal inflammatory mediators are absorbed, partially driving the systemic inflammation 
associated with malnutrition, atherosclerosis and mortality that is common in dialysis patients 
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2 – Peritoneal inflammation drives fibrosis with a decrease in the osmotic conductance to glucose 
and the subsequent risks of UF failure, technique failure and EPS 
3 – Peritoneal inflammation drives angiogenesis, and thereby is responsible for the increase in PSTR 
associated with long term PD, of relevance because increased PSTR still contributes to increased 
mortality 
4 – The level of peritoneal inflammation could alter the susceptibility of patients to develop 
infectious peritonitis by altering local immune responses 
Of these hypotheses, this thesis provides some supportive evidence for the first 2.  
Taking the first hypothesis, chapters 3, 4 and 5 all provide strong evidence of an association between 
dialysate and plasma IL-6 levels. Furthermore, as shown in chapter 4, for almost all patients there is 
a steep diffusion gradient from dialysate to peritoneal capillary and assuming that IL-6 production 
occurs within the peritoneal membrane rather than in the dialysate, local concentrations should be 
even higher with a steeper gradient. 
 If EPS is considered, this is generally accepted to be an inflammatory process and that systemic 
inflammation is evident in many patients, strongly suggesting that, as is the case with other local 
inflammatory conditions that causes systemic inflammation (e.g. gout), local inflammatory 
mediators diffuse into the systemic circulation. In Chapter 6, we showed that local inflammation 
precedes the diagnosis of EPS but the systemic inflammation is also evident pre-diagnosis suggesting 
that systemic evidence of local inflammation occurs earlier than realised. 
In Chapter 5, we showed that initiation of PD appears to induce a systemic inflammatory response. It 
is conceivable that this increase in inflammation is driven by absorption of dialysate contents such as 
GDPs but equally possible is the explanation that PD induces peritoneal inflammation (hence the rise 
in dialysate IL-6), which drives the increase in PSTR, and the IL-6 is absorbed and drives the increase 
in systemic inflammation.  
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As with all studies, there are caveats to this evidence (as discussed in the chapters), but the first 
hypothesis is one of the simplest explanations for the findings. The only other obvious rival 
hypothesis for the associations described would be a genotypic association where IL-6 alleles 
associated with increased IL-6 production cause an increase in both peritoneal and systemic 
production simultaneously, however this would not be such a convincing explanation for the findings 
in the case of EPS or for the changes occurring at the start of PD. 
The supportive evidence for the second hypothesis is weaker but still suggestive. In chapter 7 we, as 
well as another group subsequently, (195) showed that patients with subsequent EPS have a 
decreased osmotic conductance to glucose compared with time matched controls, likely due to 
fibrosis. In chapter 5, we also showed that patients with subsequent EPS had worse peritoneal 
inflammation. The simplest explanation would be that the inflammation drives the fibrosis, as is 
thought to occur in many conditions, but this evidence is circumstantial.  
10.3 Clinical Relevance 
Although the peritoneum is inflamed during PD, this is not in itself clinically relevant so further work 
is required to establish the true clinical relevance. Most of the potentially relevant mechanisms by 
which peritoneal inflammation could have a clinical impact are discussed in the preceding section 
(10.2), but one further mechanism lies in the impact on PSTR. We have shown that this still predicts 
mortality in the most current study to examine this despite some articles suggesting that this 
concern is in the past, (242) and inflammation is the strongest determinant of this. There is a need to 
monitor current practice patterns as Icodextrin and APD have both been shown to improve the 
mortality associated with faster PSTR.  
We have also demonstrated that decreased UF capacity, increased dialysate glucose requirements 
and increased dialysate inflammatory markers detect patients more likely to develop EPS. This 
suggests that it may be possible to use these factors to identify accurately the patients who require a 
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switch to HD to prevent EPS, without having to switch patients who would not have developed EPS. 
Once the prognostic model described in Chapter 8 has been fully developed and validated, data from 
the ongoing PD-CRAFT study will allow the testing of this theory. 
By investigating the association between local and systemic effects of PD, we have shown that even 
in non-diabetic PD patients, increased dialysate glucose adversely affects systemic glucose 
metabolism. The obvious clinical implication of this is to minimise the dialysate glucose load, but this 
should not substantially alter current clinical management as there is already data linking dialysate 
glucose load to adverse effects in the peritoneal membrane (56), suggesting that dialysate glucose 
should be minimised. There is also data suggesting that glucose avoidance might be associated with 
harm if not managed carefully. (243) This study does however add further weight to need for new 
PD solutions not reliant on glucose and justifies further study, investigating the role of glucose 
loading in visceral fat accumulation and metabolic syndrome, and whether these effects are 
independently associated with mortality in an appropriately powered study. 
10.4 Further Studies 
Numerous further studies are possible, to investigate some of these findings. For studies that could 
be completed using the existing data possibilities include: 
1 Investigating the possibility of using a combination of 24 hour UF and PET data to estimate the 
osmotic conductance to glucose, which could allow in-depth investigations of the timescale of 
fibrotic development, and mediators which play a role in it 
2 Studying the role of angiogenesis. In particular, it would be possible to test whether baseline 
inflammation predicts future PSTR, and subsequently, whether angiogenic factors are predictive 
of future PSTR over and above the effect of inflammation 
3  Whether peritonitis predicts an increase in long term inflammation, or inflammation predicts 
peritonitis, has not previously been studied with sufficient large patient numbers to detect 
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potentially subtle changes. To study this with GFS data would require some checking of the 
peritonitis data 
4 One unexpected finding was the association between higher systolic BP and lower dialysate IL-6 
levels. This requires an initial replication to validate the finding. If true, one hypothesis to 
explain it would be that a higher BP increases peritoneal perfusion, thereby increasing the 
clearance of dialysate cytokines to the circulation. This would be testable in further studies 
5 Dialysate IL-6 and/or TNF-α could be added to the prognostic model of EPS in the validation 
phase of PD-CRAFT to see if this does improve the predictive power of existing factors 
6 The existing repeated measures data in GFS could be used as a validation of the preliminary 
finding of a fall in peritoneal inflammation between months 2 and 18 of PD, as well as providing 
a more powerful model to detect the expected decrease in PSTR  
7 A more detailed study to confirm the provisional finding that PD induces systemic inflammation 
with further clinical detail to delineate the relative roles of catheter insertion and dialysate 
8 An animal model to test the hypothesis that peritoneal/dialysate IL-6 can induce systemic 
inflammmation 
9 Development of a model to estimate the osmotic conductance to glucose from the existing data 
sets through inclusion of 24 hour UF rates combined with PET data, which would allow 
associations with fibrosis to be tested more directly 
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11 Appendices 
11.1 Appendix A – Supplementary Analysis of Predictors of Dialysate IL-6 
In Chapter 4, determinants of dialysate IL-6 concentrations were investigated. In the primary 
analysis, PSTR was excluded as this is highly likely to be an effect of IL-6, rather than a cause of high 
levels of IL-6, however there is potentially a complicated interaction with solution types. A fast PSTR 
will be treated with higher glucose concentrations and converting to using Icodextrin solutions, but 
higher glucose concentrations and the use of Icodextrin solutions are two of the main mechanisms 
by which PD may be inducing peritoneal inflammation. Table 11-1 shows a further analysis, using the 
same data and methodology as that for Table 4-5, but including PSTR as a predictor to attempt to 
distinguish an effect of solution type.  
The inclusion of PSTR makes little difference to the overall results. The change in the predicted effect 
of dialysate glucose concentration makes the effect statistically insignificant in the incident patients, 
and it remains insignificant in the prevalent group. The effect of Icodextrin on dialysate IL-6 remains 
significant although the magnitude is attenuated. The p value for BMI in the prevalent patients drops 
to below 0.05, suggesting a possible effect of BMI on dialysate IL-6, but this is a secondary analysis 
so this must be viewed with significant caution. 
This suggests that Icodextrin has an additional effect on peritoneal inflammation, over and above 
the general effect of PD. This is consistent with the existing literature. Martikainen reported a 
randomised, cross-over trial of 22 patients, where stable PD patients had 8 weeks of either nocturnal 
Icodextrin or daytime amino-acid dialysate, with 8 weeks washout, then 8 weeks of the other 
therapy.(51) Dialysate taken from the end of the nocturnal dwell at the start and end of each regime 
demonstrated that IL-6 rose with both Icodextrin and amino-acid dialysate, whilst Icodextrin was 
associated with an increase in dialysate TNF-α as well as plasma CRP.  
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Table 11-1: Predictors of Dialysate IL-6 Including PSTR 
 
Incident Prevalent 
Coefficient (95% CI) 
p 
value 
Coefficient (95% CI) 
p 
value 
Age  
(per decade) 
0.030 * 
(0.007, 0.053) 
0.01 
0.05 ** 
(0.02, 0.08) 
0.003 
BMI 
0.003  
(-0.005, 0.011) 
0.4 
0.01 * 
(0.001, 0.02) 
0.03 
APD usage 
-0.03  
(-0.18, 0.12) 
0.7 
-0.01 * 
(-0.3, -0.003) 
0.046 
Systolic BP 
(per 10 mmHg) 
-0.03  
(-0.04, -0.01) 
0.7 
-0.03 ** 
(-0.05, -0.007) 
0.009 
Male Gender 
0.01  
(-0.06, 0.09) 
0.7 
0.02  
(-0.07, 0.11) 
0.6 
Duration of PD 
(per year) 
-0.1  
(-0.8, 0.6) 
0.8 
0.003  
(-0.03, 0.03) 
0.8 
Biocompatible solution 
usage 
0.01  
(-0.07, 0.1) 
0.8 
0.13  
(-0.001, 0.26) 
0.052 
Icodextrin usage 
0.2 ** 
(0.1, 0.3) 
<0.001 
0.1 * 
(0.02, 0.3) 
0.03 
Average Daily Glucose 
(per g/L) 
0.009  
(-0.001, 0.019) 
0.08 
-0.008 
 (-0.02, 0.005) 
0.2 
PSTR 
(per 0.1 D/P Cr) 
0.10 ** 
(0.07, 0.14) 
<0.001 
0.15 ** 
(-0.11, 0.19) 
<0.001 
Dialysate TNF 
0.7 ** 
(0.4, 0.9) 
<0.001 
0.6 ** 
(0.2, 0.9) 
0.001 
Dialysate IFN 
0.04  
(-0.08, 0.15) 
0.5 
-0.02  
(-0.16, 0.13) 
0.8 
Plasma IL6 
0.3 ** 
(0.2, 0.4) 
<0.001 
0.3 ** 
(0.1, 0.5) 
0.004 
Plasma TNF 
-0.1  
(-0.4, 0.1) 
0.2 
0.3  
(-0.04, 0.6) 
0.09 
Plasma IFN 
0.04  
(-0.08, 0.2) 
0.5 
-0.1  
(-0.3, 0.05) 
0.2 
Plasma IL1 
-0.04  
(-0.4, 0.3) 
0.8 
-0.04  
(-0.4, 0.3) 
0.8 
Diabetes 
-0.02  
(-0.10, 0.06) 
0.6 
0.03  
(-0.09, 0.16) 
0.6 
Comorbidity 
0.02  
(-0.02, 0.07) 
0.3 
-0.006  
(-0.06, 0.05) 
0.8 
Residual Renal Function 
(per litre) 
0.006  
(-0.04, 0.06) 
0.8 
-0.11 ** 
(-0.18, -0.03) 
0.006 
Korean 
-0.1  
(-0.3, 0.1) 
0.4 
-0.4  
(-1.0, 0.2) 
0.2 
* p<0.05, **p<0.01 
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There has been one RCT study of dialysate markers with patients randomised to 12 months of a 
regime described as ‘biocompatible’ of Icodextrin with biocompatible dialysate and one amino acid 
dialysate or a regime of standard glucose-based dialysate.(55) The dialysate sample was taken from 
the overnight dwell of Icodextrin or standard glucose dialysate, with the ‘biocompatible’ group 
developing higher dialysate levels of IL-6, CA125 and adiponectin. A secondary analysis of the Balanz 
trial has shown that biocompatible dialysate had no effect on dialysate IL-6 levels, (244) compatible 
with the finding from the Global Fluid Study. Whether amino acid dialysate affects dialysate cytokine 
levels is not known but Icodextrin seems the most likely explanation for the increase in IL-6. Of note, 
the ‘biocompatible’ group in this study also had faster PSTR by the end of the study. 
Moriishi reported a cohort study of 8 patients with dialysate white cell counts and IL-6 levels 
measured before and after switching a nocturnal dwell from 2.5% glucose to Icodextrin.(52) The 
white cell count rose with Icodextrin although IL-6 did not change. This study was very small and as a 
single cross-over non-randomised study, can only be considered as weak evidence. 
Opatrna reported 33 patients allocated to a Physioneal only group or Physioneal with overnight 
Icodextrin based on whether the UF from a 4 hour PET was greater than or less than 400ml. The 
Icodextrin group had a faster baseline PSTR and had higher dialysate IL-6 levels but this study has 
significant indication bias.(53) 
Taken in combination with the previous studies, our study shows that it is highly likely that 
Icodextrin increases peritoneal inflammation. 
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11.2 Appendix B - Assumption Checks for Chapter 4 
 
All models were built after checking the variance inflation factor (VIF) of covariates using a maximum 
allowed VIF score of 5 and, where necessary, the correlation matrices. 
11.2.1 Post-estimation Checks for Multilevel Models  
The process for model checking is illustrated by the checks applied to the multilevel model of D/P Cr 
in incident patients, shown in Figure 11-1, Figure 11-2, Figure 11-3 and Figure 11-4. Level 1 residuals 
were checked for normality with a by-eye assessment of normal quantile plots, and transformations 
from the ‘ladder-of-powers’ applied to achieve normality as necessary. The leverage and influence 
residuals were checked with boxplots and extreme outliers identified. Individuals with these 
residuals were identified and the data checked and corrected. Where the data was clinically 
implausible and could not be corrected, the data was set to missing, but if the data was clinically 
plausible the data was retained. If the data was retained, a sensitivity analysis excluding this point 
was performed but the results at no point significantly changed the outcome of the model. The 
standardised residuals were also plotted against the predicted values of D/P Cr to check for 
homoscedasticity. 
 
 
Figure 11-1: Patient Level Residual Normal Quantile Plot for Incident Model of D/P Cr 
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Figure 11-2: Leverage Residuals for Model of D/P Cr 
 
 
Figure 11-3: Boxplot of Influence Residuals for Incident Model of D/P Cr 
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Figure 11-4: Homoscedasticity Check for D/P Cr Model in Incident Patients 
 
 
11.2.2 Post Estimation Checks for Cox Models 
 
All Cox models were checked for proportional hazards by linear regression of scaled Schoenfeld 
residuals on time, via the estat phtest within Stata. (245) The global test was used initially, and if the 
null hypothesis was rejected, individual covariates were tested and log-log plots run. None of the 
models presented in this thesis violated the non-proportional hazards. 
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11.3 Appendix C – Note on Statistical Tests in Chapter 7 
 
Since publication of Chapter 7 as an original article, it has become clear that there may be more 
appropriate statistical tests as the t-tests used do not take account of clustering from case-control 
matching. One option would be conditional logistic regression, with the dependent variable a binary 
variable for case/control and the predictor variable the PSTR, UF capacity or glucose exposure. This 
design would require the same test to be repeated at multiple time points, so another option would 
be the same approach as that taken in Chapter 6 taking account of the repeated measures. This 
strategy would involve a 3 level model with the dependent variable one of the continuous variables 
(PSTR, UF capacity or Glucose exposure), with a random effect for measurements (level 1), for 
patients (level 2) and for case-control groups (level 3). Whether a patient is a case or control would 
then be a level 2 predictor variable. 
The analysis in chapter 7 was the first one to completed, before the other chapters. 
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11.4 Appendix D – Additional Data checking for PDDB Data 
 
Sense Checking 
If PD episode record has a previous modality of CKD, there should be no PD episode with start date 
earlier 
If the PD episode has finished, with a reason of peritonitis, there should be a peritonitis record 
within the last month 
If the PD episode has finished, and the outcome is transplant, the reason should be transplant, and 
vice versa 
If the PD episode has finished, and the outcome is died, the reason should be died, and vice versa 
If the PD episode has finished, and the outcome is recovered, the reason should be recovered, and 
vice versa 
If the PD episode has finished, and the reason is transferred, the outcome should be PD 
If the PD episode has finished, and the reason is one of: peritonitis, adequacy, uf failure type I, uf 
failure type II, other technique failure, exit site infection, tunnel infection, patient choice, diagnosed 
eps, then the outcome should be HD 
If the PD episode has finished, and the reason is withdrawal of treatment, the outcome should be 
died 
If the outcome is ‘died’, there should be a date of death in the demographics data and it should be 
the same as PD finish date 
If the blood test and the PET data are from the same day, the blood test creatinine and the PET 
plasma creatinine should be the same 
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If there is a date of death in the demographics data, there must be a PD finish date. In this situation, 
the reason in the PD episode data can be different to ‘died’ if the PD finish date is before the date of 
death 
If the primary renal diagnosis is diabetic renal disease (code 80), the comorbidity data must include 
diabetes = true 
If there is more than one comorbidity record, a comorbidity recorded in the earlier record must be 
recorded in the second record too 
If PD regime type = APD, the sum of all bag volumes must be greater than or equal to the sum of all 
exchange volumes excluding the long dwell and extra fill exchange volumes 
If PD regime type = APD, the PD adequacy overnight volume in must equal the sum of the bag 
volumes in PD regime 
If PD regime type = APD, and long dwell type != dry day the long dwell volume in/out and 
urea/creatinine must be entered and the volume in (adequacy field) must = long dwell exchange 
volume (regime field) and vice versa (if long dwell=dry day the longdwell fields in adequacy must be 
null) 
If urine volume = 0 the urine urea/creatinine/sodium/protein must all = null or 0 
If PD regime type = CAPD, all PD adequacy volume outs must be within 75% of the respective volume 
in 
If PD regime type = APD, the PD adequacy overnight volume out must be within 3000 of volume in 
If blood test glucose>20 comorbidity diabetes = true 
If PD regime fluid type = Baxter Dianeal, Baxter Physioneal or Fresenius type, Glucose strength !=0 & 
!=1.1 
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If PD regime fluid type = Baxter Extraneal or Nutrineal, Glucose strength = 0 
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11.5 Appendix E - Full Results for Models 
 
11.5.1 Chapter 4 Models 
11.5.1.1 Full Model for D/P Cr in Incident Patients 
Log likelihood 429.9235 
Deviance -859.847 
 
Table 11-2: Level Summary for Full Model of D/P Cr in Incident Patients 
 
 Observations per Group 
Variable Groups Minimum Maximum Average 
cent 10 4 151 48.9 
 
Table 11-3: Coefficients for Full Model of D/P Cr in Incident Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
age10 0.001414 0.003247 0.44 0.663 -0.0049499 0.0077785 
bmi -0.00234 0.001109 -2.11 0.035 -0.0045152 -0.0001689 
typepd -0.02171 0.02088 -1.04 0.298 -0.062634 0.0192122 
bpsys10 0.004514 0.002185 2.07 0.039 0.000231 0.0087959 
sex 0.022628 0.009969 2.27 0.023 0.0030892 0.042166 
lengthpdmo~h 0.080375 0.025614 3.14 0.002 0.030172 0.1305775 
lengthpdmo~2 -0.0198 0.008706 -2.27 0.023 -0.0368593 -0.0027308 
biocomp -0.00531 0.012429 -0.43 0.669 -0.02967 0.0190525 
icodex 0.057619 0.014349 4.02 0 0.0294949 0.0857432 
avdayglu 0.004889 0.001388 3.52 0 0.0021684 0.0076094 
logdil6 0.082844 0.011918 6.95 0 0.0594861 0.1062017 
logdtnf 0.036039 0.03333 1.08 0.28 -0.0292867 0.1013653 
logdifn -0.00945 0.015995 -0.59 0.555 -0.0407973 0.0219013 
logpil6 -0.02146 0.018353 -1.17 0.242 -0.0574324 0.0145091 
logptnf 0.021147 0.033243 0.64 0.525 -0.0440076 0.086301 
logpifn -0.00875 0.016738 -0.52 0.601 -0.0415532 0.0240594 
logpil1 0.024295 0.044026 0.55 0.581 -0.061995 0.110585 
diab 0.023716 0.011466 2.07 0.039 0.0012436 0.0461889 
comorbscore 0.000455 0.006123 0.07 0.941 -0.0115458 0.0124553 
urinevolli~e 0.025861 0.006947 3.72 0 0.0122455 0.0394773 
korean 0.085472 0.038631 2.21 0.027 0.0097569 0.1611876 
cons 0.393873 0.071954 5.47 0 0.252845 0.5349006 
 
Table 11-4: Variance Estimates for Full Model of D/P Cr in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.002652 0.00134 2.63E-05 0.0052783 
Level 1: id var(cons) 0.009609 0.000621 0.008392 0.0108254 
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11.5.1.2 Random Intercept Model for D/P Cr in Incident Patients 
 
 
Table 11-5: Level Summary for Random Intercept Multilevel Model of D/P Cr in Incident Patients 
 
 Observations per Group 
Variable Groups Minimum Maximum Average 
cent 10 7 154 56.7 
 
 
Table 11-6: Coefficients for Random Intercept Model of D/P Cr in Incident Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
cons 0.699555 0.015536 45.03 0 0.669106 0.730004 
 
Table 11-7: Variance Estimates for Random Intercept Model of D/P Cr in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.002008 0.001066 -8.2E-05 0.004098 
Level 1: id var(cons) 0.013169 0.000789 0.011623 0.014715 
 
  
Log likelihood 412.817 
Deviance -825.634 
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11.5.1.3 Full Model for D/P Cr in Prevalent Patients 
 
 
 
Table 11-8: Level Summary for Full Model of D/P Cr in Prevalent Patients 
 
 Observations per Group 
Variable Groups Minimum Maximum Average 
cent 10 3 87 32.5 
 
 
Table 11-9: Coefficients for Full Model of D/P Cr in Prevalent Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
age10 -0.00268 0.004006 -0.67 0.504 -0.01053 0.005173 
bmi -0.00105 0.001261 -0.83 0.404 -0.00352 0.00142 
typepd -0.01294 0.017744 -0.73 0.466 -0.04772 0.021839 
bpsys10 0.002195 0.002742 0.8 0.423 -0.00318 0.00757 
sex 0.021195 0.010888 1.95 0.052 -0.00014 0.042535 
lengthpdyear 0.010941 0.00352 3.11 0.002 0.004043 0.01784 
biocomp -0.03871 0.015792 -2.45 0.014 -0.06966 -0.00776 
icodex 0.034497 0.015369 2.24 0.025 0.004375 0.064619 
avdayglu 0.003523 0.001564 2.25 0.024 0.000458 0.006589 
logdil6 0.087526 0.012393 7.06 0 0.063236 0.111816 
logdtnf -0.00243 0.043396 -0.06 0.955 -0.08749 0.082621 
logdifn 0.008418 0.017438 0.48 0.629 -0.02576 0.042597 
logpil6 -0.00257 0.023682 -0.11 0.914 -0.04899 0.043844 
logptnf -0.0589 0.036095 -1.63 0.103 -0.12965 0.011843 
logpifn -0.0059 0.020211 -0.29 0.771 -0.04551 0.033718 
logpil1 -0.01301 0.045966 -0.28 0.777 -0.1031 0.077082 
diab 0.002982 0.015367 0.19 0.846 -0.02714 0.033101 
comorbscore 0.003173 0.006712 0.47 0.636 -0.00998 0.016329 
urinevolli~e 0.021261 0.009226 2.3 0.021 0.003179 0.039343 
korean 0.055787 0.028009 1.99 0.046 0.00089 0.110685 
cons 0.577935 0.068056 8.49 0 0.444547 0.711322 
 
Table 11-10: Variance Estimates for Full Model of D/P Cr in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.001147 0.000705 -0.00023 0.002528 
Level 1: id var(cons) 0.008881 0.000707 0.007495 0.010266 
 
  
Log likelihood 299.3478 
Deviance -598.696 
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11.5.1.4 Random Intercept Model for D/P Cr in Prevalent Patients 
 
 
 
Table 11-11: Level Summary for Random Intercept Model of D/P Cr in Prevalent Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 4 105 38.1 
 
 
Table 11-12: Coefficients for Random Intercept Model of D/P Cr in Prevalent Patients 
dpcr Coef. Std. Err. z P>z 95% Confidence Interval 
cons 0.689887 0.01583 43.58 0 0.65886 0.720914 
 
Table 11-13: Variance Estimates for Random Intercept Model of D/P Cr in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.001945 0.001107 -0.00022 0.004114 
Level 1: id var(cons) 0.012038 0.000883 0.010307 0.013769 
 
 
  
Log likelihood 292.7065 
Deviance -585.413 
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11.5.1.5 Full Model for Dialysate IL-6 in Incident Patients 
 
 
 
Table 11-14: Level Summary for Full Model of Dialysate IL-6 in Incident Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 5 151 49.7 
 
Table 11-15: Coefficients for Full Model of Dialysate IL-6 in Incident Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
age10 0.037885 0.0123141 3.08 0.002 0.01375 0.062021 
bmi 0.000915 0.0042185 0.22 0.828 -0.00735 0.009183 
typepd -0.05747 0.078543 -0.73 0.464 -0.21141 0.096472 
bpsys10 -0.01865 0.0082357 -2.26 0.024 -0.03479 -0.00251 
sex 0.038809 0.0381828 1.02 0.309 -0.03603 0.113646 
lengthpdyear 0.143455 0.3549725 0.4 0.686 -0.55228 0.839188 
biocomp 0.000568 0.046829 0.01 0.99 -0.09122 0.092351 
icodex 0.303538 0.0522712 5.81 0 0.201089 0.405988 
avdayglu 0.014247 0.0051945 2.74 0.006 0.004066 0.024428 
logdtnf 0.800452 0.119087 6.72 0 0.567046 1.033858 
logdifn 0.005593 0.0609767 0.09 0.927 -0.11392 0.125105 
logpil6 0.317591 0.0689031 4.61 0 0.182543 0.452638 
logptnf -0.18886 0.1244842 -1.52 0.129 -0.43285 0.055121 
logpifn 0.06221 0.0635425 0.98 0.328 -0.06233 0.186751 
logpil1 -0.01272 0.1687628 -0.08 0.94 -0.34349 0.318044 
diab 0.009814 0.0439606 0.22 0.823 -0.07635 0.095975 
comorbscore 0.015673 0.0233533 0.67 0.502 -0.0301 0.061444 
urinevolli~e 0.032694 0.0264494 1.24 0.216 -0.01915 0.084534 
korean -0.02275 0.1075738 -0.21 0.832 -0.23359 0.188088 
cons 0.341007 0.2641004 1.29 0.197 -0.17662 0.858634 
 
Table 11-16: Variance Estimates for Full Model of Dialysate IL-6 in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.0177819 0.0099784 -0.00178 0.037339 
Level 1: id var(cons) 0.1433934 0.0091857 0.12539 0.161397 
 
  
Log likelihood -231.31 
Deviance 462.6205 
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11.5.1.6 Random Intercept Model for Dialysate IL-6 in Incident Patients 
 
Table 11-17: Level Summary for Random Intercept Model for Dialysate IL-6 in Incident Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 7 153 56.3 
 
Log likelihood -363.436 
Deviance 726.8721 
 
Table 11-18: Coefficients for Random Intercept Model for Dialysate IL-6 in Incident Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
cons 0.800349 0.07826 10.23 0 0.646963 0.953734 
 
Table 11-19: Variance Estimates for Random Intercept Model for Dialysate IL-6 in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.054453 0.02702 0.001496 0.10741 
Level 1: id var(cons) 0.20367 0.012249 0.179662 0.227677 
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11.5.1.7 Full Model for Dialysate IL-6 in Prevalent Patients 
 
Table 11-20: Level Summary for Full Model of Dialysate IL-6 in Prevalent Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 3 88 32.8 
 
Log likelihood -188.728 
Deviance 377.4554 
 
Table 11-21: Coefficients for Full Model of Dialysate IL-6 in Prevalent Patients 
logdil6 Coef. Std. Err. z P>z 95% Confidence Interval 
age10 0.051059 0.017508 2.92 0.004 0.016744 0.085373 
bmi 0.010918 0.005575 1.96 0.05 -9.09E-06 0.021845 
typepd -0.17697 0.077524 -2.28 0.022 -0.32892 -0.02503 
bpsys10 -0.03106 0.012006 -2.59 0.01 -0.05459 -0.00753 
sex 0.059505 0.048081 1.24 0.216 -0.03473 0.153742 
lengthpdyear 0.023439 0.015612 1.5 0.133 -0.00716 0.054038 
biocomp 0.076668 0.070251 1.09 0.275 -0.06102 0.214357 
icodex 0.219818 0.067272 3.27 0.001 0.087968 0.351668 
avdayglu -0.00238 0.006963 -0.34 0.732 -0.01603 0.011263 
logdtnf 0.666616 0.189182 3.52 0 0.295825 1.037407 
logdifn 0.002529 0.077119 0.03 0.974 -0.14862 0.15368 
logpil6 0.326744 0.103813 3.15 0.002 0.123274 0.530214 
logptnf 0.181172 0.163303 1.11 0.267 -0.13889 0.501239 
logpifn -0.1419 0.088986 -1.59 0.111 -0.31631 0.032507 
logpil1 -0.06615 0.203804 -0.32 0.745 -0.4656 0.333294 
diab 0.035793 0.068137 0.53 0.599 -0.09775 0.169339 
comorbscore -0.00114 0.029785 -0.04 0.969 -0.05952 0.057237 
urinevolli~e -0.08838 0.040686 -2.17 0.03 -0.16813 -0.00864 
korean -0.13804 0.149183 -0.93 0.355 -0.43043 0.154353 
cons 0.552408 0.303952 1.82 0.069 -0.04333 1.148142 
 
Table 11-22: Variance Estimates for Full Model of Dialysate IL-6 in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.036681 0.020476 -0.00345 0.076814 
Level 1: id var(cons) 0.175226 0.013889 0.148005 0.202447 
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11.5.1.8 Random Intercept Model for Dialysate IL-6 in Prevalent Patients 
 
Table 11-23: Level Summary for Random Intercept Model of Dialysate IL-6 in Prevalent Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 4 103 37.8 
 
 
Log likelihood -285.468 
Deviance 570.935 
 
 
Table 11-24: Coefficients for Random Intercept Model of Dialysate IL-6 in Prevalent Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
cons 0.848769 0.090813 9.35 0 0.670779 1.026759 
 
 
Table 11-25: Variance Estimates for Random Intercept Model of Dialysate IL-6 in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.069849 0.036332 -0.00136 0.141057 
Level 1: id var(cons) 0.250393 0.018456 0.214219 0.286567 
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11.5.1.9 Full Model for Plasma IL-6 in Incident Patients 
 
Table 11-26: Level Summary of Full Model of Plasma IL-6 in Incident Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 5 151 49.7 
 
Log likelihood -5.8023958 
Deviance 11.604792 
 
Table 11-27: Coefficients for Full Model of Plasma IL-6 in Incident Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
age10 0.0229046 0.007897 2.9 0.004 0.007427 0.038382 
bmi 0.0001357 0.002681 0.05 0.96 -0.00512 0.005389 
typepd 0.0406607 0.049519 0.82 0.412 -0.0564 0.137717 
bpsys10 0.0031928 0.005267 0.61 0.544 -0.00713 0.013517 
sex 0.0466678 0.024353 1.92 0.055 -0.00106 0.094398 
lengthpdyear -0.1937804 0.209258 -0.93 0.354 -0.60392 0.216357 
biocomp 0.0030713 0.029127 0.11 0.916 -0.05402 0.060159 
icodex 0.0432039 0.033363 1.29 0.195 -0.02219 0.108594 
avdayglu 0.0026081 0.003206 0.81 0.416 -0.00368 0.008892 
logdil6 0.1251345 0.027721 4.51 0 0.070803 0.179466 
logdtnf -0.1564878 0.077363 -2.02 0.043 -0.30812 -0.00486 
logdifn 0.0724148 0.038314 1.89 0.059 -0.00268 0.147509 
logptnf 0.3860026 0.073364 5.26 0 0.242212 0.529793 
logpifn 0.0490346 0.040691 1.21 0.228 -0.03072 0.128786 
logpil1 0.2105526 0.106831 1.97 0.049 0.001169 0.419937 
diab -0.0482247 0.028114 -1.72 0.086 -0.10333 0.006877 
comorbscore 0.0482531 0.01482 3.26 0.001 0.019206 0.0773 
urinevolli~e -0.0182947 0.016753 -1.09 0.275 -0.05113 0.014541 
korean 0.0338079 0.04028 0.84 0.401 -0.04514 0.112756 
cons -0.386214 0.161469 -2.39 0.017 -0.70269 -0.06974 
 
 
Table 11-28: Variance Estimates for Full Model of Plasma IL-6 in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.001188 0.001132 -0.00103 0.003407 
Level 1: id var(cons) 0.059188 0.003787 0.051764 0.066611 
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11.5.1.10 Random Intercept Model for Plasma IL-6 in Incident Patients 
 
Table 11-29: Level Summary of Random Intercept Model of Plasma IL-6 in Incident Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 6 153 55.7 
 
Log likelihood -81.0924 
Deviance 162.1849 
 
Table 11-30: Coefficients for Random Intercept Model of Plasma IL-6 in Incident Patients 
logdil6 Coef. Std. Err. z P>z 95% Confidence Interval 
cons 0.413245 0.02762 14.96 0 0.359111 0.46738 
 
 
Table 11-31: Variance Estimates for Random Intercept Model of Plasma IL-6 in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.005443 0.003327 -0.00108 0.011964 
Level 1: id var(cons) 0.076357 0.004614 0.067313 0.085401 
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11.5.1.11 Full Model for Plasma IL-6 for Prevalent Patients 
 
Table 11-32: Level Summary for Full Model of Plasma IL-6 in Prevalent Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 3 88 32.8 
 
Log likelihood       24.86937 
Deviance              -49.7387 
 
Table 11-33: Coefficients for Full Model of Plasma IL-6 in Prevalent Patients 
 Coef. Std. Err. z P>z 
95% Confidence 
Interval 
age10 0.008086 0.009305 0.87 0.385 -0.01015 0.026324 
bmi 0.004496 0.002936 1.53 0.126 -0.00126 0.01025 
typepd -0.00401 0.040933 -0.1 0.922 -0.08424 0.076214 
bpsys10 -0.00723 0.006377 -1.13 0.257 -0.01973 0.005265 
sex 0.023522 0.02536 0.93 0.354 -0.02618 0.073226 
lengthpdyear 0.014752 0.008114 1.82 0.069 -0.00115 0.030655 
biocomp -0.01799 0.036581 -0.49 0.623 -0.08969 0.053708 
icodex -0.01348 0.035513 -0.38 0.704 -0.08309 0.056123 
avdayglu -0.00191 0.003604 -0.53 0.596 -0.00898 0.005151 
logdil6 0.086009 0.028178 3.05 0.002 0.030781 0.141237 
logdtnf -0.14635 0.099532 -1.47 0.141 -0.34143 0.048732 
logdifn 0.052694 0.040279 1.31 0.191 -0.02625 0.131639 
logptnf 0.404238 0.076752 5.27 0 0.253808 0.554669 
logpifn 0.142358 0.046362 3.07 0.002 0.051489 0.233227 
logpil1 0.317477 0.105838 3 0.003 0.110038 0.524916 
diab 0.075107 0.035636 2.11 0.035 0.005263 0.144951 
comorbscore 0.020197 0.015715 1.29 0.199 -0.0106 0.050999 
urinevolli~e -0.00771 0.021514 -0.36 0.72 -0.04988 0.034453 
korean -0.03236 0.047242 -0.69 0.493 -0.12495 0.060231 
cons -0.2496 0.154417 -1.62 0.106 -0.55225 0.053055 
 
Table 11-34: Variance Estimates for Full Model of Plasma IL-6 in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.002167 0.001813 -0.00139 0.00572 
Level 1: id var(cons) 0.049131 0.003888 0.04151 0.056751 
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11.5.1.12 Random Intercept Model for Plasma IL-6 in Prevalent Patients 
 
Table 11-35: Level Summary for Random Intercept Model of Plasma IL-6 in Prevalent Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 3 105 37.9 
 
Log likelihood -42.4198 
Deviance 84.83951 
 
Table 11-36: Coefficients for Random Intercept Model of Plasma IL-6 in Prevalent Patients 
logdil6 Coef. Std. Err. z P>z 95% Confidence Interval 
cons 0.40487 0.013901 29.12 0 0.377624 0.432116 
 
 
Table 11-37: Variance Estimates for Random Intercept Model of Plasma IL-6 in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0 0 0 0 
Level 1: id var(cons) 0.073239 0.00532 0.062811 0.083667 
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11.5.1.13 Cox Model for Incident Patients 
 
No. of subjects      =          503                  Number of obs   =       503 
No. of failures      =          225 
Time at risk         =   31302.1109 
                                                      Wald chi2(15)   =    208.91 
Log pseudolikelihood =   -725.68389                 Prob > chi2     =    0.0000 
 
Table 11-38: Coefficients for Cox Survival Model in Incident Patients 
  
Haz. 
Ratio 
Robust 
SE z P>z 
95% Confidence 
Interval 
logdtnf 0.963213 0.52718 -0.07 0.945 0.329494 2.815766 
logdil6 0.932663 0.163013 -0.4 0.69 0.662141 1.313709 
logdifn 1.190621 0.32012 0.65 0.516 0.702931 2.016667 
logpil1 0.577001 0.393083 -0.81 0.42 0.151808 2.193103 
logptnf 3.412823 1.734047 2.42 0.016 1.260725 9.238622 
logpil6 2.161273 0.62147 2.68 0.007 1.230122 3.797265 
logpifn 0.85546 0.246682 -0.54 0.588 0.486122 1.505406 
age 1.060887 0.007865 7.97 0 1.045584 1.076414 
sex 0.933476 0.146787 -0.44 0.662 0.68589 1.270435 
comorbscore 1.684828 0.134537 6.53 0 1.440738 1.97027 
urinevolli~e 0.951494 0.110534 -0.43 0.669 0.757745 1.194784 
lengthpdmo~h 1.046634 0.145613 0.33 0.743 0.79684 1.374732 
alb 0.942203 0.015974 -3.51 0 0.911409 0.974038 
dpcr10 1.093906 0.063859 1.54 0.124 0.97564 1.226508 
bmi 1.009792 0.020963 0.47 0.639 0.969531 1.051725 
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11.5.1.14 Cox Model for Prevalent Patients 
 
Stratified Cox regr. -- no ties 
 
No. of subjects      =          345                  Number of obs   =       345 
No. of failures      =          171 
Time at risk         =       680973 
                                                      Wald chi2(15)   =    195.02 
Log pseudolikelihood =    -516.0168                 Prob > chi2     =    0.0000 
 
Table 11-39: Coefficients for Cox Survival Model in Prevalent Patients 
  
Haz. 
Ratio 
Robust 
SE z P>z 
95% Confidence 
Interval 
logdtnf 0.90839 0.641631 -0.14 0.892 0.227528 3.62668 
logdil6 0.958582 0.194264 -0.21 0.835 0.644358 1.426039 
logdifn 1.195768 0.371555 0.58 0.565 0.650365 2.198551 
logpil1 0.539634 0.326887 -1.02 0.309 0.164618 1.768973 
logptnf 2.099505 1.42828 1.09 0.276 0.553413 7.964968 
logpil6 2.685174 1.005032 2.64 0.008 1.289368 5.592012 
logpifn 1.19547 0.373936 0.57 0.568 0.647572 2.206933 
age 1.057003 0.007322 8 0 1.042749 1.071451 
sex 1.28113 0.218211 1.45 0.146 0.917509 1.788859 
comorbscore 1.368792 0.101122 4.25 0 1.184276 1.582055 
urinevolli~e 0.648289 0.09722 -2.89 0.004 0.483192 0.869797 
lengthpdyear 1.13504 
0.05 
1746 2.78 0.005 1.038018 1.241131 
alb 0.988001 0.020798 -0.57 0.566 0.948068 1.029617 
dpcr10 1.188856 0.103022 2 0.046 1.003153 1.408937 
bmi 1.009726 0.017329 0.56 0.573 0.976327 1.044267 
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11.5.2 Chapter 5 Models 
 
11.5.2.1 Full Model for Plasma TNF-α 
 
Table 11-40: Level Summary for Full Model of Plasma TNF-alpha in All Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 20 242 83.1 
 
Log likelihood 456.928 
Deviance -913.856 
 
Table 11-41: Coefficients for Full Model of Plasma TNF alpha in All Patients 
 Coef. Std. Err. z P>z 95% Confidence Interval 
age -0.00021 0.000348 -0.61 0.545 -0.00089 0.000471 
bmi -0.00106 0.001151 -0.92 0.358 -0.00331 0.001198 
typepd 0.017009 0.018209 0.93 0.35 -0.01868 0.052698 
bpsys -3.1E-05 0.000235 -0.13 0.894 -0.00049 0.000429 
sex 0.01656 0.010148 1.63 0.103 -0.00333 0.03645 
lengthpdyear -0.00149 0.004065 -0.37 0.714 -0.00946 0.006479 
biocomp -0.02974 0.013194 -2.25 0.024 -0.0556 -0.00388 
icodex -0.00945 0.014322 -0.66 0.509 -0.03752 0.018621 
avdayglu 3.727595 1.429484 2.61 0.009 0.925857 6.529333 
logdil6 -0.00813 0.011874 -0.68 0.493 -0.0314 0.01514 
logdtnf 0.050495 0.035452 1.42 0.154 -0.01899 0.11998 
logdifn -0.02318 0.016101 -1.44 0.15 -0.05473 0.00838 
logpil6 0.142185 0.019098 7.45 0 0.104755 0.179616 
logpifn 0.179527 0.016672 10.77 0 0.146851 0.212202 
logpil1 0.075337 0.044142 1.71 0.088 -0.01118 0.161854 
diab 0.01268 0.012694 1 0.318 -0.0122 0.037559 
comorbscore -0.01038 0.006259 -1.66 0.097 -0.02265 0.001887 
urinevol -3.3E-05 7.52E-06 -4.37 0 -4.8E-05 -1.8E-05 
koreanvsno~n -0.01501 0.074106 -0.2 0.839 -0.16025 0.130236 
cons 0.926885 0.067334 13.77 0 0.794913 1.058856 
 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.011101 0.0051317 0.001043 0.021159 
Level 1: id var(cons) 0.018659 0.0009209 0.016854 0.020464 
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11.5.3 Chapter 6 Results 
 
11.5.3.1 Full Model for Dialysate IL-6 in EPS Case-Control Study 
 
Table 11-42: Level Summary of Full Model of Dialysate IL-6 in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 13.5 
id 38 1 9 3.9 
 
Log likelihood -237.637 
Deviance 475.2746 
 
Table 11-43: Coefficients for Full Model of Dialysate IL-6 in EPS Case Control Study 
logdil6 Coef. Std. Err. z P>z 
95% Confidence 
Interval 
eps 0.792009 0.390661 2.03 0.043 0.026327 1.55769 
ttillendyear 0.272882 0.074029 3.69 0 0.127788 0.417976 
ageatpdfin~h 0.009291 0.011865 0.78 0.434 -0.01396 0.032545 
cons 2.486986 0.768855 3.23 0.001 0.980058 3.993915 
 
Table 11-44: Variance Estimates for Full Model of Dialysate IL-6 in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.162202 0.218017 -0.2651 0.589507 
Level 2: id var(cons) 0.700469 0.288604 0.134816 1.266121 
Level 1: samplenumber var(cons) 1.041903 0.139339 0.768803 1.315003 
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11.5.3.2 Full Model for Dialysate TNF-α in EPS Case-Control Study 
 
Table 11-45: Level Summary for Full Model of Dialysate TNF alpha in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 13.5 
id 38 1 9 3.9 
 
Log 
likelihood -139.532 
Deviance 279.0647 
 
Table 11-46: Coefficients for Full Model of Dialysate TNF alpha in EPS Case Control Study 
 Coef. Std. Err. z P>z 95% Confidence Interval 
eps 0.642222 0.209165 3.07 0.002 0.232266 1.052177 
ttillendyear 0.048472 0.038028 1.27 0.202 -0.02606 0.123006 
ageatpdfin~h 0.019248 0.006046 3.18 0.001 0.007398 0.031098 
cons -0.67483 0.385964 -1.75 0.08 -1.43131 0.081647 
 
Table 11-47: Variance Estimates for Full Model of Dialysate TNF alpha in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.006949 0.047776 -0.08669 0.100588 
Level 2: id var(cons) 0.212745 0.08412 0.047873 0.377617 
Level 1: samplenumber var(cons) 0.277613 0.037111 0.204878 0.350349 
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11.5.3.3 Full Model for Dialysate IFN-γ in EPS Case-Control Study 
 
Table 11-48: Level Summary for Full Model of Dialysate IFN gamma in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 13.5 
id 38 1 9 3.9 
 
Log likelihood -221.075 
Deviance 442.1491 
 
Table 11-49: Coefficients for Full Model of Dialysate IFN gamma in EPS Case Control Study 
 Coef. Std. Err. z P>z 95% Confidence Interval 
eps 0.616639 0.343559 1.79 0.073 -0.05672 1.290003 
ttillendyear 0.085193 0.066258 1.29 0.199 -0.04467 0.215057 
ageatpdfin~h 0.015503 0.010558 1.47 0.142 -0.00519 0.036196 
cons 0.345255 0.687128 0.5 0.615 -1.00149 1.692 
 
Table 11-50: Variance Estimates for Full Model of Dialysate IFN gamma in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.161688 0.183069 -0.19712 0.520496 
Level 2: id var(cons) 0.528714 0.221822 0.093952 0.963476 
Level 1: samplenumber var(cons) 0.835408 0.111696 0.616488 1.054329 
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11.5.3.4 Full Model for Dialysate IL-1β in EPS Case-Control Study 
 
Table 11-51: Level Summary for Full Model of Dialysate IL-1 beta in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 13.5 
id 38 1 9 3.9 
 
Table 11-52: Coefficients for Full Model of IL-1 beta in EPS Case Control Study 
 
Coef. Std. Err. z P>z 
95% Confidence 
Interval 
eps 1.06241 0.595879 1.78 0.075 
-
0.10549 2.230312 
ttillendyear 0.192594 0.141293 1.36 0.173 
-
0.08433 0.469522 
ageatpdfin~h 0.02212 0.017296 1.28 0.201 
-
0.01178 0.056019 
cons -0.94932 1.104751 -0.86 0.39 -3.1146 1.215951 
 
 
Table 11-53: Variance Estimates for Full Model of Dialysate IL-1 beta in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.22239 0.42245 -0.6056 1.050377 
Level 2: id var(cons) 0.975642 0.601962 -0.20418 2.155466 
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11.5.3.5 Full Model for Plasma IL-6 in EPS Case-Control Study 
 
Table 11-54: Level Summary for Full Model of Plasma IL-6 in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 11.7 
id 38 1 8 3.4 
 
Log likelihood -116.596 
Deviance 233.1918 
 
Table 11-55: Coefficients for Full Model of Plasma IL-6 in EPS Case Control Study 
 
Coef. Std. Err. z P>z 95% Confidence Interval 
eps 0.420961 0.181537 2.32 0.02 0.065156 0.776766 
ttillendyear 0.13184 0.039359 3.35 0.001 0.054698 0.208982 
ageatpdfin~h 0.01587 0.005361 2.96 0.003 0.005363 0.026377 
cons 0.384441 0.342016 1.12 0.261 -0.2859 1.05478 
 
 
Table 11-56: Variance Estimates for Full Model of Plasma IL-6 in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 
95% Confidence 
Interval 
Level 3: casecontrolnumber var(cons) 0.019084 0.042471 -0.06416 0.102325 
Level 2: id var(cons) 0.130592 0.064869 0.003451 0.257733 
Level 1: samplenumber var(cons) 0.274992 0.040177 0.196248 0.353737 
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11.5.3.6 Full Model for Plasma TNF-α in EPS Case-Control Study 
 
Table 11-57: Level Summary for Full Model of Plasma TNF alpha in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 11.7 
id 38 1 8 3.4 
 
Log likelihood -68.1586 
Deviance 136.3172 
 
Table 11-58: Coefficients for Full Model of Plasma TNF alpha in EPS Case Control Study 
 
Coef. Std. Err. z P>z 
95% Confidence 
Interval 
eps 0.13261 0.131657 1.01 0.314 -0.12543 0.390653 
ttillendyear 0.045348 0.026781 1.69 0.09 -0.00714 0.097838 
ageatpdfin~h 0.009801 0.003874 2.53 0.011 0.002209 0.017393 
cons 1.888265 0.246582 7.66 0 1.404973 2.371558 
 
Table 11-59: Variance Estimates for Full Model of Plasma TNF alpha in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.00733 0.021342 -0.0345 0.049159 
Level 2: id var(cons) 0.077533 0.034553 0.00981 0.145255 
Level 1: samplenumber var(cons) 0.122544 0.017901 0.087459 0.157628 
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11.5.3.7 Full Model for Plasma IFN-γ in EPS Case-Control Study 
 
Table 11-60: Level Summary for Full Model of Plasma IFN gamma in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 11.7 
id 38 1 8 3.4 
 
Log likelihood -148.457 
Deviance 296.9133 
 
 
Table 11-61: Coefficients for Full Model of Plasma IFN gamma in EPS Case Control Study 
 
Coef. Std. Err. z P>z 95% Confidence Interval 
eps -0.29641 0.199213 -1.49 0.137 -0.68686 0.094042 
ttillendyear 0.11943 0.050042 2.39 0.017 0.02135 0.217511 
ageatpdfin~h 0.013761 0.006547 2.1 0.036 0.000929 0.026593 
cons 0.759605 0.448845 1.69 0.091 -0.12012 1.639325 
 
 
Table 11-62: Variance Estimate for Full Model of Plasma IFN gamma in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.226471 0.13413 -0.03642 0.48936 
Level 2: id var(cons) 0.108408 0.073452 -0.03556 0.252372 
Level 1: samplenumber var(cons) 0.444058 0.064334 0.317965 0.57015 
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11.5.3.8 Full Model for Plasma IL-1β in EPS Case-Control Study 
 
Table 11-63: Level Summary for Full Model of Plasma IL-1 beta in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 23 11.7 
id 38 1 8 3.4 
 
 
Table 11-64: Coefficients for Full Model of Plasma IL-1 beta in EPS Case Control Study 
 
Coef. Std. Err. z P>z 95% Confidence Interval 
eps 0.658029 0.669498 0.98 0.326 -0.65416 1.97022 
ttillendyear -0.20968 0.173924 -1.21 0.228 -0.55056 0.131206 
ageatpdfin~h -0.02309 0.020668 -1.12 0.264 -0.0636 0.017414 
cons 1.7807 1.338543 1.33 0.183 -0.8428 4.404196 
 
 
Table 11-65: Variance Estimates for Full Model of Plasma IL-1 beta in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0.753702 0.731585 -0.68018 2.187582 
Level 2: id var(cons) 0.984881 0.753065 -0.4911 2.460861 
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11.5.3.9 Full Model for D/P Cr in EPS Case-Control Study 
 
Table 11-66: Level Summary for Full Model of D/P Cr in EPS Case Control Study 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
casecontro~r 11 3 25 13.4 
id 38 1 11 3.9 
 
 
Log likelihood 127.0728 
Deviance -254.146 
  
Table 11-67: Coefficients for Full Model of D/P Cr in EPS Case Control Study 
 
Coef. Std. Err. z P>z 95% Confidence Interval 
eps 0.024151 0.0399176 0.61 0.545 -0.05409 0.102389 
ttillendyear 0.034722 0.0060311 5.76 0 0.022901 0.046542 
ageatpdfin~h -0.00166 0.0011378 -1.46 0.143 -0.00389 0.000565 
cons 0.931729 0.0726756 12.82 0 0.789287 1.07417 
 
 
Table 11-68: Variance Estimates for Full Model of D/P Cr in EPS Case Control Study 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 3: casecontrolnumber var(cons) 0 0 0 0 
Level 2: id var(cons) 0.0088881 0.002596 0.0038 0.013977 
Level 1: samplenumber var(cons) 0.0067799 0.000916 0.004984 0.008576 
 
 
 
  
 183 
 
11.5.4 Chapter 8 Results 
 
11.5.4.1 Competing Risks of EPS 
 
Competing-risks regression                         No. of obs       =     17504 
                                                     No. of subjects  =     17504 
Failure event  : event == 1                         No. failed       =       100 
Competing event: event == 2                         No. competing    =      9479 
                                                     No. censored     =      7925 
 
                                                     Wald chi2(5)     =    162.30 
Log pseudolikelihood = -799.98746                  Prob > chi2      =    0.0000 
 
Table 11-69: Coefficients for Competing Risks Model of EPS 
 SHR Robust SE z P>z 95% Confidence Interval 
dm 0.757647 0.223716 -0.94 0.347 0.424743 1.351472 
sex 0.972065 0.195825 -0.14 0.888 0.654966 1.442686 
age 0.957651 0.00548 -7.56 0 0.946971 0.968452 
3.ds 6.865962 1.44182 9.17 0 4.549389 10.36215 
diseasecode 0.504925 0.129552 -2.66 0.008 0.305371 0.834882 
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11.5.4.2 Cox Model for EPS 
 
No. of subjects =        17504                      Number of obs   =     17504 
No. of failures =          100 
Time at risk    =     14524311 
                                                     LR chi2(5)      =     91.13 
Log likelihood  =   -680.88427                  Prob > chi2     =    0.0000 
 
Table 11-70: Coefficients for Cox Model of EPS 
 HR Std. Err. z P>z 95% Confidence Interval 
dm 1.472894 0.417053 1.37 0.171 0.845574 2.565613 
sex 1.292691 0.267005 1.24 0.214 0.862342 1.937805 
age 0.977165 0.006702 -3.37 0.001 0.964117 0.990391 
3.ds 8.585785 1.888924 9.77 0 5.578413 13.21446 
diseasecode 0.589214 0.142229 -2.19 0.028 0.367116 0.945677 
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11.5.4.3 Cox Model for Death 
 
No. of subjects =        17504                       Number of obs   =     17504 
No. of failures =         9479 
Time at risk    =     14524311 
                                                      LR chi2(5)      =   2380.05 
Log likelihood  =   -81546.141                      Prob > chi2     =    0.0000 
 
Table 11-71: Coefficients for Cox Model of Death 
 HR Std. Err. z P>z 95% Confidence Interval 
dm 1.430263 0.033193 15.42 0 1.366663 1.496823 
sex 1.026139 0.021424 1.24 0.217 0.984996 1.069 
age 1.030916 0.000873 35.95 0 1.029206 1.032628 
3.ds 1.185559 0.048675 4.15 0 1.093895 1.284903 
diseasecode 1.347782 0.035187 11.43 0 1.280552 1.418542 
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11.5.5 Chapter 9 Results 
 
11.5.5.1 Multilevel Model for Reciprocal of Random blood glucose in Non-Diabetic 
Incident Patients 
 
 
Table 11-72: Level Summary for Model of Reciprocal of Random blood glucose in Incident Patients 
 
 
Observations per Group 
Level 
Variable Groups Minimum   Maximum Average 
cent 10 2 80 28.6 
 
Log likelihood 507.3061 
Deviance -1014.61 
 
 
Table 11-73: Coefficients for Model of Reciprocal of Random blood glucose in Incident Patients 
 
Coef. Std. Err. z P>z 95% Confidence Interval 
totdayglu 0.000133 7.76E-05 1.71 0.087 -1.9E-05 0.000285 
korean -0.02712 0.013399 -2.02 0.043 -0.05338 -0.00086 
bmi -0.00084 0.000564 -1.5 0.134 -0.00195 0.000261 
age -0.00071 0.000164 -4.34 0 -0.00103 -0.00039 
bpsys -0.00013 0.000121 -1.08 0.281 -0.00037 0.000107 
dpcr 0.035501 0.025477 1.39 0.163 -0.01443 0.085435 
lengthpd -0.0002 0.000139 -1.43 0.154 -0.00047 7.42E-05 
alb 0.000133 0.000617 0.22 0.829 -0.00108 0.001342 
sodium 0.001989 0.000712 2.79 0.005 0.000593 0.003385 
logpil6 -0.00279 0.00847 -0.33 0.742 -0.01939 0.01381 
urinevol 1.84E-06 3.72E-06 0.5 0.62 -5.45E-06 9.14E-06 
comorbscore -5.5E-05 0.003491 -0.02 0.987 -0.0069 0.006786 
icodex 0.007697 0.007735 1 0.32 -0.00746 0.022858 
cons -0.04663 0.10518 -0.44 0.658 -0.25278 0.159519 
 
Table 11-74: Variance Estimates for Model of Reciprocal of Random blood glucose in Incident Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.000262 0.000154 -3.9E-05 0.000564 
Level 1: id var(cons) 0.001597 0.000136 0.001331 0.001863 
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11.5.5.2 Multilevel Model for Reciprocal of Random blood glucose in Non-Diabetic 
Prevalent Patients 
 
Table 11-75: Level Summary for Model of Reciprocal of Random blood glucose in Prevalent Patients 
 
 
Observations per Group 
Variable Groups Minimum   Maximum Average 
cent 10 2 57 20.9 
 
Log likelihood 375.969 
Deviance -751.938 
 
Table 11-76: Coefficients for Model of Reciprocal of Random blood glucose in Prevalent Patients 
 
Coef. Std. Err. z P>z 95% Confidence Interval 
totdayglu -0.00031 8.21E-05 -3.72 0 -0.00047 -0.00014 
korean -0.01055 0.020292 -0.52 0.603 -0.05032 0.029219 
bmi -0.00061 0.0007 -0.87 0.382 -0.00198 0.000761 
age -0.0004 0.000193 -2.05 0.04 -0.00077 -1.8E-05 
bpsys 0.000204 0.000136 1.5 0.134 -6.3E-05 0.000471 
dpcr -0.02408 0.027952 -0.86 0.389 -0.07886 0.030706 
lengthpd -5.94E-07 4.59E-06 -0.13 0.897 -9.60E-06 8.41E-06 
alb 0.001061 0.000716 1.48 0.139 -0.00034 0.002465 
sodium 0.001511 0.000862 1.75 0.08 -0.00018 0.003201 
logpil6 -0.01008 0.012198 -0.83 0.408 -0.03399 0.013822 
urinevol -1.76E-06 5.54E-06 -0.32 0.751 -1.3E-05 9.09E-06 
comorbscore 0.003857 0.003466 1.11 0.266 -0.00294 0.01065 
icodex -0.14915 0.043924 -3.4 0.001 -0.23524 -0.06306 
icobyglu 0.001963 0.000634 3.1 0.002 0.000721 0.003204 
icobyglu2 -5.17E-06 2.10E-06 -2.47 0.014 -9.28E-06 -1.06E-06 
cons -0.00409 0.123332 -0.03 0.974 -0.24581 0.237639 
 
Table 11-77: Variance Estimates for Model of Reciprocal of Random blood glucose in Prevalent Patients 
Random-effects Parameters Estimate Std. Err. 95% Confidence Interval 
Level 2: cent var(cons) 0.000741 0.000389 -2.1E-05 0.001503 
Level 1: id var(cons) 0.001446 0.000145 0.001162 0.00173 
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11.5.6 Cox Survival Model for Non-Diabetic Incident Patients 
 
No. of subjects      =          303                  Number of obs   =       303 
No. of failures      =          109 
Time at risk         =  20525.04314 
                                                      Wald chi2(9)    =     82.18 
Log pseudolikelihood =   -288.35275                 Prob > chi2     =    0.0000 
 
Table 11-78: Coefficients for Cox Survival Model in Non-Diabetic Incident Patients 
_t HR Robust SE z P>z 95% Confidence Interval 
age 1.066915 0.012714 5.44 0 1.042284 1.092128 
logpil6 3.074614 0.925275 3.73 0 1.704628 5.545638 
comorbscore 1.479189 0.172078 3.37 0.001 1.177609 1.858002 
urinevolli~e 0.800935 0.120475 -1.48 0.14 0.596432 1.075556 
lengthpdmo~h 1.135769 0.28154 0.51 0.608 0.698699 1.846248 
alb 0.95664 0.021496 -1.97 0.049 0.915423 0.999713 
dpcr10 1.052437 0.075537 0.71 0.476 0.914329 1.211405 
glucat             
1 0.947671 0.225575 -0.23 0.821 0.594354 1.51102 
2 1.151431 0.403989 0.4 0.688 0.578879 2.290281 
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11.5.7 Cox Survival Model for Non-Diabetic Prevalent Patients 
 
No. of subjects      =          232                  Number of obs   =       232 
No. of failures      =           97 
Time at risk         =       502483 
                                                      Wald chi2(9)    =    130.66 
Log pseudolikelihood =   -244.84819                 Prob > chi2     =    0.0000 
 
 
Table 11-79: Coefficients for Cox Survival Model for Non-Diabetic Prevalent Patients 
_t HR Robust SE z P>z 95% Confidence Interval 
age 1.059133 0.009953 6.11 0 1.039805 1.078821 
logpil6 3.08304 1.457272 2.38 0.017 1.220783 7.786094 
comorbscore 1.392261 0.13807 3.34 0.001 1.146324 1.690962 
urinevolli~e 0.646956 0.152002 -1.85 0.064 0.408212 1.025331 
lengthpdmo~h 1.012945 0.005116 2.55 0.011 1.002966 1.023022 
alb 0.974382 0.024285 -1.04 0.298 0.927929 1.02316 
dpcr10 1.237036 0.121545 2.16 0.03 1.020346 1.499743 
glucat             
1 1.454432 0.360257 1.51 0.13 0.895064 2.363376 
2 1.323676 0.611125 0.61 0.544 0.535541 3.271682 
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